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ABSTRACT OF DISSERTATION

THE ROLE OF FAT GRAFTING AND ADIPOSE-DERIVED STEM CELLS
IN BREAST RECONSTRUCTION
Fat grafting is a common surgical procedure that involves the transfer of fat from one
area of the body to another in order to improve contour deformities, such as in breast
reconstruction. Advantages of the technique include using autologous tissue rather than a
foreign body and the added benefit of having liposuction to remove fat from an
undesirable location. Although adipose tissue could be the ideal soft tissue filler, fat
grafting is plagued by tremendous variability in long-term retention, with volume
survival rates of 20-80%, resulting in suboptimal outcomes and repetitive procedures.
The mechanisms contributing to long-term fat graft survival and resorption are not well
understood. The discovery of multipotent mesenchymal adipose tissue-derived stem cells
(ASCs) in subcutaneous adipose tissue has encouraged the study of their role in fat graft
survival. ASCs are observed to survive after grafting, and in fact play a major role in
adipocyte survival, regeneration and differentiation through adipogenesis and paracrine
effects. In fact, lipoaspirate supplemented with ASCs has been shown to improve
angiogenesis and long-term graft retention through the release of factors. Many adipose
graft enrichment strategies encompassing growth factors, platelet-rich plasma, stem cells,
gene therapy and tissue engineering have been attempted to augment and improve the
viability of fat grafts. Therefore, a systematic review was undertaken to optimize safety
and outcomes related to these enrichment strategies.
Recently, concerns have been raised from several regulatory bodies, including the FDA,
regarding safety of fat grafting in the setting of breast reconstruction. ASCs within
lipoaspirate have been postulated to create an inflammatory tumor microenvironment, to
encourage angiogenesis, and to potentially contribute to tumorigenesis. Therefore, a
review of both local data and a systematic review was undertaken to determine
oncological outcomes of fat grafting to the breast.
Finally, we test the hypothesis that ASCs derived from obese donors exhibit
compromised ASC functionality, leading to reduced fat graft retention when compared to
non-obese subjects. Collectively, the studies that comprise this dissertation generate and
critically appraise evidence for the safety, efficacy and outcomes of fat grafting in the
setting of breast reconstruction.

Keywords: adipose tissue; adipose-derived stem cell; plastic and reconstructive surgery;
lipotransfer, fat grafting, obesity
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Chapter 1: Introduction

Autologous fat grafting is a common surgical procedure that involves the transfer of fat
from one area of the body to another in order to improve contour deformities. Fat grafting
refers to the procedure in which fat is harvested by liposuction from a part of the body
where it is unwanted and injected into an area where it can be used to add volume or
correct a contour deformity. Advantages of the technique include using autologous fatty
tissue rather than a foreign body and the added benefit of having liposuction to remove
fat from an undesirable location.

There is tremendous clinical interest in the utilization of fat grafting for soft tissue
reconstruction, with thousands of cases performed each year in the treatment of volume
loss due to trauma, scars, wounds, fistulas, disease, congenital defects, or the natural
process of aging (7). In the setting of breast reconstruction, for example, fat grafting
provides significant aesthetic improvement in breast reconstruction (8), is a viable option
for improving the quality of irradiated breast skin (9), and can help to alleviate postmastectomy pain syndrome (10). Ideally, fat grafting could become an alternative to
breast implants or complex microvascular tissue flap surgery in breast reconstruction (8,
11-13). Although fat could become the ideal soft tissue filler, it is plagued by its
tremendous variability in long-term graft retention, with volume survival rates of 2080%, resulting in suboptimal outcomes and repetitive procedures (14).
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The mechanisms contributing to long-term fat graft survival and resorption are not well
understood. The recent discovery of multipotent mesenchymal adipose tissue-derived
stem cells (ASCs) in subcutaneous adipose tissue has encouraged the study of their role
in enhancing fat grafts for applications in tissue engineering, wound healing, soft tissue
augmentation and fat graft survival. Avascular fat grafts initially rely on diffusion for
survival until revascularization occurs. Revascularization of the free fat graft is essential
to graft survival and is influenced by ASCs, which are more resistant to hypoxic
conditions when compared to adipocytes. ASCs are observed to survive after grafting,
and in fact play a major role in adipocyte survival and differentiation. These ASCs
survive for up to 3 days and regenerate adipose tissue through adipogenesis and paracrine
effects. ASCs also promote revascularization of ischemic free fat grafts through the
release of proangiogenic paracrine growth factors, including vascular endothelial growth
factor (VEGF). In fact, lipoaspirate supplemented with ASCs has been shown to improve
angiogenesis and long-term graft retention through the release of these factors. Several
adipose graft enrichment strategies encompassing growth factors, platelet-rich plasma,
adipose-derived and bone marrow stem cells, gene therapy and tissue engineering have
been attempted to augment and improve the viability of fat grafts.

While there is tremendous interest in the use of fat grafting for aesthetic and
reconstructive breast surgery, concerns have been raised from several regulatory bodies,
including the Food and Drug Administration and professional organizations, regarding
efficacy and safety in the setting of breast reconstruction. ASCs have been postulated to
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create an inflammatory tumor microenvironment, to encourage angiogenesis, and to
possibly differentiate into carcinoma associated fibroblasts, potentially contributing to
tumorigenesis. However, concerns regarding the practice of fat grafting are not limited
solely to the propagation of oncological transformation.

In 1987, the American Society of Plastic Surgeons (ASPS) issued a report condemning
the practice of fat grafting to breast tissue due to the lack of long-term clinical trials and
the possibility that scarring and calcification resulting from the procedure could interfere
with breast cancer diagnosis. Research in the field has resulted in a reversal of the
previously recommended moratorium with an investigation by the ASPS Task Force
revealing no evidence of fat grafting impeding cancer detection or any indication that the
procedure stimulates cancer recurrence. In light of the recent FDA regulatory changes
regarding the processing of fat, a systematic review was undertaken to determine the
safety, efficacy, satisfaction, and oncological outcomes of fat grafting to the breast.

Due to the significant variability in fat grafting outcomes and tremendous interest of
ASCs graft retention, the final study attempts to describe the impact of a specific donor
physiological condition, obesity, on ASC functionality. Obesity (BMI > 30 kg/m2) is a
growing epidemic in the United States, affecting more than 33% of adults. Obesity is
characterized by chronic low-grade systemic inflammation; however, the effects of
obesity on the intrinsic cellular properties of ASCs are largely unknown. The objective of
this final study is to characterize the effects of obesity on ASC functionality and fat graft
retention in breast reconstruction patients. ASCs isolated and cultured from the
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lipoaspirate of lean and obese women undergoing fat grafting for breast reconstruction
were compared by ASC yield, viability, growth kinetics, capacity for multi-lineage
differentiation into adipogenic and osteogenic lineages, and growth factor expression in
vitro. Understanding how obesity affects ASC function may help to elucidate why lean
patients anecdotally have better fat graft retention compared to obese patients.

Collectively, the objectives and specific aims of this dissertation are to generate and
critically appraise evidence for the safety, efficacy and outcomes of fat grafting in the
setting of breast reconstruction. Chapter 2 of this dissertation begins with a general
introduction to adipose and breast tissue and the role of ASCs. Chapter 3 discusses the
FDA regulatory issues regarding fat grafting. Chapter 4 identifies and appraises
systematic evidence for autologous fat grafting to the breast, which includes a review of
the safety, efficacy, satisfaction, and oncological outcomes. Chapter 5 continues this
theme with a local review of the same variables. Chapter 6 is a review article on the
impact of ASCs in fat grafting. Chapter 7 is a systematic review of the effects of obesity
on ASC function. Chapter 8 is an experimental study exploring the effects of obesity on
ASC functionality and its relationship to fat graft retention in breast reconstruction
patients. Chapter 9 is a systematic review of adipose graft enrichment strategies. Finally,
Chapter 10 summarizes the evidence and discusses the clinical implications and
limitations, and recommends specific direction for future research.
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Chapter 2: Adipose and Breast Tissue and
Adipose-Derived Stem Cells

Chapter 2 provides a primer and discussion of the literature on adipose and breast tissue
and the role of adipose-derived stem cells. Adipose tissue is not only the primary site of
storage for excess energy, but is also a metabolically active and dynamic endocrine organ
that is capable of synthesizing many biologically active compounds. This tissue is not
only composed of adipocytes, but also of other cell types that make up the stromal
vascular fraction. In order to understand fat grafting in breast reconstruction, it is
important to understand adipose tissue, breast tissue and the role of adipose-derived stem
cells. The following subsections describe the function of adipose tissue, the isolation and
identification of adipose-derived stem cells, the development and regenerative potential
of these cells, and ongoing clinical trials involving them. Finally, the cell types
composing breast tissue is briefly discussed.
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2.1 Adipose: Cell Types Composing the Tissue

This section is based on an article published in The SAGE Encyclopedia of Stem Cell
Research, Second Edition and reproduced here with permission of SAGE Publications
Inc.

Vyas K, Jawahir N. (2015). Adipose, Cell Types Composing the Tissue. In E Bouhassira,
Vyas KS (Ed.), The SAGE Encyclopedia of Stem Cell Research, Second Edition. Vol 1,
pp 3-6. Thousand Oaks, CA: SAGE Publications, Inc.
http://dx.doi.org/10.4135/9781483347660.n3
10.4135/9781483347660.n3

Adipose tissue is a loose connective tissue with the primary function of storing lipids that
can be harvested for energy. This function is performed by adipocytes, which comprise
the vast majority of cells in adipose tissue. However, multiple other cell types can be
found in adipose tissue; these cells are grouped under the category of the stromal vascular
fraction (SVF). Cells of the SVF include preadipocytes, fibroblasts, vascular endothelial
and smooth muscle cells, mesenchymal stem cells, endothelial progenitor cells, and
immune cells such as anti-inflammatory M2 macrophages and T regulatory cells. An
understanding of the cell types in adipose tissue is crucial for many relevant clinical
applications, such as approaches to dealing with obesity and also potential therapeutic
uses of adipose stem cells for various disease processes.
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Function of Adipocytes
“Adipose tissue” often refers to white adipose tissue, which generally comprises around
20 percent (with great variation) of human body mass. In many mammals, including
human infants, brown adipose tissue is also present for thermogenic function in the
absence of shivering. Human adults also have remnants of brown adipose tissue,
generally in the neck or upper chest region, but white adipose tissue is the most prevalent
and clinically relevant.

White adipocytes. The majority of white adipose tissue is located either subcutaneously
or viscerally, although small deposits can be found in a variety of locations, from within
the bone marrow to around the epicardium, within joints and in craniofacial pads.
Subcutaneous adipose tissue is located in the hypodermis throughout the body and
especially in regions such as the hips, abdomen, or thighs. Visceral adipose tissue is
packed in between organs of the abdomen, and is thought to be the most clinically
relevant for disease processes such as obesity and type 2 diabetes mellitus. The primary
cell type in white adipose tissue is the white adipocyte.

White adipocytes have a distinctive histological appearance of a single (unilocular) large
lipid droplet surrounded by a thin layer of cytoplasm with a flattened peripheral nucleus.
Multiple hormone and other receptors are present on the surface of white adipocytes; this,
coupled with endogenous adipocyte hormone production, gives white adipose tissue
tremendous endocrine function in addition to its storage capacities. In particular, white
adipocytes play key endocrine roles in energy metabolism and sex hormone levels.
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One way that energy metabolism is regulated is through white adipocytes’ synthesis and
secretion of leptin, a peptide hormone that inhibits appetite in the hypothalamus.
Circulating levels of leptin are proportional to the amount of white adipose tissue in the
body, and leptin resistance has been implicated in obesity. Energy metabolism is also
regulated by the presence of insulin receptors on white adipocytes, which inhibit lipolysis
in the presence of sufficient glucose in the bloodstream.
Sex hormone levels in the body are influenced by white adipocytes’ ability to synthesize
estradiol, via their production of the enzyme aromatase that converts androgens into
estrogen. However, the primary function of the white adipocyte overall is to store lipid.
Lipid content of adipose tissue overall increases with age, due to hypertrophy of white
adipocytes. Although excess energy intake can result in the formation of new adipocytes,
weight loss results in merely shrinkage of existing adipocytes rather than a decrease in
number.

Brown adipocytes

Brown adipocytes have a greater ratio of cytoplasm to lipid content, and multiple smaller
lipid droplets (multilocular) when compared to white adipocytes. The cytoplasm contains
multiple mitochondria, which lend to the brown color of the cell and work to generate
heat via lipid oxidation. Unlike white adipocytes, brown adipocytes express uncouplingprotein 1 (UCP-1), which drives the generation of heat by dissipating the mitochondrial
proton gradient (leading to direct heat production rather than ATP production and
storage). Brown adipose tissue in general also exhibits greater vascularization, due to a
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greater need for oxygen by the mitochondria. Recent research has looked into the
possible expression of UCP-1 by white adipose tissue as a method of combating obesity.

Function of Stromal Vascular Fraction
Preadipocytes

Preadipocytes are fibroblast-like cells derived from mesenchymal stem cells.
Preadipocytes are committed to the adipocyte lineage and are regularly present in adipose
tissue in small quantities, where they serve both to replenish dying adipocytes (adipocyte
turnover is around 10 percent per year) and to increase existing adipocyte numbers when
energy stores are plentiful. Preadipocytes often reside in close proximity to the
vasculature of adipose tissue and express the transcription factor PPAR, which has been
identified as essential to adipogenesis. Preadipocytes require a specific, high-lipid
microenvironment in order to differentiate into adipocytes; however, in the case of
obesity, preadipocyte numbers actually decrease, perhaps as a compensatory mechanism
to prevent excess irreversible adipocyte formation.

One of the factors that allow preadipocytes to maintain stable reservoirs of adipogenesis
is their expression of telomere reverse transcriptase, which prevents the shortening of
telomeres and subsequent DNA degradation over generations of replication. Differing
populations of preadipocytes give rise to brown and white adipocytes, and within white
adipocytes, there are regional differences as well. For example, visceral preadipocytes
take much longer than their subcutaneous counterparts to differentiate and mature into
adipocytes; this may explain the hypertrophy and greater lipid accumulation of visceral
adipocytes.
9

A greater amount of lipids in each adipocyte in turn influences the adipokines (signaling
proteins from adipose tissue) that are secreted, which can have profound clinical effects.
For example, visceral adipocytes secrete much less of the adipokine adiponectin, and this
has been shown to decrease insulin sensitivity and ramp up pro-inflammatory processes
in visceral adipose tissue compared to subcutaneous. Research on how to alter
preadipocyte gene expression, and thereby change adipocyte characteristics, has been
relevant both for obesity and also in potential approaches to treating lipodystrophic
disorders.

Mesenchymal stem cells

From mesodermal origin, mesenchymal stem cells (MSCs) are present in many different
connective tissues, such as within the bone marrow. In the microenvironment of adipose
tissue, MSCs generally differentiate into preadipocytes. However, MSCs can still be
induced to develop into osteogenic, chondrogenic, myogenic, and other lineages, and
have been heralded for their great research potential. Harvested via liposuction, in vitro
studies of processed lipoaspirate (PLA) have yielded MSCs that are being studied for
their use in autologous stem cell transplant. Human adipose tissue shows great potential
for potential stem cell use due to its availability, quantity, and ease of obtainment.

Endothelial progenitor cells

Separate from mesenchymal stem cells, endothelial progenitor cells (EPCs) have been
identified that give rise to adipose tissue vasculature. These EPCs are free-circulating and
bone marrow derived, and usually present in the SVF in small quantities. They contain
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angiogenic and/or hematopoietic cell markers. It has been postulated that in obesity, there
are greater numbers of EPCs trapped in the adipose tissue rather than free to circulate,
and thus angiogenic ability overall is reduced in obese patients. EPCs have also been the
subject of much research recently involving potential transplantation to rebuild vessels
damaged by atherosclerosis and stenosis.

Immune cells

Both T-regulatory immune cells and macrophages are resident to the SVF. The Tregulatory cells (T-regs) are immune suppressive cells formed from the activation of T
cells in the absence of costimulatory signals, and their presence in adipose tissue has
shown to be induced by markers generated from MSCs in adipose. T-regs in turn help
promote the presence of macrophages. The macrophages present in adipose tissue are
interesting in that they possess markers for both pro- and anti-inflammatory processes.
On a surface level, adipose tissue macrophages (ATMs) express markers and receptors
similar to M2-type macrophages, which promote tissue repair. ATMs, like M2
macrophages, can also be induced to secrete anti-inflammatory proteins like IL-10 and
IL-1 receptor antagonist.
However, these same ATMs also secrete inflammatory proteins such as TNF-α, IL-1, and
IL-6 in quantities high enough to offset any anti-inflammatory activity by both the ATMs
and T-regs. It is postulated that the ATM protein secretion is under the regulation of
adipocytes, which also secrete these inflammatory proteins themselves, and both of these
processes contribute to the low-grade inflammatory state often present in obesity.
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Other cells

Vascular and extracellular matrix cells that are present throughout the body are also
found in adipose tissue. Similar to vasculature throughout the body, the vessels of
adipose tissue consist of endothelial and smooth muscle cells. These endothelial cells
include both ordinary endothelial cells like those found elsewhere and also specialized
endothelial cells that appear to be able to induce preadipocyte generation. Fibroblasts also
help secrete collagen and other extracellular matrix components that help form the
structure of adipose tissue.

Overall, many different cells in adipose tissue have vast potential for further research
investigation. Especially with the rise of obesity, there has been a much greater
international interest in learning more about the components of adipose tissue and how
they can be altered. In particular, MSCs and preadipocytes show promise for future use
both in treating obesity and a plethora of other disorders.

Both adipocytes and components of the stromal vascular function are integral parts of
adipose tissue, and understanding their functions will be a critical cornerstone of future
learning.

Further Readings
Esteve, Ràfols M. “Adipose Tissue: Cell Heterogeneity and Functional Diversity.”
Endocrinol Nutr (July 5, 2013).
Majka, S. M., Y. Barak, and D. J. Klemm. “Concise Review: Adipocyte Origins:
Weighing the Possibilities.” Stem Cells (July 2011).
Riordan, N. H., T. E. Ichim, W. P. Min, H. Wang, F. Solano, F. Lara, M. Alfaro, J. P.
Rodriguez, R. J. Harman, A. N. Patel, M. P. Murphy, R. R. Lee, and B. Minev. “Non12

Expanded Adipose Stromal Vascular Fraction Cell Therapy for Multiple Sclerosis.”
Journal of Translational Medicine (April 24, 2009).
Rosen, E. D. and B. M. Spiegelman. “Adipocytes as Regulators of Energy Balance and
Glucose Homeostasis.” Nature (December 14, 2006).
Zeyda, M., D. Farmer, J. Todoric, O. Aszmann, M. Speiser, G. Györi, G. J. Zlabinger,
and T. M. Stulnig. “Human Adipose Tissue Macrophages Are of an Anti-Inflammatory
Phenotype but Capable of Excessive Pro-Inflammatory Mediator Production.”
International Journal of Obesity (London) (September 2007)
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The parenchyma of adipose tissue consists of adipocytes suspended in a connective tissue
matrix, which functions as both a crucial endocrine organ as well as a site for metabolic
activity. Two types of adipose tissue have been identified: brown and white. Brown
adipose tissue (BAT) in humans is present at birth and provides non-shivering heat
generation, while white adipose tissue (WAT) is present in adults and is a highly
metabolic, endocrine organ. Pathology can occur both from adipose tissue deficiency as
well as excess.

Brown Adipose Tissue (BAT)

Non-shivering thermogenesis. Brown adipocytes utilize oxygen and lipids as substrates to
produce heat. The functional thermogenic unit consists of a brown adipocyte maintained
within a structural network of connective tissue with access to a rich blood supply and
innervation. The vascular network serves the BAT by both delivering substrate and
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signaling molecules to the organ as well as carrying away the heat product to the body.
Therefore, access to an ample vascular network is necessary in order to achieve maximal
generation and distribution of the BAT-generated heat. Heat generation is achieved by a
mitochondrial protein known as uncoupling protein-1 (UCP1) or thermogenin. It allows
for combustion of fatty acids in the respiratory chain without the production of ATP;
instead, heat is the form of energy that is released.

Signal transmission. The ventromedial (VML) hypothalamic nucleus of the brain
coordinates information regarding body energy reserves and body temperature. When a
thermogenic demand is sensed by the VML, the information is relayed via the
sympathetic nervous system. The neurotransmitter norepinephrine (NE) is released and
binds β-3 adrenergic receptors in the BAT to trigger an intracellular cascade that
eventually leads to the generation of heat and an increased body temperature.

Thermogenic demand. Pre-adipocytes represent a rapidly accessible stem cell population
that can replicate and differentiate into mature BAT under situations of increased
thermogenic demand.

White Adipose Tissue (WAT)

Steroid hormone metabolism. Adipose tissue serves a crucial role in processing steroid
hormones produced in the adrenal glands and gonads. This processing is referred to as
“tissue-specific pre-receptor steroid hormone metabolism” and is necessary for full
activation or inactivation of the circulating steroid hormones. The enzymes required to
perform this process are extensive and include cytochrome P450-dependent aromatase,

15

3β-hydroxysteroid dehydrogenase (HSD), 3αHSD, 11βHSD1, 17βHSD, 17αhydroxylase, 5α-reductase, and UDP-glucuronosyltransferase 2B15.

Aromatase is an especially important adipose enzyme in that it converts androgens into
estrogens. In postmenopausal women, gonadal synthesis of estrogens becomes
diminished and adipose tissue accounts for all of the circulating estrogen.

Reservoir for energy storage. Despite the large capacity of adipose tissue to secrete
proteins and metabolize steroid hormones, the major secretory product of WAT is fatty
acids. Adipocytes store triglycerides internally as a lipid droplet through an enzymatic
process. First, triacylglycerides absorbed from the diet or synthesized in the liver reach
their storage site (adipose tissue) and are converted into fatty acids via the enzyme
lipoprotein lipase (LPL). They are then combined with the metabolic glucose product
glycerol phosphate to reform triacylglyceride inside the adipocyte. When the cell receives
signals that the body requires use of the free fatty acids for energy, they are then broken
down via an enzyme called hormone sensitive lipase (HSL) that breaks apart the stored
triglycerides to release free fatty acids. HSL responds to hormones such as
catecholamines and glucagon to increase the free fatty acid concentration in the plasma
so that it can be utilized for energy. Therefore, the sympathetic nervous system is a
primary modulator of triacylglycerol breakdown.

Endocrine functions. Adipose tissue as an organ consists of several different tissue types
including adipocytes, connective tissue, nerves, stromovascular cells, and immune cells.
These tissues function in synchrony to express and secrete several hormonal and nonhormonal products including leptin, angiotensinogen, adipsin, acylation-stimulating
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protein, retinol-binding protein, tumor necrosis factor alpha (TNFα), interlukin-6,
plasminogen activator inhibitor-1, adiponectin, complement components, and resistin.
Several of these mediators are discussed below.

Secreted proteins


Leptin is a polypeptide (16-kDa) containing 167 amino acids and has a structural
configuration similar to that of cytokines. Although leptin can be synthesized in
several sites of the body including the stomach, placenta, and mammary glands,
the predominant site of its synthesis is in WAT. The primary role of leptin is to
serve as a messenger to the body that the level of energy is at a sufficient state.
Therefore, adipose tissue mass and nutritional status are the main mediators of
leptin and directly correlate to circulating levels. These levels rapidly decline with
caloric restriction and weight loss. Leptin can also be modulated by other
chemical mediators: it is increased by insulin, steroids, and TNFα, and is
decreased by β3-adrenergic activity, androgens, free fatty acids, growth hormone
(GH), and peroxisome proliferator-activated receptor-γ agonists. Genetically
modified mice that have a recessive knockout of the leptin gene are referred to as
ob/ob mice and are profoundly obese. The lack of circulating leptin leads to an
absent detection of energy sufficiency and causes the mice to eat to excess.
Therefore these mice are often applied as research models for type 2 diabetes.



TNFα is a transmembrane protein (26-kDa) that becomes biologically active after
cleavage. Levels of TNFα positively correlate with obesity and insulin resistance.
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Induction of insulin resistance can be achieved in vitro and in vivo via chronic
TNFα exposure.


Interleukin-6 (IL-6) is similar to TNFα in that it is a cytokine produced by
adipose tissue that also is associated with obesity and insulin resistance, and
circulating levels have been shown to decrease with weight loss. It also serves as
a predictor of type 2 diabetes as well as cardiovascular disease.

Adipose tissue excess (obesity). Associations of obesity are referred to as metabolic
syndrome and are characterized by insulin resistance, hyperglycemia, dyslipidemia,
hypertension, and prothrombotic and proinflammatory states.

Adipose tissue deficiency (lipodystrophy). A deficiency of adipose is also associated with
characteristics of metabolic syndrome.

Further Readings
Cannon, B. and Jan Nedergaard. “Brown Adipose Tissue: Function and Physiological
Significance.” Physiological Reviews, v.84/1 (January 1, 2004).
Kershaw, E. E. and J. S. Flier. “Adipose Tissue as an Endocrine Organ.” Journal of
Clinical Endocrinology and Metabolism, v.89 (2004).
Trayhurn, P. and J. H. Beattie. “Physiological Role of Adipose Tissue: White Adipose
Tissue as an Endocrine and Secretory Organ.” Proceedings of the Nutrition Society,
v.14/3 (2001).
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Adipose tissues play major roles in storage and active regulation of metabolism. In
addition to these functions, adipose tissue has properties that give it potential application
for tissue regeneration or transfer. Adipose may be a source of unique, pluripotent
(possessing the ability to form into cells originating from any of the three germ layers:
ectoderm, mesoderm, endoderm) stem cells. The utilization of stem cells and cytokines
can lead to tissue repair and the regeneration of damaged tissues. Other multipotent
(possessing the ability to differentiate into multiple but limited cell types) progenitor cells
can be drawn in an undifferentiated state. Progenitor cells are considered to have already
committed to differentiation on a specific cellular pathway. There may be fewer political,
legal, and ethical issues with adipose stem and progenitor cells as compared to embryonic
stem cell use.
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Multi-Lineage Potential

Stem cells must have the ability to continually divide (self-renewal), maintain viability
long term, and have the potential to differentiate. Stem cells extracted from bone marrow
(mesenchymal stem cells) have shown multi-lineage potential through extensive study
and have been suggested as alternatives to embryonic stem cells in mesodermal defect
repair and disease management. However, issues with pain, morbidity, and low cell
number during extraction impede the practical use of bone marrow stem cells.

Like stems cells derived from bone marrow, adipose tissue is of mesodermal origin.
Adipose-derived stem cells (ADSCs) can differentiate in vitro (isolated studies in
experimental biology) toward osteogenic (bone), adipogenic (fat), myogenic (muscle),
and chondrogenic (connective tissue) lineages when treated with established lineagespecific factors. Studies have shown that ADSCs show lineage-specific genes to
distinctive cell lines such as osteocytes or myocytes when stimulated to develop into
different cells.

ADSCs can differentiate into adipocytes, chondrocytes, and osteoblasts, a feature known
as multipotency. A single ADSC is also capable of cloning itself and then further
differentiating into multiple lineages, a capacity known as clonogenicity. For example,
human ADSCs show in vitro evidence of differentiation along myocyte lineage pathways.
When cultured with myocyte lineage factors, adipocytes fuse and express protein markers
of skeletal myocyte lineage. This suggests that these cells have the potential to repair
damaged skeletal muscle. ADSCs can also differentiate into osteoblast-like cells by
depositing calcium phosphate mineral into their extracellular matrix and expressing
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osteogenic genes and proteins. Evidence suggests that these cells have the potential to
accelerate repair at fracture sites.

The range of differentiation that ADSCs possess extends beyond bone, muscle, and
connective tissue. There may be possibility of repairing gastrointestinal and urinary tract
smooth muscle defects with ADSCs. Factors can also differentiate these cells along the
cardiac myocyte pathway and may be a source of regeneration for cardiac tissues
damaged from infarction or ischemic injury. Preliminary studies have also implicated
ADSCs in the regeneration of the central and peripheral nervous system following
traumatic injury.

Adhesion proteins associated with hematopoietic stem cells can form on ADSCs, which
can also secrete cytokines (substances secreted by cells of the immune system) and
promote differentiation along the B-cell, T-cell, and myeloid (white blood cell) lineages.
This possible application can extend to conditions that weaken patients’ immune systems
such as those patients undergoing high-dose chemotherapy or suffering from inborn
errors of metabolisms.

Harvesting Adipose-Derived Stem Cells

Adipose tissue is an exciting resource for tissue regeneration and soft tissue repair
because it houses one of the richest reservoirs of stem cells in the human body. Thus,
stem cells collected from adipose tissue do not need to be cultured in order to obtain a
therapeutically vital number of cells. Well-nourished humans store excess calories in
adipose tissue that increase cell volume and expansion of the number of differentiated
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adipose cells, suggesting that adipose tissue progenitor cells exist within adult fat tissue.
ADSCs can also be harvested easily with little harm to the patient through the process of
liposuction, making adipose stem and progenitor cells much more accessible than bone
marrow cells. ADSCs cultured in vitro have shown consistent profiles of cell-surface
proteins, which include adhesion proteins, receptor molecules, surface enzymes, extracellular matrix proteins and glycoproteins, skeletal proteins, hematopoietic (involved in
blood formation) cell markers, complement regulatory proteins, and histocompatibility
antigens (immune system components).

The immunophenotype of ADSCs resemble other adult stem cells from bone marrow and
skeletal muscle. Methods of harvesting the tissue have dramatic effects on the ability of
the cells to proliferate and differentiate in culture. Several studies report a negative
correlation between patient age and the yield of donor cells and proliferation. Many
concerns remain for the standardization and optimization of methods for cell isolation,
culture, and application.

Future Development

ADSCs may prove to be an ideal option for tissue engineering in regenerative medicine
since they are self-renewable, plentiful, and easily accessible through minimally invasive
procedures. Studies suggest that ADSCs can be used in the treatment of type 1 diabetes
mellitus, obesity, cardiovascular disease, lipodystrophy, and neurodegenerative diseases.
For example, ADSCs have the ability to be carriers for gene delivery vehicles through
transduction, the process by which foreign DNA is introduced into another cell through a
viral vector. In surgical application, ADSCs can aid with neovascularization of free fat
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grafts (transplanted adipose tissue). Much more preclinical research and development
must be dedicated to ADSCs before they can be used in treatment. Optimizing methods
to harvest and preserve viable adipose tissue is of vital importance, but patient safety
must be the priority.

Further Readings
Brayfield, C., K. Marra, and J. P. Rubin. “Adipose Stem Cells for Soft Tissue
Regeneration.” Handchir Mikrochir Plast Chir, v.42 (2010).
Gimble, J. M. and F. Guilak. “Adipose-Derived Adult Stem Cells: Isolation,
Characterization, and Different Potential.” Cytotherapy, v.5/5 (2003)
Shen, Jie-fei, Atsunori Sugawara, Joe Yamashita, Hideo Ogura, and Soh Sato.
“Dedifferentiated Fat Cells: An Alternative Source of Adult Multipotent Cells From the
Adipose Tissue.” International Journal of Oral Science, v.3 (2011).
Yarak, Samira. “Human Adipose-Derived Stem Cells: Current Challenges and Clinical
Perspectives.” Anais Brasileiros de Dermatologia, v.85/5 (2010).
Zuk, Patricia A., et al. “Human Adipose Tissue Is a Source of Multipotent Stem Cells.”
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Adipose-derived stem cells, or ASCs, are a unique population of stem cells isolated from
adipose tissue. These multipotent stem cells present an alternative to the widely used
embryonic and hematopoietic stem cell lineages for laboratory and clinical applications
in regenerative medicine. Adipose tissue is abundant in the body and exists in several
forms, including bone marrow, mammary tissue, and mechanical, brown (multilocular),
and white (unilocular) adipose tissues.

Traditional methods of gathering stem cells include the controversial isolation of
embryonic stem cells and the painful process of procuring stem cells from bone marrow.
In contrast to these methods, an efficient manner of isolating and producing reliable stem
cell populations from abundant, easily accessible adipose tissue presents an appealing
alternative for clinical therapeutic applications. Thus far, adipose stem cells have been
shown capable of multipotent mesodermal differentiation, as well as potential
endodermal and ectodermal lineages in vitro.
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Evidence for Adipocyte Precursor Cells

Progressive osseous heteroplasia (POH), a pathologic condition that leads to heterotopic
bone formation within subcutaneous adipose and, eventually, muscle tissue, demonstrates
the presence of adipocytes, osteoblasts, and chondrocytes upon histologic examination of
the resultant lesions. Pathologic evidence from this rare, autosomal-dominant, inherited
genetic defect suggests that ADCs are at least capable of differentiation into the
aforementioned mesodermal lineages. Along with POH, lupus and Paget disease are also
known to present with calcification of subcutaneous adipose, providing further evidence
for the presence of multipotent ASCs within adipose tissue. Additionally, research using
ligand-induced adipogenesis for the chemotherapeutic treatment of liposarcomas suggests
that these cancers may derive from a stem cell progenitor; stimulation by both long-chain
fatty acids and synthetic steroid compounds induces adipocyte formation from
liposarcoma-derived cells. Furthermore, radioactive tracing to measure adipocyte
turnover rates in obese patients indicates a lifespan of six to 15 months for these fully
differentiated adult adipocytes, a value that seems to indicate the presence of a controlled
replacement mechanism of mature cells by resident stem cell–adipocyte precursors.
Evaluation of individuals who have undergone rapid weight loss through either metabolic
or procedural means also supports this concept: Not only do existing adipocytes increase
in volume but new adipocytes emerge in a homeostatic process to maintain a relatively
constant level of adipose tissue within the organism.
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Origin of ASCs

Adipose tissue is abundant in the body and exists in several forms, including bone
marrow, mammary tissue, and mechanical, brown, and white adipose tissues. It is
speculated that ASCs arrive in adipose tissue via distribution of circulating fibroblasts
derived from the bone marrow that then colonize the respective adipose tissues
throughout the body. Transplanted bone marrow-derived fibroblasts similar to the ones
already discussed have been shown capable of differentiating into adipocytes upon proper
chemical stimulation and in the presence of a lipid-rich diet; however, the exact origin
and distribution of ASC populations remains unknown. Regarding the relative abundance
of stem cell populations within the body’s various adipose depots, current evidence
suggests that richer concentrations of progenitor cells exist in the arm and abdomen
relative to samples taken from the thigh or breast. Further studies, along with effective
isolation techniques, are still needed to optimize processes for procuring ASCs in the
most efficient manner from donors.

Cell Isolation From Adipose Tissue

Older methods of isolating cells from adipose tissue involved thoroughly rinsing minced
animal fat pads, digestion with collagenases, and centrifugation to separate the desired
stromal vascular fraction (SVF) that contained the processed lipoaspirate cells within a
heterogeneous mixture. Finally, the plastic-adherent cells within the isolated SVF were
selectively purified on the surface of tissue-culture flasks to enrich the concentration of
adipocyte precursors.
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Researchers are developing more efficient isolation methods that use advances in
liposuction and reconstructive plastic surgery; in this process, plastic surgeons use a
cannula to infuse subcutaneous adipose tissue with an anesthetic-containing saline
solution. The procedure produces aspirations of adipose-tissue fragments containing
viable adipocyte precursors within the SVF. Following collection of tissue samples,
centrifugation at 1,200 G optimizes the ASC fraction recovered from the liposuction
aspirate. However, surgical procedures involving ultrasound-assisted liposuction have
shown adverse effects on the quantity of viable cells abstracted via the procedure. Once
isolated, ASCs double in vitro within two to four days. Since massive quantities of tissue
must be handled to isolate significant quantities of desired cells, methods such as
rotating, temperature-controlled collagenase incubators, and bag-within-a-bag sieves are
being tested to assist in procuring the desired cellular fraction from liposuction aspirate
samples. Thanks to the development of these novel techniques for efficiently isolating
ASCs, larger-scale commercial isolation methods are in development and becoming a
realistic possibility for clinical application.

Purification and Identification

To identify a stem cell, researchers evaluate the presence and absence of various surface
marker proteins, or antigens, which are important for immune recognition by leukocytes.
Studies analyzing the immunophenotype of cells abstracted from liposuction aspirate find
much consistency in the surface markers of these adipose-derived cells, indicating that
there is, in fact, a unique population of adipocyte precursors present within the aspirate.
Among the antigens used to identify stem cell populations, ASCs have been identified as
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positive for CD29, CD34, CD54, CD90, CD105, CD166, and human leukocyte antigen
(HLA)-ABC markers; they are negative for CD31, CD45, CD106, CD146, and HLA-DR
markers. Additionally, ASCs may be purified from the heterogeneous subcutaneous
adipose and vascular fraction SC+VF by exploiting their plastic-adherent characteristic
and their multipotent differentiation potential.

Multipotency of ASCs

It is now well known that adipose-derived stem cells can differentiate into adipocytes,
chondrocytes, and osteoblasts. Not only are they capable of this multipotency, but their
clonogenicity has been established as well. That is, a single ASC has been shown capable
of cloning itself and then further differentiating into multiple lineages, eliminating the
possibility of multiple precursors producing the respective observed lineages. Beyond the
mesodermal tripotency seen in conditions of pathologic calcification, researchers have
more recently successfully induced in vivo ASC differentiation into neurogenic
ectodermal cells consistent with neurons, oligodendrocytes, and Schwann cells. Other
confirmatory studies have elicited ASC commitment to hepatogenic, pancreaticogenic,
myogenic, hematopoietic supporting, and endodermal lineages by targeting various
chemical inductive factors to the cells.

Both endogenous and synthetic chemicals have successfully induced differentiation into
determinate cell lineages. Cardiomyocytes have been induced using the iron transporter,
transferrin, interleukins 3 and 6, as well as vascular endothelial growth factor.
Endothelial cells, on the other hand, result from ASC exposure to basic fibroblast growth
factor, and epidermal growth factor. Differentiation into many cell lineages indicates that
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ASCs contain vast potential, perhaps far wider than that initially suggested by
pathological evidence; it is even theorized that these cells are pluripotent, much like
embryonic stem cells.

Clinical Trials With Therapeutic ASCs

Compared to hematopoietic stem cells, ASCs exhibit greater long-term genetic stability
and are more immunoprivileged (i.e., evidence suggests they are effective at preventing
severe graft-versus-host disease). Therefore, presently, these cells seem potentially safer
and more effective than their adult stem cell counterparts. Currently, dozens of clinical
trials are underway to evaluate their efficacy in various regenerative treatments.
Immunosuppressive studies have shown that ASCs suppress T-cell–mediated immunity
and inflammation while activating regulatory T cells, which downregulate inflammatory
mediators and reduce the tissue response of inflammatory cells. Other clinical trials are
investigating applications in cardiovascular and hepatic disease, type 1 and 2 diabetes,
amyotrophic lateral sclerosis, multiple sclerosis, immunosuppression, limb ischemia, and
bone reconstruction.

Regenerative capacities for lumpectomy patients and perianal fistulas are also being
investigated. Current theories on the mechanism of action for ASCs include the paracrine
secretion of signaling molecules like cytokines or growth factors that would guide the
differentiation of local cells to the necessary type to speed recovery; in the treatment of
ischemia, ASCs may help remove toxins by producing antioxidants and free-radical
scavengers to aid in tissue recovery.

29

While many clinical trials are underway to address the safety and efficacy of ASCs, much
remains to be seen regarding the potential these versatile cells have in therapeutic and
regenerative settings. The vast array of possible treatments being explored will
undoubtedly continue to revolutionize the management of disease.

Further Readings
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Stem Cell Reviews and Reports, v.7/2 (June 2011).
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Human adipose tissue serves as an important endocrine and metabolic organ. Adipose
tissue is a complex tissue composed mainly of mature adipocytes surrounded by a
connective tissue matrix, in addition to stromovascular cells, nerve tissue, and immune
cells. Together, these components play an important role in insulating the body, storing
energy as lipids, and producing and metabolizing hormones. By secreting factors such as
leptin, resistin, estrogen, and cytokines, adipocytes act as the major component of a
highly active endocrine organ that targets various tissues in the body to maintain
homeostasis. A lack or complete absence of adipose tissue (lipodystrophy) or
overproduction of adipose tissue (obesity) can result in metabolic complications such as
type 2 diabetes, insulin resistance, hepatic steatosis, and hypertriglyceridemia. The plastic
nature of adipose tissue, with its regenerative properties and ability to expand and
contract in response to shifts in energy balance, is most evident in the obesity epidemic.
For many years, scientists and clinicians have investigated the development of adipose
tissue at the cellular level; however, with modern biotechnological advances in stem cell
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research, the study of adipogenesis has been focused on the discovery and function of
adipose-derived stem cells (ASCs). Capable of differentiating into cells of
nonmesodermal and mesodermal origin, ASCs serve as an important target for adipose
tissue engineering and regenerative medicine.

Adipose Tissue: A Source of Multipotent Stem Cells

Stems cells are cell populations that possess multilineage potential, self-renewing
capacity, and long-term viability. Originating from the stroma of bone marrow,
mesenchymal stem cells (MSCs) have been widely studied as an example of adult stem
cells that are capable of differentiating into chondrocytes, osteoblasts, adipocytes, and
myoblasts in vivo and in vitro. While MSCs are promising candidates for disease
management and mesenchymal defect repair, the use of MSCs in the clinic has been
limited due to complications associated with morbidity, pain, and low cell count/tissue
volume upon harvest.

In recent years, researchers have focused attention to adipose tissue as an alternative
source of adult stem cells. Much like bone marrow, adipose tissue is derived from
mesenchymal origin and contains an easily isolated stroma. ASCs exhibit stable
proliferation and growth kinetics in culture and in the presence of specific inducing
factors can differentiate into chondrogenic, osteogenic, adipogenic, and myogenic
lineages. Due to the ubiquitous nature of human adipose tissue, large quantities of ASCs
can be easily obtained with little patient discomfort or donor site morbidity.
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The multipotent nature of ASCs is evident in various human pathologies. In children with
progressive osseous heteroplasia (POH), an autosomal dominant genetic defect that
causes ectopic bone formation within subcutaneous adipose depots, chondrocytes and
osteoblasts can be found within colonies of adipocytes. Histologic analysis implies a
tripotent capacity of ASCs to differentiate into cells of chondrogenic, osteogenic, and
adipogenic origin. Obesity also presents additional evidence supporting the presence of
stem cells in adipose tissue. Adipocytes have a turnover rate ranging between 6 and 15
months. While various behavioral, genetic, and epigenetic factors can contribute to
obesity, in vivo studies have demonstrated the existence of stem cell populations that
replace mature adipocytes throughout the lifetime of humans.

Adipose-Derived Stem Cell Isolation

Humans contain five major types of adipose tissue: bone marrow, mammary, mechanical,
brown, and white. Each type of adipose depot serves a unique biological function and
contains a distinct stem cell profile. White adipose tissue contains higher amounts of
multipotent stem cells compared to brown adipose tissue, with subcutaneous depots
providing higher yields of ASCs compared to visceral fat. Within subcutaneous white
adipose tissue, greater numbers of stem cells have been harvested from arm regions
compared to the abdomen, thigh, and breast. ASCs recovered from superficial abdominal
regions were found to be the most resistant to apoptosis. Furthermore, ASCs from
younger donors have demonstrated greater cell adhesion and proliferation compared to
older donors. It has yet to be determined which adipose tissue depot serves as the optimal
location for stem cell recovery.
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Samples of subcutaneous adipose tissue are often obtained from subjects under local
anesthesia. Current methods for isolating ASCs depend on collagenase digestion of tissue
followed by centrifugation to isolate primary adipocytes from the stromal vascular
fraction (SVF). ASCs display morphology similar to fibroblasts, which makes phenotypic
identification difficult, and do not exhibit the intercellular lipid droplets that are found in
adipocytes. Isolated ASCs are grown in monolayer culture utilizing specific cell culture
techniques.

Regeneration, Repair, and Tissue Engineering

Traditionally, rehabilitation of injured or diseased organs and tissues has required tissue
replacement through the use of autologous tissues since the body rejects tissue transplants
with foreign antigen. With advances in modern biotechnology, researchers have placed
an emphasis on developing tissue-engineered substitutes that are better suited in
restoring, maintaining, and improving tissue function. The technology of tissue
engineering involves an interdisciplinary field of physicians, engineers, and scientists
who utilize adult stem cells to be directly implanted into the host or expanded in culture.
In the latter technique, stem cells are differentiated and combined with tissue-engineered
scaffolds and growth factors to develop tissue and organ systems. Tissue engineering can
be used as a tool for transplantation, rehabilitation, and reconstructive surgery.

ASCs have the potential to regenerate and repair different types of tissues through a
variety of mechanisms. ASCs can provide a beneficial impact on diseased or injured
tissues/organs by producing and secreting soluble factors. Some of the growth factors and
cytokines secreted by ASCs include hepatocyte growth factor (HGF), insulin-like growth
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factor (IGF-1), vascular endothelial growth factor (VEGF), tumor necrosis factor (TNFα), fibroblast growth factor (FGF), adiponectin, transforming growth factor-β (TGF-β)
and other angiogenic, anti-apoptotic, and anti-inflammatory factors. Certain soluble
factors can also promote tissue repair and wound healing by recruiting endogenous stem
cells. This newly formed stem cell population acts in a paracrine manner that can be
stimulated to differentiate along the lineage pathway required for tissue repair.

ASCs can act as a viable source of free-radical scavengers, antioxidant chemicals, and
chaperone/heat shock proteins. In injured regions such as ischemic sites, ASCs act in
such a manner to clear the local environment of toxic substances, thereby improving
recovery of surviving cells. Recent studies have demonstrated the capacity for bone
marrow–derived MSCs to deliver mitochondria to injured cells and rescue aerobic
metabolism. Comparable studies on ASCs may uncover a similar potential to contribute
mitochondria.

Therapeutic benefits of ASCs also differ between autologous (derived from the same
individual’s body) and allogenic (derived from genetically dissimilar individual)
transplantation. While autologous ASCs can be beneficial from histocompatibility,
infectious, and regulatory perspectives, it is rare for patients to provide their own
therapeutic cells. Researchers have determined that a human’s ASCs that are passaged in
cell culture, compared to freshly isolated cells, have reduced surface histocompatibility
antigen expression and suppressed immune reactivity when cultured together with
allogenic cells. While this implies that passaged ASCs may not produce a cytotoxic Tcell response when transplanted in vivo, comprehensive testing is required before clinical
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implementation. If proven correct, the use of allogenic ASCs in regenerative medicine
holds the potential to lower costs of cell therapies, to improve availability of stem cells,
and to reduce complications associated with organ and tissue failure.

The Future of ASCs

Deriving stem cells from adipose tissue has proven to be an efficacious, safe, and simple
process with little donor site morbidity. Furthermore, stem cell yields from adipose tissue
are far greater than most stem cell reservoirs in the human body. While they may be
suitable candidates in regenerative medicine, various limitations still remain. One of the
major concerns with the use of ASCs is that very few in vivo clinical trials have been
conducted compared to the large number of in vitro preclinical studies. In addition, many
scientific questions remain unclear. Firstly, the specific transcription factors and key
molecular events that allocate ASCs to a particular lineage have not been identified.
Secondly, evidence implies that the ability for ASCs to differentiate may depend on the
anatomic source and the donor’s age and gender. Furthermore, methods for large-scale
manufacturing with appropriate quality control and quality assurance have yet to be
developed. To fulfill expectations and to determine if ASC-based therapies can be
successfully implemented in treatment, further investigation is required.
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2.6 Adipose: Existing or Potential Regenerative Medicine Strategies
This section is based on an article published in The SAGE Encyclopedia of Stem Cell
Research, Second Edition and reproduced here with permission of SAGE Publications
Inc.

Vyas K, Song K. (2015). Adipose, Existing or Potential Regenerative Medicine
Strategies. In E Bouhassira, Vyas KS (Ed.), The SAGE Encyclopedia of Stem Cell
Research, Second Edition. Vol 1, pp 11-13. Thousand Oaks, CA: SAGE
http://dx.doi.org/10.4135/9781483347660.n6
10.4135/9781483347660.n6

A stem cell is a cell that has the ability to self-renew and differentiate into one or more
types of cells. Therefore, stem cells hold great promise for regeneration and repair of
tissues. Recent study has focused on their use for the treatment of Parkinson disease,
Alzheimer disease, cancer, myocardial infarction injuries, breast reconstruction, diabetes
mellitus, autoimmune diseases, and much more. Unlike the embryologic stem cells that
aroused much controversy, adipose-derived stem cells (ASCs) are derived from adults
and are noncontroversial. Furthermore, research suggests ASCs are a better stem cell
source than the conventional mesenchymal stem cells—the bone marrow stem cells
(BMSCs).

Shift From BMSCs to the ASCs

Historically, BMSCs were the most frequently used mesenchymal stem cell pool.
However, ASCs are more advantageous in several respects. The pool of ASCs is larger
than that of BMSCs. They can be collected by liposuction with local anesthesia, whereas
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bone marrow acquisition is more invasive, requires general anesthesia, and carries a
greater risk for mortality. Furthermore, clinical data show that ASCs have a higher
proliferation rate than BMSCs. ASCs can grow to 90 percent confluence within three
days compared to BMSCs, which can take a week to reach the same mark.

Potential of ASCs

ASCs are multipotent and mesenchymal in origin. Initially, ASCs were studied for
differentiation into chondrogenic, myogenic, and osteogenic cell types. However, further
research showed transdifferentiation capacity extending beyond the traditional
mesenchymal lineage. ASCs are now known to be capable of skeletal myogenesis,
cardiac myogenesis, neurogenesis, and angiogenesis.

ASC use in regenerative therapy involves redirection from normal reparative function to
generation of new tissue in areas that are diseased or received trauma. In addition to their
proliferative capacity, ASCs also decrease inflammation and release growth factors,
allowing focused healing. Their anti-inflammatory nature suggests potential for treating
autoimmune and inflammatory diseases, such as rheumatoid arthritis, inflammatory
bowel disease, and graft-versus-host disease.

Clinical Applications and Published Clinical Trials

ASC therapy is gaining popularity. Most studies report no adverse effects and the
majority of outcomes were beneficial. However, rigorous trials are lacking and most
publications are case reports and noncontrolled studies.
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The clinical applications of ASCs discussed in this article are spinal cord injury; diabetes
mellitus; breast reconstruction and augmentation; facial lipoatrophy; rheumatoid arthritis;
multiple sclerosis; hematologic and immunologic disorders; complex perianal or
enterocutaneous fistulas and tracheomediastinal fistula; bone tissue repair; cardiovascular
disease; cancer; and musculoskeletal regeneration.

Spinal Cord Injury

Stem cells have been studied intensely for spinal cord injury because the damaged axons
and neurotransmitter-producing neurons cannot be regenerated by the human body. As a
result, individuals with spinal cord injury suffer loss of sensory and motor function below
the site of injury. Scientists started working with stem cells with the hope that they would
promote new regeneration of neurons to promote healing. Indeed, in 2011, eight patients
with spinal cord injury who were treated with intravenous infusions of autologous ASCs
were shown to have improved motor function after 12 weeks.

Type 1 Diabetes Mellitus

Type 1 diabetes mellitus occurs because of autoimmune attack on pancreatic cells. The
number of beta islet cells is reduced as a result, leading to decrease in insulin and Cpeptide production. ASCs were studied for their ability to regenerate pancreatic beta islet
cells. In a study of ASC therapy administered to five patients with diabetes, results
showed a 30% to 50% decrease in insulin requirements and increase in serum C-peptide
levels during a follow-up period of 2.9 months. No adverse effects were noted.
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Breast Reconstruction and Augmentation and Facial Lipoatrophy

It should come as no surprise that ASCs have the potential for adipose tissue
regeneration. In 2008, ASCs were used successfully for breast augmentation. Normally,
the body resorbs injections of unprocessed adipose tissues. However, when patients were
injected with a mixture of ASCs and unprocessed adipose tissue, they retained the
volume over the next 12 months. Similar success was shown in facial lipoatrophy.

Autoimmune Diseases

ASCs have potential for treatment of autoimmune diseases. In 2010, there was a case
report of ASC use in a 67-year-old woman with rheumatoid arthritis. She was treated
with autologous ASCs isolated from liposuction; subsequently, she reported reduced joint
pain and stiffness. Additionally, authors measured the levels of rheumatoid factor as a
more objective measurement and noted a decrease after treatment. The patient had no
side effects.

ASCs have also been used for the treatment of multiple sclerosis, another autoimmune
disease. Three patients with multiple sclerosis received intravenous infusions of ASCs,
allogeneic CD34+ cells, and mesenchymal cells. Patients reported significant
improvement of symptoms.
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Hematologic and Immunologic Disorders

Researchers have also studied ASCs for the treatment of graft-versus-host disease,
idiopathic thrombocytopenic purpura, and pure red-cell aplasia. Patients were given
intravenous infusion of allogeneic ASCs. Treatment was successful in graft-versus-host
disease and pure red-cell aplasia; in idiopathic thrombocytopenic purpura, remission was
achieved. However, the effect of ASCs on alloreactivity in patients who have undergone
solid-organ transplantation is not yet known.

Fistulas

Potential use of ASCs for fistulas has been demonstrated in treatment of perianal,
enterocutaneous, and tracheomediastinal fistulas. To study the effect of ASCs on perianal
and enterocutaneous fistulas, the fistulas of the patients were injected with autologous
ASCs mixed with proteinaceous fibrin glue. Results of phase 1 and 2 clinical trials
showed four times the healing compared to the control group. Again, no adverse effects
were reported.

To study the effect of ASCs on a patient with lung cancer-induced tracheomediastinal
fistula, the patient’s fistula was injected with autologous ASCs mixed with fibrin glue.
Epithelialization of the fistula was observed three months later and was completely
closed one year after treatment. This case is particularly encouraging, as fistula
progression into blood vessels occurs frequently and is often fatal. No side effect was
noted.
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Bone Tissue Repair

In 2004, there was a case report on a seven-year-old girl who had a calvarial defect from
a severe head injury. The first attempt at treatment, fixation of calvarial fragments via
titanium miniplates, was unsuccessful. She was then treated with a mixture of autologous
ASCs and autologous bone from the iliac crest. Three months after the surgery, computed
tomography scan confirmed successful calvarial bone formation.

Cardiovascular Diseases and Cancer

Not all studies with ASCs have shown positive results. Study of ASCs for treatment of
acute myocardial infarction and cancer are two examples where results have been
inconsistent.

Musculoskeletal Regeneration (Clinical Study on Animal Models)

Musculoskeletal regeneration is an area of intense research because there is a limited pool
of muscle progenitor cells, called satellite cells. Therefore, ASCs were used as a potential
therapy for muscular disorders. In 2006, intravenous injection of allogeneic ASCs was
shown to restore muscle function in murine muscular dystrophy. Successful use of ASCs
in intervertebral disc regeneration has been also reported. In addition, topical
administration of adipose stem cells on rabbits’ tendons accelerated tendon repair rate
and tensile strength was increased, supporting the transdifferentiation potential of the
ASCs in vivo and in vitro.
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Conclusion

Though their effectiveness is still unproven, treatment with ASCs in regenerative
medicine appears promising. However, their benefit in the treatment of cancer is
particularly weak and presents a major concern, since ASCs secrete cytokines that may
affect cancer metastases. More research is needed for conclusive evidence, and further
work will be required to determine the safety of ASCs.

Likewise, standard protocols for ASC studies do not exist yet. The ideal procedure for
acquiring ASCs, the optimal number of stem cells that should be used for each procedure,
and the safe number of stem cells that can be injected into different organs will have to be
determined.

Further Readings
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2.7 Breast: Cell Types Composing the Tissue
This section is based on an article published in The SAGE Encyclopedia of Stem Cell
Research, Second Edition and reproduced here with permission of SAGE Publications
Inc.

Vyas K, Guidugil T. (2015). Breast, Cell Types Composing the Tissue. In E Bouhassira,
Vyas KS (Ed.), The SAGE Encyclopedia of Stem Cell Research, Second Edition. Vol
1, pp 140-142. Thousand Oaks, CA: SAGE Publications, Inc.
http://dx.doi.org/10.4135/9781483347660.n54
10.4135/9781483347660.n54

This article provides a brief introduction to the cell types that compose human breast
tissue. It focuses on the anatomy of the human breast, the major types of tissues and cells
in breast tissue, and the role stem cells play in normal breast tissue and pathologies.

The human breast is located on the upper ventral region on the body and is a
distinguishing feature of mammals. The breast is part of the skin and, therefore, part of
the integumentary system. Breast tissue is composed of three main types of tissue:
glandular tissue, connective tissue, and adipose tissue. The breast contains no muscle
tissue. These components have various functions in the breast, which will be discussed
further. The breast contains many lobes, which are composed of lobules. The lobules are
composed of the aforementioned adipose tissue. These lobules give the breast its size and
shape. All of these tissues are made up of various cell types that have different functions.
The importance of stem cells in breast tissue is enormous. Breast cancer is the second
leading cause of death for women in the United States, and it is a great concern among
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health care professionals. Therefore, understanding how stem cells operate is critical for
how some breast pathologies are treated. The use of stem cells in regenerative medicine
has become more realistic in the past several years.

Anatomy of Breast Tissue

The base of the breast is attached to the thoracic cavity by the pectoralis muscles. The
space located between the pectoralis muscle and the breast is referred to as the
retromammary space. This space is responsible for providing mobility to the breast. The
next layer of tissue is a layer of fat called adipose tissue, which forms the majority of the
breast. Then the suspensory Cooper’s ligaments extend from the superficial fascia, which
is located on top of the layer of adipose tissue, into the breast to provide support. The
lobules composed of adipose tissue form into a cone shape, which converge into the
nipple. The areola, a dark pigmented area, surrounds the nipple. There are four major
types of tissue in the human breast: epithelium, stroma, adipose tissue, and glandular
tissue. The epithelium lines the surfaces and cavities throughout the body. The stroma is
the connective tissue in the body. Adipose tissue makes up the majority of breast tissue
and is composed of adipocytes (fat cells), preadipocytes, fibroblasts, endothelial cells,
and various immune cells. There are two main types of adipose tissue: white adipose
tissue and brown adipose tissue. The breast is also composed of glandular tissue. The
breast is an apocrine gland that contains many sebaceous glands, which secrete sebum to
waterproof the skin. Another apocrine function of the breast is to produce milk for
infants.
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Introduction to Stem Cells

A stem cell is an undifferentiated cell that is capable of giving rise to more cells of the
same type indefinitely, and from which other types of cells can arise through
differentiation. There are two main types of stem cells: pluripotent stem cells and
multipotent stem cells. Pluripotent stem cells have the ability to differentiate into any of
the three types of germ layers: endoderm, mesoderm, and ectoderm. Multipotent stem
cells have the ability to differentiate into multiple, yet limited cell types. An example of
this is a blood stem cell that can differentiate into lymphocytes, monocytes, or
neutrophils but cannot differentiate into bone cells or heart cells.

Cell Types in Breast Tissue

There are three major epithelial cell types in breast tissue. The epithelial cell types are
basal cells, luminal cells, and myoepithelial cells. The epithelium is composed of luminal
cells and myoepithelial cells. These major cell types express different patterns of keratin
that helps distinguish between them.

Luminal cells

These inner cells are surrounded by myoepithelial cells, which help expel secretions and
assist in the movement of fluid. The luminal cells consist of differentiated cells and also
many types of cells that are in between luminal cells and stem cells.

Basal cells

These outer cells consist mostly of differentiated cells with several mammary stem cells.
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Myoepithelial cells

These cells are sandwiched between the stroma and luminal cells in breast tissue. They
are frequently found in the glandular epithelium and are involved in expelling secretions
from the exocrine glands.

Adipose-Derived Stem Cells (ASCs)

As discussed earlier, adipose tissue is composed of adipocytes, or fat cells. ASCs have
remarkable plasticity and have the ability to differentiate into several different cell types,
including adipocytes, cardiomyocytes, chondrocytes, epidermal cells, endothelial cells,
hepatocytes, myocytes, osteoblasts, cells similar to glial cells, and cells similar to
neurons.

These characteristics make ASCs a very useful type of stem cell. Furthermore, ASCs
have shown the ability to differentiate into cells with angiogenic characteristics since they
are derived from the stromal vascular fraction. The stromal vascular fraction of adipose
tissue is the important portion because it contains a significant amount of preadipocytes,
mesenchymal stem cells, endothelial progenitor cells, and immune cells such as T-cells,
B-cells, mast cells, and macrophages. Also, ASCs have been identified as cells that
secrete growth factors such as insulin-like growth factor (IGF), hepatocyte growth factor
(HGF), pro-angiogenic growth factor, and vascular endothelial growth factor (VEGF).
These characteristics of ASCs make them extremely valuable tools for regenerative
medicine.
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Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells have the ability to differentiate into osteoblasts, chondrocytes,
myocytes, neurons, and adipocytes. MSCs are derived from mesoderm, which forms
connective tissue in the body. However, the MSCs in breast tissue are derived from breast
adipose tissue. These MSCs work to stimulate the growth of tumor cells in breast cancer,
and can make the disease metastasize. MSCs play a role in basal-type cancer by
degrading the extracellular matrix and facilitating the invasion of basal-like cancer cells.
Further research on the role of MSCs in breast cancer progression should be performed.
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Chapter 3: Regulatory Issues Regarding Fat Grafting

This section is based on an article published in Plastic Surgery Pulse and reproduced here
with permission of © 2009 Quality Medical Publishing, Inc.

Vyas KS, Vasconez, H. Regulatory issues regarding fat grafting. Plastic Surgery Pulse
News 2015;7(2).
http://www.plasticsurgerypulsenews.com/21/article_dtl.php?QnCategoryID=193&QnArti
cleID=385&QnCurPage=2 Accessed June 3, 2016.
Autologous fat grafting or lipotransfer is a dynamic and widely accepted modality to
improve functional and aesthetic form for volume loss or deformity due to aging, facial
and body lipodystrophies, congenital anomalies, breast augmentation and reconstruction,
wound healing, and other soft tissue deficiencies. Fat grafting has been praised as the
ideal soft tissue filler due to its abundant supply, low donor site morbidity, versatility,
and biocompatibility. A recent survey of American Society of Plastic Surgery (ASPS)
members reported that 85% of facial aesthetic surgeons used the technique in face-lift
procedures.1 Adipose-derived stem cells (ASCs) within adipose tissue have also
demonstrated efficacy in wound healing and tissue engineering.2 Although fat grafting
has been utilized for over a century, its popularity has markedly increased in recent times.
Notable deviations and abuses from accepted practice have also become more common.

In December 2014, the Food and Drug Administration (FDA) released three guidance
documents that would change the regulation of human cells, tissues, and cellular- or
tissue-based products (HCT/Ps) from adipose tissue, effectively restricting fat grafting
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procedures to a study environment and requiring registration and report manufacturers (in
this case, surgeons). These documents addressed same surgical procedure
exception,3 minimal manipulation of HCT/Ps,4 and HCT/Ps derived from adipose
tissue.5 In the case of fat grafting in breast reconstruction and the use of stromal vascular
fraction (SVF) and adipose-derived stem cells (ASCs), HCT/Ps from adipose tissue
would be considered as biologic drugs, and surgeons would need to apply for premarket
FDA approval and a license.

While the draft guidance is not yet finalized, it does provide the latest report to date of the
FDA's perspective on the use of fat injections in breast reconstruction and the use of
ASCs. A team of ASPS experts has reviewed the guidance documents and drafted a
response to elucidate why these FDA interpretations are misguided.

HCT/Ps
The FDA regulates human cells and tissues to control the spread of communicable
diseases. HCT/Ps are defined as products containing human cells or tissues intended for
implantation, transplantation, infusion, or transfer into a human recipient. Notably,
organs and blood products are regulated through other mechanisms. There are two types
of HCT/P depending on the risk category: 361 (lower-risk) and 351 (higher-risk)
HCT/Ps.
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361 HCT/Ps
A subset of category 361 includes procedures that take place in the same operative
session, which are exempt from FDA regulation, but are guided by laws established by
state medical boards and professional societies. 361 HCT/Ps require registration and
product listing with the FDA. Products fall under this category with the following
conditions. This lower-risk category:


is minimally manipulated (for cells and nonstructural tissue, processing does not
alter the relevant biologic characteristics; for structural tissue, processing does not
alter the original characteristics of the tissue related to the tissue's utility for
reconstruction, repair, or replacement).



is intended for homologous use (that is, the HCT/P performs the same function in
the recipient and the donor).



does not combine cells, tissues, drugs, or devices.



does not have systemic effect or does not depend on metabolic activity of other
living cells for its primary function (or if metabolic, is autologous and for use in a
first- or second-degree relative).

351 HCT/Ps
351 HCT/Ps include drugs and biologics that are under the jurisdiction of FDA regulation
and require a biologic license from the FDA.
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Minimal Manipulation
Defining "minimal manipulation" is an important consideration because regulatory
pathways differ; if the product is more than "minimally manipulated," then the product
must go through the therapeutic "351 HCT/P" category of FDA regulation. Exceptions to
the rule include removal of an HCT/P from an individual and implant of the HCT/P to the
same individual during the same surgical procedure (such as an autologous skin graft
harvested and utilized for burn reconstruction), or licensed products.

The primary function of HCT/Ps in the donor is used to determine whether the function is
structural or nonstructural, and therefore how HCT/Ps should be regulated. The structural
components of adipose tissue include adipocytes and the extracellular matrix.
Decellularized fat tissue-derived extracellular matrix is considered more than minimally
manipulated because processing alters the ability of the tissue to provide structural
function. Manipulation of cells or tissues includes enzymatic digestion, separation of cell
populations, cell culture and expansion, introduction of drugs or growth factors, and
cryopreservation. Processing steps such as rinsing, cleansing, or sizing of the tissue are
exempt.

ASPS has requested that the FDA expand the scope of exemptions to include
centrifugation of lipoaspirate in preparation for fat grafting, morselized cartilage for
grafting, and dilation of a vessel graft using a solution containing a pharmacologic agent,
for example, in free tissue transfer. ASPS has also drafted a response to redefine adipose
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tissue as serving both structural and nonstructural functions, including endocrine,
immune, and regenerative functions, such as in the treatment of radiation dermatitis.

According to the current guidance statements, ASCs derived from the SVF for
reconstruction and repair in the same operative session constitute a biologic drug and
must be approved by the FDA in advance and tested in clinical trials before routine use in
patients. The classification of ASCs as drugs by the FDA would add costs, resources, and
time for surgeons who perform therapies with ASCs.

Homologous Use
Another issue is the definition of "homologous use." Although fat has many functions,
including endocrine, metabolic, and immunologic, the FDA considers fat solely as a
structural tissue that functions to cushion and support other subcutaneous tissues and
defines the breast as having a sole function of lactation. Therefore, decellularizing
adipose tissue eliminates its structural capacity, makes it more than minimally
manipulated, and represents a nonhomologous use when applied to the breast.
Furthermore, any surgeon who wishes to utilize SVF and isolate cells from a structural
tissue must now submit an Investigational New Drug Application (IND) to the FDA and
have an approved Institutional Review Board (IRB) application.

ASPS Response
The ASPS has proposed replacing the concept of "main donor function" to "intended
use." The FDA defines skin with relationship to its external function (as a barrier to
retain moisture and protection from the external environment); however, acellular dermal
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matrix (ADM) is used internally in breast reconstruction. The structural function is
preserved in ADM and should represent homologous use.

ASPS has proposed that the definition of adipose tissue be expanded from solely
structural to both structural and nonstructural, depending on intended use. The breast
should be considered as a structural tissue with important functions in both lactation and
sexual function. ASPS has proposed that fat grafting for breast reconstruction should be
considered for homologous structural use that is only minimally manipulated.
Furthermore, isolation and digestion of SVF from adipose tissue does not alter the
relevant biologic characteristics of individual cells and therefore should be considered
minimal manipulation.

ASPS is also working to secure a meeting with the FDA's Center for Biologics
Evaluation and Research and has addressed the draft guidance documents. The General
Registry of Autologous Fat Transfer (GRAFT) of the Plastic Surgery Foundation (PSF) is
a quality improvement initiative to establish a nationwide web-based registry of fat
grafting for aesthetic and reconstructive breast surgery. Data collection will begin in
October 2015 and will include patient demographics, procedural variables, complications,
and the incidence of new or recurrent breast cancers. This data will be used to clarify the
safety of fat grafting and to establish best practice guidelines.

Plastic surgery leadership, including ASPS and PSF among others, is working to preserve
the future of fat grafting and of our specialty.
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Chapter 4: Autologous Fat Grafting to the Breast: A Systematic Review of Safety,
Efficacy, Satisfaction, and Oncological Outcomes

Summary

Background: There is tremendous interest in the use of autologous fat grafting (AFG)
for aesthetic and reconstructive breast surgery. However, concerns have been raised
regarding its safety and efficacy. The primary objective of this systematic review was to
determine the safety, efficacy, satisfaction, and oncological outcomes of AFG to the
breast.
Methods: A systematic review was undertaken in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.
Electronic databases searched included PubMed, MEDLINE, EMBASE, SCOPUS,
Cochrane Library, and clinical trial registries on autologous fat grafting to breast tissue.
Title and abstract screening and full text assessment undertaken separately by two
independent researchers. Data was extracted and organized in a database. Random effects
models were used to estimate pooled complication rates, breast cancer recurrence rates,
and patient satisfaction. Meta-regression was performed using a random effects model to
determine factors that predicted the outcomes of interest.
Results: A total of 100 articles involving 7,817 patients with a mean follow-up period of
25.8 months (1-156 months) were included. No randomized controlled studies were
found. 2.77 percent of the patients undergoing fat grafting to healthy breast tissue
experienced major complications requiring a surgical intervention or hospitalization. Fat
necrosis was the commonest reported complication (48.16%), biopsy of a subsequent
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breast lump was required in 140 cases. Two patients with breast cancer (0.11%) after
AFG for cosmetic purposes were reported. 137 patients with breast cancer (2.26%) after
AFG for reconstructive purposes were reported. Average breast volume gain ranged from
27.1% to 106% relative to the grafted fat volume.
Conclusions: AFG is a potentially useful aesthetic and reconstructive tool with a
relatively low complication rate. The majority of patients and clinicians are satisfied or
very satisfied with the results. Long term clinical and radiological follow-up is required.

Background
The technique of autologous lipotransfer for cosmetic indications has long been
employed in the field of plastic and reconstructive surgery. Gustav Neuber was amongst
the first to introduce the concept of fat transplantation in 1893 through his work in the
treatment of facial defects with lipofilling [1]. This technique was first adapted for the
breast in 1895 by Czerny for the reconstruction of post-mastectomy defects through the
transplant of an autologous lipoma [2]. In 1987, Bircoll and Novack further improved
upon the practice of fat grafting through the use of autologous lipoaspirate for
transplantation [3]. The procedure is now being used quite frequently for numerous
indications. However, this evolution and rise in employment of the technique through the
years has spawned concerns for safety by practitioners in the field. One such issue is the
concern that autologous adipose stem cells are tumorigenic. Studies have shown, in both
animal and human models, that adipose cells exert a positive regulatory effect on the
proliferation of tumor cell lines [4, 5]. It was suggested by Freese et al., in their
systematic review of the oncological impact of adipose derived stem cells, that these
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adipose cells create an inflammatory tumor microenvironment, encourage angiogenesis,
and possibly differentiate into carcinoma associated fibroblasts [6]. Concerns regarding
the practice of fat grafting were initially not limited solely to the propagation of
oncological transformation. In 1987, the American Society of Plastic Surgeons (ASPS)
issued a report condemning the practice of fat grafting to breast tissue due to the lack of
long-term clinical trials and the possibility that scarring and calcification resulting from
the procedure could interfere with breast cancer diagnosis [7]. Continued research in the
field has resulted in a reversal of the previously recommended moratorium with an
investigation by the ASPS Task Force revealing no evidence of fat grafting impeding
cancer detection or any indication that the procedure stimulates cancer recurrence [8].
However, though this report by the ASPS departed from the previous stance that fat
grafting should be avoided, the task force was unable to make a confident
recommendation due to a paucity of available data. Instead, the authors stated that the
technique is a “promising and clinically relevant research topic” with the need for further
study and investigation.

Due to the requirement for further insight into this procedure, our study was undertaken
to systematically review the literature in order to investigate autologous fat grafting
(AFG) for both reconstructive and cosmetic breast procedures. In order to further
elucidate the efficacy and safety of AFG indicated for both cosmetic breast augmentation
and reconstruction post-mastectomy/breast conserving therapy the rate of complication
occurrence, oncological occurrence, and patient satisfaction resulting from AFG was
analyzed.
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Methods
A Literature search was undertaken in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Electronic databases
searched included PubMed, MEDLINE, Cochrane Library, and clinical trial registries on
autologous fat grafting to breast tissue. Title and abstract screening and full text
assessment was undertaken separately by independent researchers. Data was extracted by
two researchers and organized in a database. Random effects models were used to
estimate pooled complication rates, breast cancer recurrence rates, and patient
satisfaction. Meta-regression was performed using a random effects model to determine
factors that predicted the outcomes of interest.

Variables of Interest
The outcomes of interest in this study were complication events (grouped into those
requiring hospitalization or surgery and those not requiring hospitalization or surgery),
breast cancer recurrence, and patient satisfaction. Satisfaction was determined from
articles explicitly noting subjective patient reports of “good” or “excellent.” Numerical
satisfaction surveys were not included in the analysis. Independent variables extracted for
the analysis were procedure indication (cosmetic or oncological), follow-up time
(months), and mean volume of autologous fat injected (mL).
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Statistical Analysis
The data analysis was divided into two phases. First, random effects models (selected due
to the heterogeneity of study populations) were used to estimate pooled complication
rates, breast cancer recurrence rates, and patient satisfaction rates. A total rate and
individual rates for either cosmetic or oncological subgroups were calculated. Studies
with a sample size of 1 were excluded from the meta-analysis (n=21). Second, metaregression with a random effects model was performed for our outcomes of interest.
Predictor variables included in the model were the independent variables extracted and
any relevant other outcomes, such as complication rates as factors predicting patient
satisfaction. Data were analyzed using Comprehensive Meta-Analysis version 3.0
(Biostat Inc., Englewood, New Jersey, USA).

Results
Out of 100 articles, 7,817 patients with a mean follow-up period of 25.8 months (1-156
months) were analyzed. A mean volume of 166.0 mL of autologous fat per breast was
injected, and average breast volume gain ranged from 27.1% to 106% relative to the
grafted fat volume.

Through meta-analysis, the pooled rate of complications requiring surgical intervention
or hospitalization was 2.62% (n=52 studies, p<0.001). The rate of complications not
requiring hospitalization determined was 8.40% (n=60 studies, p<0.001). Fat necrosis
was the commonest reported complication (48.16%), and biopsy of a subsequent breast
lump was required in 140 cases. The pooled rate of breast cancer complication was

61

2.54% (p<0.001), with an estimated rate in the cosmetic and oncological cohorts of
1.70% and 3.04%, respectively (n=64 studies, p<0.0001). Two patients with breast cancer
(0.11%) after AFG for cosmetic purposes were reported. 137 patients with breast cancer
(2.26%) after AFG for reconstructive purposes were reported. Patient satisfaction rate
determined by meta-analysis was 88.93% for the cosmetic cohort, 80.88% for the
oncological cohort, and 84.72% overall (n=21 studies, p<0.001).

For the meta-regression results, multiple factors were significantly associated with an
effect on complications requiring hospitalization (n=35 studies). Mean volume injected
predicted a slightly higher rate (b=0.005, p=0.010), while post-operative cancer
recurrence (b=-0.094, p=0.006) and cosmetic indication (b=-0.579, p=0.033) predicted a
significantly lower complication rate. None of these factors were significantly associated
with complications not requiring hospitalization or surgical intervention. In the analysis
for patient satisfaction rate (n=16), cosmetic indication was significantly associated with
a lower satisfaction rate (b=-1.515, p=0.044). Mean volume injected and complications,
both requiring and not requiring hospitalization, were not associated with satisfaction
rate. Post-operative cancer recurrence (n=35 studies) was negatively associated with
cosmetic indication (b=-1.673, p=0.001) and complications requiring hospitalization (b=0.109, p=<0.001), while number of follow-up months was a predictor for breast cancer
recurrence (b=0.025, p=0.025). Mean volume of fat injected and complications not
requiring hospitalization were not associated with cancer recurrence.
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Discussion
Many options exist for breast reconstruction after breast cancer therapy and cosmetic
breast augmentation. One of the most popular options for elective breast augmentation in
the past has been implant-based technique. In 2015, the ASPS reported that 279,143
breast augmentations were carried out with the use of these implants. Though a popular
and decidedly common procedure, this technique is not without its own risks and
complications. In a report published by the FDA in 2011, twenty to forty percent of
patients receiving primary augmentation and forty to seventy percent of patients
receiving breast reconstruction via implant procedures required reoperation upon the
breast in the first eight to ten years after the initial operation [9]. In one study of Allergen
silicone implants, rupture was experienced in 10.1% of cases in breast augmentation and
in 27.2% of reconstructions post cancer treatment. Additionally, significant rates of side
effects such as capsular contracture were also reported by the study. Upon analysis of the
data obtained by our review, the overall complication rates for breast augmentation and
breast reconstruction with fat grafting appear to compare favorably with complication
incidences experienced with breast implantation. Our study determined the rate of serious
complications requiring surgery or hospitalization to be 2.62% and the rate of minor
complications to be 8.40%. This result suggests superiority to other reconstruction
methods when compared to a study by Alderman et al. investigating breast reconstruction
complication rates of TRAM and implant based procedures. This study found that
complications occurred in 45.4% of their study population with 31.6% of patients
experiencing major complications [10]. When compared to this study and the reoperation
rates for silicone implant placement cited by the FDA, the use of fat grafting in breast
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augmentation and reconstruction appears to not only be an equivalently safe alternative
technique, but possibly a superior method for these procedures in terms of surgical
complications.

Beyond the surgical and perioperative complications of fat grafting, a major focus of
concern by the medical community has been upon the oncological safety of grafting
adipose tissue to the breast. Numerous studies have indicated a link between adipose
derived stem cells and oncological promotion. One such study found that adipose tissue
contained multiple progenitor cells that encouraged metastasis and cancer growth [11].
Many clinical trials have also been undertaken to investigate this link of autologous
lipotransfer to oncological stimulation in breast tissue. One such study carried out by
Petit et al. investigated the rate of breast cancer recurrence in 59 patients with
intraepithelial neoplasia after undergoing reconstruction with lipofilling [12]. This study
determined that patients undergoing fat grafting experienced an 18% five-year
locoregional recurrence rate compared to a 3% recurrence rate in those patients not
undergoing a lipofilling procedure. While this result did not bode well for the prospects
of fat grafting in breast procedures, other studies have indicated more encouraging
findings. In a study by Kronowitz et al. of 719 breasts reconstructed with lipofilling and
670 without following segmental or total mastectomy indicated for breast cancer
treatment, locoregional recurrence was observed in 1.3% of the cases undergoing
lipofilling and 2.4% of breasts reconstructed without fat grafting [13]. This equated to a
five-year locoregional recurrence rate of 1.6% and 4.1% for the lipofilling and nonlipofilling reconstruction cohorts, respectively. The data compiled by our analysis
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indicated a similar oncologic safety profile with a pooled breast cancer complication rate
of 2.54%, 1.70% in the cosmetic augmentation cohort and 3.04% in the oncological
reconstruction cohort. In contrast to the study by Petit et al., these rates are indicative of a
very low occurrence of malignant stimulation by the transplanted fat grafted to both
healthy and previously cancerous tissue. Based upon these results, it appears that fat
grafting can be employed for breast reconstruction and augmentation purposes without
placing the patient at an overtly elevated risk for the development or recurrence of breast
malignancy.

In addition to exhibiting an acceptable complication and oncological incidence rate, fat
grafting to breast was also shown to result in excellent patient satisfaction based upon our
analysis. Of the patients receiving lipofilling for reconstructive and cosmetic purposes,
satisfaction rates of 80.8% and 88.93% were observed respectively. The pooled
satisfaction rate amongst all patient cohorts was determined to be 84.72% overall (n=21
studies, p<0.001). This level of satisfaction compares favorably to the level of
contentment achieved through the use of implant based procedures. One study of 1529
women receiving breast implants for both cosmetic and reconstructive purposes by
Handel et al. revealed an average satisfaction level of 4.4 out of 5 resulting from breast
augmentation and 4.0 out of 5 for those undergoing reconstruction with implants [14].
Another study of 450 patients receiving saline implants carried out by Cunningham et al.
revealed 93% of patients were satisfied or very satisfied with the result of their breast
augmentation [15]. Based upon these comparisons, fat grafting appears to be nearly as
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efficacious in achieving patient satisfaction following breast augmentation and
reconstruction as implant based techniques.

Conclusions
Based upon the results of the analysis, it appears that autologous fat grafting for the
purposes of breast augmentation and reconstruction is both efficacious and safe.
Oncological and surgical complication rates determined by this study indicate favorable
results when compared to studies of other reconstructive methods. Additionally, patient
satisfaction appears to be non-inferior when compared to implant based techniques.
Currently, it appears the technique of autologous fat grafting is a viable tool for breast
procedures both in the cosmetic and reconstructive setting.

References
1.
2.
3.
4.
5.

6.

7.
8.
9.

Neuber, G.A., Fettransplantation. Chir Kongr Verhandl Deutsche Gesellschaft
für Chirurgie, 1893. 22(66).
Czerny, V., Plastischer Ersatz der Brustdruse durch ein Lipom. Chir Kong
Verhandl, 1895. 2(216).
Bircoll, M. and B.H. Novack, Autologous fat transplantation employing
liposuction techniques. Ann Plast Surg, 1987. 18(4): p. 327-9.
Massa, M., et al., Interaction Between Breast Cancer Cells and Adipose Tissue
Cells Derived from Fat Grafting. Aesthet Surg J, 2016. 36(3): p. 358-63.
Elliott, B.E., et al., Capacity of adipose tissue to promote growth and metastasis
of a murine mammary carcinoma: effect of estrogen and progesterone. Int J
Cancer, 1992. 51(3): p. 416-24.
Freese, K.E., et al., Adipose-derived stems cells and their role in human cancer
development, growth, progression, and metastasis: a systematic review. Cancer
Res, 2015. 75(7): p. 1161-8.
Report on autologous fat transplantation. ASPRS Ad-Hoc Committee on New
Procedures, September 30, 1987. Plast Surg Nurs, 1987. 7(4): p. 140-1.
Gutowski, K.A., Current applications and safety of autologous fat grafts: a report
of the ASPS fat graft task force. Plast Reconstr Surg, 2009. 124(1): p. 272-80.
U.S. Food and Drug Administration Center for Devices and Radiological Health,
FDA Update on the Safety of Silicone Gel-Filled Breast Implants. 2011.

66

10.

11.

12.
13.

14.

15.

16.
17.
18.

19.

20.

21.

22.

23.

24.

25.

Alderman, A.K., et al., Complications in postmastectomy breast reconstruction:
two-year results of the Michigan Breast Reconstruction Outcome Study. Plast
Reconstr Surg, 2002. 109(7): p. 2265-74.
Orecchioni, S., et al., Complementary populations of human adipose CD34+
progenitor cells promote growth, angiogenesis, and metastasis of breast cancer.
Cancer Res, 2013. 73(19): p. 5880-91.
Petit, J.Y., et al., Evaluation of fat grafting safety in patients with intraepithelial
neoplasia: a matched-cohort study. Ann Oncol, 2013. 24(6): p. 1479-84.
Kronowitz, S.J., et al., Lipofilling of the Breast Does Not Increase the Risk of
Recurrence of Breast Cancer: A Matched Controlled Study. Plast Reconstr Surg,
2016. 137(2): p. 385-93.
Handel, N., et al., A long-term study of outcomes, complications, and patient
satisfaction with breast implants. Plast Reconstr Surg, 2006. 117(3): p. 757-67;
discussion 768-72.
Cunningham, B.L., A. Lokeh, and K.A. Gutowski, Saline-filled breast implant
safety and efficacy: a multicenter retrospective review. Plast Reconstr Surg, 2000.
105(6): p. 2143-9; discussion 2150-1.
Li, F.C., B. Chen, and L. Cheng, Breast augmentation with autologous fat
injection: a report of 105 cases. Ann Plast Surg, 2014. 73 Suppl 1: p. S37-42.
Derder, M., et al., The use of lipofilling to treat congenital hypoplastic breast
anomalies: preliminary experiences. Ann Plast Surg, 2014. 73(4): p. 371-7.
Klit, A., P.A. Siemssen, and C.S. Gramkow, Treatment of congenital unilateral
hypoplastic breast anomalies using autologous fat grafting: A study of 11
consecutive patients. J Plast Reconstr Aesthet Surg, 2015. 68(8): p. 1106-11.
Peltoniemi, H.H., et al., Stem cell enrichment does not warrant a higher graft
survival in lipofilling of the breast: a prospective comparative study. J Plast
Reconstr Aesthet Surg, 2013. 66(11): p. 1494-503.
Auclair, E., P. Blondeel, and D.A. Del Vecchio, Composite breast augmentation:
soft-tissue planning using implants and fat. Plast Reconstr Surg, 2013. 132(3): p.
558-68.
Bulgin, D., E. Vrabic, and E. Hodzic, Autologous bone-marrow-derivedmononuclear-cells-enriched fat transplantation in breast augmentation:
evaluation of clinical outcomes and aesthetic results in a 30-year-old female.
Case Rep Surg, 2013. 2013: p. 782069.
Khouri, R.K., et al., Brava and autologous fat transfer is a safe and effective
breast augmentation alternative: results of a 6-year, 81-patient, prospective
multicenter study. Plast Reconstr Surg, 2012. 129(5): p. 1173-87.
Kim, H., E.J. Yang, and S.I. Bang, Bilateral liponecrotic pseudocysts after breast
augmentation by fat injection: a case report. Aesthetic Plast Surg, 2012. 36(2): p.
359-62.
Del Vecchio, D.A., "SIEF"--simultaneous implant exchange with fat: a new
option in revision breast implant surgery. Plast Reconstr Surg, 2012. 130(6): p.
1187-96.
Del Vecchio, D.A. and L.P. Bucky, Breast augmentation using preexpansion and
autologous fat transplantation: a clinical radiographic study. Plast Reconstr
Surg, 2011. 127(6): p. 2441-50.
67

26.
27.
28.

29.

30.
31.
32.
33.
34.
35.

36.

37.

38.
39.
40.
41.
42.
43.
44.

Kamakura, T. and K. Ito, Autologous cell-enriched fat grafting for breast
augmentation. Aesthetic Plast Surg, 2011. 35(6): p. 1022-30.
Veber, M., et al., Radiographic findings after breast augmentation by autologous
fat transfer. Plast Reconstr Surg, 2011. 127(3): p. 1289-99.
Lee, K.S., et al., Sepsis with multiple abscesses after massive autologous fat
grafting for augmentation mammoplasty: a case report. Aesthetic Plast Surg,
2011. 35(4): p. 641-5.
Wang, C.F., et al., Clinical analyses of clustered microcalcifications after
autologous fat injection for breast augmentation. Plast Reconstr Surg, 2011.
127(4): p. 1669-73.
Yang, H. and H. Lee, Successful use of squeezed-fat grafts to correct a breast
affected by Poland syndrome. Aesthetic Plast Surg, 2011. 35(3): p. 418-25.
Delay, E., et al., Lipomodeling of Poland's syndrome: a new treatment of the
thoracic deformity. Aesthetic Plast Surg, 2010. 34(2): p. 218-25.
Talbot, S.G., B.M. Parrett, and M.J. Yaremchuk, Sepsis after autologous fat
grafting. Plast Reconstr Surg, 2010. 126(4): p. 162e-164e.
Yoshimura, K., et al., Progenitor-enriched adipose tissue transplantation as
rescue for breast implant complications. Breast J, 2010. 16(2): p. 169-75.
Ueberreiter, K., et al., [BEAULI--a new and easy method for large-volume fat
grafts]. Handchir Mikrochir Plast Chir, 2010. 42(6): p. 379-85.
Herold, C., et al., [The use of mamma MRI volumetry to evaluate the rate of fat
survival after autologous lipotransfer]. Handchir Mikrochir Plast Chir, 2010.
42(2): p. 129-34.
Mu, D.L., et al., Breast augmentation by autologous fat injection grafting:
management and clinical analysis of complications. Ann Plast Surg, 2009. 63(2):
p. 124-7.
Illouz, Y.G. and A. Sterodimas, Autologous fat transplantation to the breast: a
personal technique with 25 years of experience. Aesthetic Plast Surg, 2009. 33(5):
p. 706-15.
Lazzaretti, M.G., et al., A late complication of fat autografting in breast
augmentation. Plast Reconstr Surg, 2009. 123(2): p. 71e-72e.
Hyakusoku, H., et al., Complications after autologous fat injection to the breast.
Plast Reconstr Surg, 2009. 123(1): p. 360-70; discussion 371-2.
Delay, E., et al., Fat injection to the breast: technique, results, and indications
based on 880 procedures over 10 years. Aesthet Surg J, 2009. 29(5): p. 360-76.
Wang, H., et al., Sonographic assessment on breast augmentation after
autologous fat graft. Plast Reconstr Surg, 2008. 122(1): p. 36e-38e.
Zocchi, M.L. and F. Zuliani, Bicompartmental breast lipostructuring. Aesthetic
Plast Surg, 2008. 32(2): p. 313-28.
Pinsolle, V., et al., Autologous fat injection in Poland's syndrome. J Plast
Reconstr Aesthet Surg, 2008. 61(7): p. 784-91.
Zheng, D.N., et al., Autologous fat grafting to the breast for cosmetic
enhancement: experience in 66 patients with long-term follow up. J Plast Reconstr
Aesthet Surg, 2008. 61(7): p. 792-8.

68

45.

46.
47.
48.

49.

50.
51.

52.
53.

54.
55.

56.

57.

58.

59.
60.
61.
62.

Yoshimura, K., et al., Cell-assisted lipotransfer for cosmetic breast augmentation:
supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg, 2008.
32(1): p. 48-55; discussion 56-7.
Carvajal, J. and J.H. Patino, Mammographic findings after breast augmentation
with autologous fat injection. Aesthet Surg J, 2008. 28(2): p. 153-62.
Coleman, S.R. and A.P. Saboeiro, Fat grafting to the breast revisited: safety and
efficacy. Plast Reconstr Surg, 2007. 119(3): p. 775-85; discussion 786-7.
Pulagam, S.R., T. Poulton, and E.P. Mamounas, Long-Term Clinical and
Radiologic Results with Autologous Fat Transplantation for Breast
Augmentation: Case Reports and Review of the Literature. The Breast Journal,
2006. 12(1): p. 63-65.
Kwak, J.Y., et al., Sonographic findings in complications of cosmetic breast
augmentation with autologous fat obtained by liposuction. J Clin Ultrasound,
2004. 32(6): p. 299-301.
Valdatta, L., et al., A case of life-threatening sepsis after breast augmentation by
fat injection. Aesthetic Plast Surg, 2001. 25(5): p. 347-9.
Castelló, J.R., J. Barros, and R. Vázquez, Giant Liponecrotic Pseudocyst after
Breast Augmentation by Fat Injection. Plastic and Reconstructive Surgery, 1999.
103(1): p. 291-293.
Maillard, G.F., Liponecrotic cysts after augmentation mammaplasty with fat
injections. Aesthetic Plast Surg, 1994. 18(4): p. 405-6.
Horl, H.W., et al., [Autologous injection of fatty tissue following liposuction--not
a method for breast augmentation]. Handchir Mikrochir Plast Chir, 1989. 21(2):
p. 59-61.
Matsudo, P.K.R. and L.S. Toledo, Experience of injected fat grafting. Aesthetic
Plastic Surgery, 1988. 12(1): p. 35-38.
Bircoll, M., Cosmetic Breast Augmentation Utilizing Autologous Fat and
Liposuction Techniques. Plastic and Reconstructive Surgery, 1987. 79(2): p. 267271.
Kaoutzanis, C., et al., Autologous Fat Grafting After Breast Reconstruction in
Postmastectomy Patients: Complications, Biopsy Rates, and Locoregional Cancer
Recurrence Rates. Ann Plast Surg, 2016. 76(3): p. 270-5.
Kim, H.Y., et al., Autologous Fat Graft in the Reconstructed Breast: Fat
Absorption Rate and Safety based on Sonographic Identification. Arch Plast Surg,
2014. 41(6): p. 740-7.
Silva-Vergara, C., et al., Oncological outcomes of lipofilling breast
reconstruction: 195 consecutive cases and literature review. J Plast Reconstr
Aesthet Surg, 2016. 69(4): p. 475-81.
Pinell-White, X.A., et al., Radiographic Implications of Fat Grafting to the
Reconstructed Breast. Breast J, 2015. 21(5): p. 520-5.
Weichman, K.E., et al., The role of autologous fat grafting in secondary
microsurgical breast reconstruction. Ann Plast Surg, 2013. 71(1): p. 24-30.
Al-Kalla, T. and E. Komorowska-Timek, Breast total male breast reconstruction
with fat grafting. Plast Reconstr Surg Glob Open, 2014. 2(11): p. e257.
Biazus, J.V., et al., Immediate Reconstruction with Autologous fat Transfer
Following Breast-Conserving Surgery. Breast J, 2015. 21(3): p. 268-75.
69

63.

64.
65.

66.
67.

68.
69.

70.
71.
72.
73.

74.

75.
76.

77.
78.

79.

Brenelli, F., et al., Oncological safety of autologous fat grafting after breast
conservative treatment: a prospective evaluation. Breast J, 2014. 20(2): p. 15965.
Uda, H., et al., Brava and autologous fat grafting for breast reconstruction after
cancer surgery. Plast Reconstr Surg, 2014. 133(2): p. 203-13.
Bonomi, R., et al., Role of lipomodelling in improving aesthetic outcomes in
patients undergoing immediate and delayed reconstructive breast surgery. Eur J
Surg Oncol, 2013. 39(10): p. 1039-45.
Chaput, B., et al., Recurrence of an invasive ductal breast carcinoma 4 months
after autologous fat grafting. Plast Reconstr Surg, 2013. 131(1): p. 123e-4e.
Ihrai, T., et al., Autologous fat grafting and breast cancer recurrences:
retrospective analysis of a series of 100 procedures in 64 patients. J Plast Surg
Hand Surg, 2013. 47(4): p. 273-5.
Le Brun, J.F., et al., [Quality of life after lipomodelling: retrospective study of 42
patients]. Ann Chir Plast Esthet, 2013. 58(3): p. 222-7.
Beck, M., et al., Evaluation of breast lipofilling after sequelae of conservative
treatment for cancer. European Journal of Plastic Surgery, 2012. 35(3): p. 221228.
Cigna, E., et al., Secondary lipofilling after breast reconstruction with implants.
Eur Rev Med Pharmacol Sci, 2012. 16(12): p. 1729-34.
Doren, E.L., et al., Sequelae of fat grafting postmastectomy: an algorithm for
management of fat necrosis. Eplasty, 2012. 12: p. e53.
Mestak, O. and M. Zimovjanova, [Breast reconstruction by autologous fat
transfer]. Rozhl Chir, 2012. 91(7): p. 373-7.
Parikh, R.P., et al., Differentiating fat necrosis from recurrent malignancy in fatgrafted breasts: an imaging classification system to guide management. Plast
Reconstr Surg, 2012. 130(4): p. 761-72.
Perez-Cano, R., et al., Prospective trial of adipose-derived regenerative cell
(ADRC)-enriched fat grafting for partial mastectomy defects: the RESTORE-2
trial. Eur J Surg Oncol, 2012. 38(5): p. 382-9.
Petit, J.Y., et al., Locoregional recurrence risk after lipofilling in breast cancer
patients. Ann Oncol, 2012. 23(3): p. 582-8.
Petit, J.Y., et al., The oncologic outcome and immediate surgical complications of
lipofilling in breast cancer patients: a multicenter study--Milan-Paris-Lyon
experience of 646 lipofilling procedures. Plast Reconstr Surg, 2011. 128(2): p.
341-6.
Rietjens, M., et al., Safety of fat grafting in secondary breast reconstruction after
cancer. J Plast Reconstr Aesthet Surg, 2011. 64(4): p. 477-83.
Rigotti, G., et al., Determining the oncological risk of autologous lipoaspirate
grafting for post-mastectomy breast reconstruction. Aesthetic Plast Surg, 2010.
34(4): p. 475-80.
Sinna, R., et al., Breast fat grafting (lipomodelling) after extended latissimus dorsi
flap breast reconstruction: a preliminary report of 200 consecutive cases. J Plast
Reconstr Aesthet Surg, 2010. 63(11): p. 1769-77.

70

80.

81.
82.
83.

84.

85.

86.
87.

88.
89.
90.

91.

92.
93.

94.

95.

96.

Delaporte, T., et al., Reconstruction mammaire par transfert graisseux exclusif : à
propos de 15 cas consécutifs. Annales de Chirurgie Plastique Esthétique, 2009.
54(4): p. 303-316.
Fitoussi, A., et al., [Secondary breast reconstruction using exclusive lipofilling].
Ann Chir Plast Esthet, 2009. 54(4): p. 374-8.
Iannace, C., et al., [Coleman lipofilling: experience of an Italian group and
review of the literature]. Chir Ital, 2009. 61(1): p. 67-75.
Kanchwala, S.K., et al., Autologous fat grafting to the reconstructed breast: the
management of acquired contour deformities. Plast Reconstr Surg, 2009. 124(2):
p. 409-18.
Panettiere, P., L. Marchetti, and D. Accorsi, The serial free fat transfer in
irradiated prosthetic breast reconstructions. Aesthetic Plast Surg, 2009. 33(5): p.
695-700.
Amar, O., et al., [Fat tissue transplant: restoration of the mammary volume after
conservative treatment of breast cancers, clinical and radiological
considerations]. Ann Chir Plast Esthet, 2008. 53(2): p. 169-77.
Cotrufo, S., A. Mandal, and E.M. Mithoff, Fat grafting to the breast revisited:
safety and efficacy. Plast Reconstr Surg, 2008. 121(1): p. 339-40.
Delay, E., et al., [Efficacy of lipomodelling for the management of sequelae of
breast cancer conservative treatment]. Ann Chir Plast Esthet, 2008. 53(2): p. 15368.
Missana, M.C., et al., Autologous fat transfer in reconstructive breast surgery:
indications, technique and results. Eur J Surg Oncol, 2007. 33(6): p. 685-90.
Pierrefeu-Lagrange, A.C., et al., [Radiological evaluation of breasts
reconstructed with lipomodeling]. Ann Chir Plast Esthet, 2006. 51(1): p. 18-28.
Spear, S.L., H.B. Wilson, and M.D. Lockwood, Fat Injection to Correct Contour
Deformities in the Reconstructed Breast. Plastic and Reconstructive Surgery,
2005. 116(5): p. 1300-1305.
Sarfati, I., et al., Adipose-tissue grafting to the post-mastectomy irradiated chest
wall: preparing the ground for implant reconstruction. J Plast Reconstr Aesthet
Surg, 2011. 64(9): p. 1161-6.
Losken, A., et al., Autologous fat grafting in secondary breast reconstruction.
Ann Plast Surg, 2011. 66(5): p. 518-22.
Serra-Renom, J.M., J.L. Munoz-Olmo, and J.M. Serra-Mestre, Fat grafting in
postmastectomy breast reconstruction with expanders and prostheses in patients
who have received radiotherapy: formation of new subcutaneous tissue. Plast
Reconstr Surg, 2010. 125(1): p. 12-8.
de Blacam, C., et al., Evaluation of clinical outcomes and aesthetic results after
autologous fat grafting for contour deformities of the reconstructed breast. Plast
Reconstr Surg, 2011. 128(5): p. 411e-418e.
Salgarello, M., G. Visconti, and A. Rusciani, Breast fat grafting with platelet-rich
plasma: a comparative clinical study and current state of the art. Plast Reconstr
Surg, 2011. 127(6): p. 2176-85.
Choi, M., et al., The volumetric analysis of fat graft survival in breast
reconstruction. Plast Reconstr Surg, 2013. 131(2): p. 185-91.

71

97.
98.
99.
100.

101.

102.

103.

104.

105.
106.

107.

108.

109.

Costantini, M., et al., Radiological findings in mammary autologous fat
injections: a multi-technique evaluation. Clin Radiol, 2013. 68(1): p. 27-33.
Hoppe, D.L., et al., Breast reconstruction de novo by water-jet assisted
autologous fat grafting--a retrospective study. Ger Med Sci, 2013. 11: p. Doc17.
Howes, B.H., et al., Autologous fat grafting for whole breast reconstruction. Plast
Reconstr Surg Glob Open, 2014. 2(3): p. e124.
Khouri, R.K., et al., Tissue-engineered breast reconstruction with Brava-assisted
fat grafting: a 7-year, 488-patient, multicenter experience. Plast Reconstr Surg,
2015. 135(3): p. 643-58.
Laporta, R., et al., Breast Reconstruction with Delayed Fat-Graft-Augmented
DIEP Flap in Patients with Insufficient Donor-Site Volume. Aesthetic Plast Surg,
2015. 39(3): p. 339-49.
Longo, B., et al., Total breast reconstruction using autologous fat grafting
following nipple-sparing mastectomy in irradiated and non-irradiated patients.
Aesthetic Plast Surg, 2014. 38(6): p. 1101-8.
Mestak, O., et al., Breast Reconstruction after a Bilateral Mastectomy Using the
BRAVA Expansion System and Fat Grafting. Plast Reconstr Surg Glob Open,
2013. 1(8): p. e71.
Molto Garcia, R., V. Gonzalez Alonso, and M.E. Villaverde Domenech, Fat
grafting in immediate breast reconstruction. Avoiding breast sequelae. Breast
Cancer, 2016. 23(1): p. 134-40.
Riggio, E., D. Bordoni, and M.B. Nava, Oncologic surveillance of breast cancer
patients after lipofilling. Aesthetic Plast Surg, 2013. 37(4): p. 728-35.
Schultz, I., A. Lindegren, and M. Wickman, Improved shape and consistency
after lipofilling of the breast: patients' evaluation of the outcome. J Plast Surg
Hand Surg, 2012. 46(2): p. 85-90.
Seth, A.K., et al., Long-term outcomes following fat grafting in prosthetic breast
reconstruction: a comparative analysis. Plast Reconstr Surg, 2012. 130(5): p.
984-90.
Tissiani, L.A. and N. Alonso, A Prospective and Controlled Clinical Trial on
Stromal Vascular Fraction Enriched Fat Grafts in Secondary Breast
Reconstruction. Stem Cells Int, 2016. 2016: p. 2636454.
Mestak, O., et al., Evaluation of Oncological Safety of Fat Grafting After BreastConserving Therapy: A Prospective Study. Ann Surg Oncol, 2016. 23(3): p. 77681.

72

Table 4-1: Fat grafting for cosmetic augmentation.
Author, Date

73

Cheng Li et
al. 2014[16]
Derder et al.
2014[17]
Klit et al.
2014[18]
Peltoniemi et
al. 2013[19]
Auclair et al.
2013[20]
Bulgin et al.
2013[21]
Khouri et al.
2012[22]
Kim et al.
2012 [23]
Del Vecchio
2012[24]
Del Vecchio
and Bucky
2011[25]
Kamakura et
al. 2011[26]

n

Mean volume
injected/breast (mL)

Surgeries
required

Minor
Complications

Major
Complications

Cancer
Occurrence
Reported

Follow-up time
(months)

105

205 (120 to 250)

1.28

3

0

0

18 (6-72)

10

285 (200-500)

2 (1-4)

1

0

0

68 (60-77)

11

210 (95-370)

1 (1-3)

0

0

0

13 (7-63)

18

292 (180-438)

1

3

0

0

197

NR

1

2

1

0

18-24
5 (1 month to 3.25
years)

1

185

1

0

0

0

12

71

282 (90-600)

1

12

1

0

44

1

NR

NR

0

1

0

42

12

625

1

0

0

0

12

25

220-550

1

0

0

0

6

20

244.9 right breast,
235.1 left

NR

2

0

0

9

74

Veber et al.
2011[27]
Lee et al.
2011[28]
Wang et al.
2011[29]
Yang and lee
2010[30]
Delay et al.
2010 [31]
Talbot et al.
2010[32]
Yoshimura et
al. 2010[33]
Uberreiter et
al. 2010[34]
Herold et al.
2010[35]
Mu et al.
2009[36]
Illouz and
sterodimas
2009[37]
Lazzarettie et
al. 2009[38]
Hyakusoku et
al. 2009[39]

31

200.8 +/-64.8

NR

8

0

0

16

1

250

NR

0

1

0

9

48

50-170

1-4

13

0

0

NR

1

972

4

1

0

0

53

1

161.8

5

0

0

0

12

1

1

0

1

0

1

15

100
R: 268+/-29, L: 259
+/- 39

0

0

0

12

52

184 (120-293)

1
2 in 85%
cases

2

0

0

6

10

(150-293)

1

0

0

0

6

157

90-360

NR

0

9

0

15

439

145 (25-180)

3 (1-5)

129

13

0

12

1

NR

NR

0

1

0

120

12

NR

NR

2

12

0

39

Delay et al.
2009[40]
Wang et al.
2008[41]
Zocchi and
Zuliani
2008[42]
Pinsolle et al.
2008[43]

Zheng et al.
2008[44]

136

NR

NR

10

1

0

12

33

50-60

3 (1-5)

1

0

0

NR

181

375 (160-745)

NR

19

0

0

12

8

96 (25-200)

2.1 (1-5)

0

1

0

NR

1.83

9

2

0

37(13-61)

1

2

0

0

6

40

101 (60-120) into
subq 73 (60-90) into
subglandular tissue
total: 270 mean R:
277+/- 39, L: 268
+/- 48

20

NR

NR

0

0

0

34.5

15

278.6

NR

4

0

2

67

1

NR

NR

1

0

0

156

1

NR

NR

0

1

0

NR

1

NR

NR

0

1

0

NR

66

75
Yoshimura et
al. 2008[45]
Carvajal and
Patino
2008[46]
Coleman and
Sabeiro
2007[47]
Pulagam et al.
2006[48]
Kwak et al.
2004[49]
Valdatta et al.
2001[50]
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Castello et al.
1999[51]
Maillard
1994[52]
Horl et al.
1989[53]
Matsudo and
Toledo
1988[54]
Bircoll and
Novack
1987[3]
Bircoll
1987[55]

1

NR

NR

0

1

0

10

1

NR

NR

0

1

0

36

1

NR

NR

0

1

0

1

21

NR

NR

8

0

0

18

1

100

1

0

0

0

36

1

90

1

0

0

0

30

Major complications described as those requiring hospitalization or additional surgical treatment.

Table 4-2. Fat grafting for reconstruction post surgical breast cancer intervention.
Author,
Date
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n

Mean volume
Injected/breast (mL)

Surgeries
required

Minor
Complications

Major
Complications

Cancer
Occurrence

Follow-up time
(months)

108

50 (15-180)

1.3 (1-4)

1

0

0

20.2 (6.3-57.4)

102

49.3 (10-183)

1-3

18

0

1

NR

195

160 (20-480)

1.6

23

3

10

31

46

29 (10-90)

3.57

NR

NR

3

50.4

100

1.12

0

1

0

18 (12-41)

1

147.8 (22-564)
70, 141, 20 mL in
successive procedures

3

0

0

0

6

20

121 (68-228)

1

6

0

0

20.75 (13-29)

Brenelli et
al. 2014[63]

59

52.3 first, (32.8, 52.8
for second and third
defects)

1.3

3

0

3

34.4 +/-15.3

Uda et al.
2014[64]

14

256 (150-400)

2.3

0

2

0

21 (6-54

Kaoutzanis
et al.
2016[56]
Kim et al.
2014[57]
SilvaVergara et
al. 2016[58]
PinellWhite at al.
2015[59]
Weichman
et al.
2013[60]
Al-Kalla et
al 2014[61]
Biazus et al.
2015[62]

78

Bonomi et
al. 2013[65]
Chaput et al.
2013 [66]
Ihrai et al.
2013[67]
Le Brun et
al. 2013
[68]
Petit et al.
2013[12]
Beck et al.
2012 [69]
Cigna et al.
2012[70]
Doren et al
2012[71]
Mestak and
zimovjanov
a 2012[72]
Parikh et al.
2012[73]

31

247 (80-455)

1.4 (1-2)

3

0

1

21 (6-36)

1

NR
1.57 (15)

NR

NR

1

4

64

NR
38 (10-80) 1st session,
60 for 2nd and third

1

0

2

46.4 SD 21.4

42

80

1.3

NR

NR

0

24.5 (12-192)

59

NR

NR

NR

NR

6

38

10

76.5

1

NR

NR

0

36

20

NR

NR

1

0

0

6

278

50 (5-200)

2

45

0

9

28 (0.56-168)

14

NR

1.4 (1-3)

NR

NR

0

3 to 12

37

42.8+/- 26.0

2.2

39

0

1

12 minimum

Perez-cano
et al.
2012[74]

79

Petit et al.
2012[75]
Petit et al.
2011[76]

Rietjens eta
al. 2011[77]
Rigotti et al.
2010[78]
Sinna et al.
2010[79]
Delaporte et
al. 2009[80]
Delay et al.
2009[40]

1st session 91 (23163), 6 months 81 (22143). Median defect
volume was 100 (35150)
1.35

10

0

0

12

NR

NR

NR

NR

8

26

513
155
oncologi
cal
patients

107.3 (5-400)

1.3

17

1

29

19.2 (1-107)

48 (6-183)

1.2

7

0

1

137

NR

NR

NR

NR

14

18.3 (6-49)
91.2 (37.2229.2)

200

176 (35-405)

1.22

2

6

0

14.5 (4-52)

15

600

3 (2-5)

NR

NR

0

28 (7-49)

734

NR

NR

29

0

0

12 clinical, 120
for oncology

67
321
AFG
group
(642
control
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Fitoussi et
al. 2009[81]
Iannace et
al. 2009[82]
Illouz and
Sterodimas
2009[37]
Kanchwala
et al.
2009[83]
Panettiere et
al. 2009
[84]
Amar et al.
2008[85]
Cotrufo et
al. 2008[86]
Delay et al.
2008[87]

1

NR

NR

NR

NR

NR

12

15

4.1

NR

NR

0

12

381

100
145 (25-180)/ session.
Total mean =540 (25900)

3 (1-5)

NR

NR

0

12

110

31 (18-48)

2

NR

NR

0

21 (6-84)

20

24.5 (8-50)

3.4 (1-7)

0

0

0

17.6 +/-6.7

15

62.3 (30-100)

1

5

0

0

9

42

NR

NR

1

0

0

7

42

1.3

NR

NR

6

20.5

1.1

NR

NR

0

11.7 (1-38.4)

1.1

NR

NR

0

NR

Missana et
al. 2007
[88]

69

154 (43-227)
prosthesis 107, LD
and prosthesis 147.2,
LD 142.5, TRAM
142.1, conservative
treatment 75

Pierrefeulagrange et
al. 2006
[89]

30

164.7 (34-290)

Pulagam et
al. 2006[48]
Spear et al.
2005[90]

Sarfati et al.
2011[91]
Losken et
al. 2011[92]

81

1

NR

1

1

0

0

37

116

4

0

0

28

115 (70-275)

1.1
3 (2-3)
prior to
implant
placemen
t

3

1

0

107

40 (5-150)

12

0

0

150+/-25 1st stage,
150+/-30

1.32
2 fat
grafts (6
cases
required
3rd stage
75 mL)

0

0

0

67

1.63

3

4

0

1 year
2.4 years (5
months-4.1
years)

120 (25 to 231) for
platelet enriched, 115
(21-169)

1.88 fat
alone,
1.82
platelet
group
Total:
1.86

8

0

0

9 months

SerraRenom et al.
2010[93]
65
de Blacam
et al.
2011[94]
49

Salgarello et
al. 2011[95] 42

NR
15 (3 weeks - 7
years)

17 (4 to 34)
8 (1 - 2.5
years)

Choi et al.
2013[96]
90
Costantini et
al. 2013[97] 24
Hoppe et al.
2013[98]
Howes et al.
2014[99]

82

Longo et al.
2014[102]

0

0

0

140 days
1 year
2.6 years (6
months to 3.7
years)

114.8+/-55

2.2

8

0

1

28

159+/-61

4 to 6
(4.15)

6

1

1

1

400

1

0

0

0

3.2
1:761
(74.3%),
2: 181
(7.7%),3:
36
(3.5%)

5

25

6

719

225 (100 to 400)
1-100 (688 70.3%),
101-200 (210 21.5%),
201-300 (55 5.6%),
301-400 18 (1.8%),
401-500 (2 0.2%),
>500 (5 0.3%)

1 year
2.5 years (6
months to 7
years)

NR

NR

26

60

20

211 (169-260)

Mean 1.1

0

0

0

23 (12-34)

21

137 (90-175) non
irradiated per session,
108 (40-160)
irradiated per session

3 non
irradiated
, 5.4
irradiated

0

34.8 (23-52)
non, 17.2 (6-3)
radiation

Khouri et al.
2015[100]
488

Kronowitz
et al.
2016[13]
Laporta et
al.
2015[101]

Group A (40 breasts):
151 (111-216) Group
B (42): 51 (12-72)
Group C (41) 93 (75108)

0

0

83

Mestak et
al.
2013[103]
Garcia et al.
2016[104]
Riggio et al.
2013[105]
Schultz et
al.
2012[106]
Seth et al.
2012[107]
Tissiani and
Alonso
2016[108]
Mestak et
al. 2016
[109]

1
37
60

43
69

840 total to right, 790
left (1: 260,
210/2:280,280/3:300,3
00)
50 (20-80)
47.13, 38.28 2nd sess,
55.12 3rd

40 (6-200)
20 to 50 (absolute
range 20 -200)

3

0

0

0

4

1

11

0

0

12

1.37

NR

NR

6

92.2 (5-132)

1.55 (13)

2

0

0

1.1 (1-4)

1

0

0

6 months or
longer
24.8+/-5.9 fg
group

19

NR

NR

1

3

0

16 month
control, 36 SG

32

NR

NR

NR

NR

2

27 (14-88)

NR: not reported. Major complications described as those requiring hospitalization or additional surgical treatment.

Chapter 5: Autologous Fat Grafting to the Breast: An Institutional Review of
Safety and Oncological Outcomes

Summary:
Background: Autologous fat grafting has been widely used for more than two
decades during breast reconstruction for postmastectomy patients. However, few
studies evaluate clinical outcomes in this patient population. The purpose of this
study was to assess complications, radiographic changes and locoregional cancer
recurrence outcomes in patients undergoing autologous fat grafting after breast
reconstruction in postmastectomy patients.

Methods: We retrospectively reviewed the records of consecutive postmastectomy
patients who underwent autologous fat grafting after breast reconstruction at a
university center over a 10-year period. Patients with at least 3 months of follow-up
were included. Medical records were reviewed for demographics, operative details,
complications, incidence of palpable masses, and/or suspicious breast imaging
findings, and locoregional cancer recurrence. Descriptive statistics were generated.

Results: The records of 124 patients undergoing lipofilling procedures from January
2006 to January 2016 were reviewed. Their ages ranged from 23 to 79 years (mean,
45.77 years). Fat grafts were harvested, processed, and injected using the Coleman
technique. The mean number of fat grafting procedures was 1.50 (range, 1-6) per

84

breast, receiving 97.2 mL of autologous adipose on average during each session. The
most common indication for reconstruction in this study was found to be for aesthetic
correction following mastectomy (90.6 % of patients). Fat grafting was most
commonly used as an adjunctive therapy following initial implant (54.9% of patients)
and flap (43.4% of patients) reconstruction. The time from first oncological surgery to
fat grafting occurred after a mean of 27.51 months and median of 14 months.
Following the completion of fat grafting, patients were followed by a plastic surgeon
for an average of 1.054 months. Twenty-six complications were found to have
occurred, resulting in a complication rate of 21.3% in this population of patients. The
most commonly reported complications were liponecrosis (19.2% of complications)
and infection (15.3% of complications). During oncologic follow up, six patients
were reported to have experienced breast cancer recurrence following autologous fat
grafting for reconstruction resulting in a recurrence rate of 4.8%. Additionally, of the
59 patients with reported radiologic follow up, seven patients exhibited radiological
abnormalities in the post-operative period (11.9%).

Conclusions: In this population of breast cancer patients who had mastectomy with
reconstruction, fat transfer was not associated with a higher risk of cancer recurrence.
Based on these preliminary findings, autologous fat grafting appears to be a relatively
safe procedure for refinement of the reconstructed breast in postmastectomy patients.
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Background:
Mastectomy and breast-conserving surgery are important tools employed in the
treatment of breast cancer. While they are life saving measures for many patients,
these procedures often result in poor aesthetic outcomes. Many methods exist for
post-surgical breast reconstruction to correct defects of oncologic therapy. One such
method is that of autologous fat grafting (AFG). The technique of AFG was first
reportedly utilized in post-mastectomy breast reconstruction by Czerny in 1895
through the use of an autologous lipoma for aesthetic repair [1]. In 1987, Bricoll and
Novack revolutionized the technique through the use of lipoaspiration for the
acquisition of the autologous adipose tissue for radical post-mastectomy
reconstruction [2]. Since this advancement, the practice has increased in popularity
and employment in the field of reconstructive surgery. To this end, AFG often serves
as an adjunctive procedure for the refinement of breast implant and flap-based
reconstructions to improve residual contour and volume deficits [3]. Adipose tissue
itself is ideal for such means as it is soft, formable, autologous, readily available, and
easily harvested [4]. Furthermore, there exists a high level of satisfaction after AFG
among both patients and providers (93.4% and 90.1%, respectively according to a
review by Groen et al.) in part due to the relatively straightforward surgical process,
low complication rate, and aesthetic outcomes associated with the procedure [5]. All
of these factors have contributed to the widespread use of AFG. In fact, a 2013 survey
of members of the American Society of Plastic Surgeons found that 62% of all
respondents commonly used AFG for reconstructive breast surgery [6].
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Despite its popularity, AFG has not always been accepted as an acceptable treatment
option for breast reconstruction. In 1987, the American Society of Plastic and
Reconstructive Surgeons (ASPRS) advised against AFG due to concerns of potential
adverse effects on breast imaging, specifically in screening for breast cancer and
recurrence [7].

Since this original ruling, several studies have shown that AFG is a reasonably safe
option for refinement of breast reconstruction in this patient population. Complication
rates, for example, remain on average between 0.9% and 8% per patient and include
relatively benign occurrences such as donor and recipient site infection, hematoma,
and palpable masses [8-10]. In 2012, the same organization issued a new position
statement, indicating that AFG in postmastectomy breast reconstruction “yields
aesthetic improvement and significant patient satisfaction,” with “relatively low”
complication rates [11]. Despite this new stance, questions still remain about the
overall safety of the technique and impact upon radiological surveillance.

The purpose of this study was to address these concerns and the efficacy of the
procedure through the analysis of clinical complications, radiographic imaging results
and cancer recurrence in postmastectomy patients who underwent AFG after breast
reconstruction.
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Methods:

We retrospectively reviewed the records of consecutive postmastectomy patients who
underwent autologous fat grafting after breast reconstruction at a university center
over a 10-year period (January 2006 to January 2016). Postmastectomy patients who
underwent autologous fat grafting after breast reconstruction with 3 months of
follow-up were identified using the Current Procedural Terminology (CPT) codes
15770, 19361, 19364, 19366, 19367, 19368, 19369, 19380, 20926, S2066, S2067,
and S2068. Medical records (operative reports for oncology and plastic surgery notes,
and follow-up notes from clinic) were reviewed for demographic characteristics,
breast cancer diagnosis and reconstructive and fat grafting operative details. The
indications, location and volume for grafting were also recorded. Data on oncologic
follow-up, fat grafting complications, incidence of palpable masses, and/or suspicious
breast imaging findings, and locoregional cancer recurrence were recorded.

The clinical and demographic characteristics included age (years) at time of breast
reconstruction, indication (cancer or cosmetic), location of cancer (right, left,
bilateral), treatment (immediate, mastectomy, or breast conservative treatment),
histopathology (ductal intraepithelial neoplasia, lobular intraepithelial neoplasia,
invasive ductal carcinoma, invasive lobular carcinoma, other), histologic Grade, pT,
pN, receptors (estrogen, progesterone, Her-2, triple negative), adjuvant therapy
(lymphadenectomy, radiotherapy, chemotherapy, hormonal therapy), and follow up to
oncologist (months).
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The oncologic follow-up and lipofilling operative data included the procedure, type of
breast reconstruction (implant, type of flap, etc), date of AFG case, number of fat
grafting sessions, volume injected in mL (specified left or right and if more than one
time), follow up to plastic surgeon after AFG case (months), time from oncologic
surgery to AFG (months), and if an inpatient or outpatient.

The lipofilling complications included presence and type of complication,
(liponecrosis/oil cyst, prosthesis rupture, hematoma, infection, donor site
complication), breast cancer recurrence and radiographic changes.

Lipofilling technique:

Autologous fat grafting was performed under general anesthesia. Fat was prepared
and grafted according to the standard Coleman technique. After harvest from the
abdomen or flanks, the fat was centrifuged with the resulting oil and serous
components decanted. The processed fat was transferred to 3-mL syringes and
injected using blunt infiltration cannulas, placing a small aliquot of fat with each
withdrawal of the cannula. All 4 surgeons' technique remained consistent throughout
the period of the study.
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Results:

For the purposes of this study, the records of 124 patients undergoing lipofilling
procedures from January 2006 to January 2016 were reviewed. The median age of the
patients at the time of first lipofilling procedure was 45.77 (range 23 to 79 years).
Patients included in this study population received a mean number of 1.5 fat grafting
sessions per breast, receiving 97.2 mL of autologous adipose on average during each
session. The most common indication for reconstruction in this study was found to be
for aesthetic correction following mastectomy (90.6 % of patients). Fat grafting was
most commonly used as an adjunctive therapy following initial implant (54.9% of
patients) and flap (43.4% of patients) reconstruction. The time from first oncological
surgery to fat grafting occurred after a mean of 27.51 months (median=14 months).
Additional clinical and lipofilling data are indicated in Tables 1 and 2, respectively.

Following the completion of fat grafting, patients were followed by a plastic surgeon
for an average of 1.054 months. Twenty-six complications were found to have
occurred, resulting in a complication rate of 21.3% in this population of patients. The
most commonly reported complications were liponecrosis (19.2% of complications)
and infection (15.3% of complications). During oncologic follow up, ten patients
were reported to have experienced breast cancer recurrence following autologous fat
grafting for reconstruction resulting in a recurrence rate of 10.5%. Additionally, of
the 59 patients with reported radiologic follow up, seven patients exhibited
radiological abnormalities in the post-operative period (11.9%).
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Table 5-1 Clinical and Demographic Characteristics
n

%

Left

52

47.3

Right

45

40.9

Bilateral

13

11.8

118

92.9

9

7.1

Mastectomy

60

50.8

Bilateral mastectomy

47

39.8

Lumpectomy

4

3.4

Other / not specified

7

5.9

Ductal intraepithelial neoplasia

28

30.8

Lobular intraepithelial neoplasia

1

1.1

Invasive ductal carcinoma

48

52.7

Invasive lobular carcinoma

5

5.5

Other

9

9.9

I

10

23.2

II

11

25.6

III

22

51.2

Location

Indication
Cancer
Cosmetic
Treatment

Histopathology

Histologic Grade
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pT
1

35

57.4

2

23

37.7

3

1

1.6

4

2

3.3

Positive lymph nodes

30

37.0

Negative lymph nodes

51

63.0

Estrogen

56

65.1

Progesterone

42

48.8

Her-2

18

20.9

Triple Negative

12

14.0

Lymphadenectomy

2

2.3

Radiotherapy

30

34.5

Chemotherapy

65

74.7

Hormonal therapy

28

32.3

pN

Receptors

Adjuvant therapy

92

Table 5-2 Oncologic follow-up and lipofilling data
n

%

Type of Breast Reconstruction
Implant

67

54.9

Flap

53

43.4

Other

2

1.6

Number of fat grafting session (mean)

1.50

Total volume Injected (mean, mL)

97.2

Follow-up to plastic surgeon after FG case (mean,
months)

1.054

Time from oncologic surgery to FG (mean, months)

27.51
(median=14
months)

Inpatient

10

8.1

Outpatient

114

91.9

93

Table 5-3 Lipofilling complications
n

%

Yes

26

21.3

No

96

78.7

Liponecrosis

5

4.1

Oil Cyst

1

0.08

Prosthesis rupture

2

1.6

Hematoma

1

0.08

Infection

4

3.3

Donor site complication

4

3.3

Yes

10 (6
specifically
after AFG)

10.5

No

85

89.5

Yes

7

11.9

No

52

88.1

Complication

If yes, type

Breast cancer recurrence

Radiographic changes
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Discussion:

In recent years, fat grafting has become an oft-used tool for reconstructive procedures
indicated in the repair of defects secondary to oncological breast surgery. Since the
reversal of the previous admonishment of the practice by the ASPS, the technique
greatly increased in frequency of use [11]. The procedure is often employed, as was
the case in this study, as an adjunctive aesthetic procedure following implant or flap
repair to correct residual defects. Due to the popularity and utility of this procedure,
several studies have investigated the safety of this procedure in terms of surgical
complications. In a systematic review of AFG in post mastectomy breast
reconstruction by Agha et al., it was determined that the overall complication rate
observed following AFG procedures was 7.3% [12]. Furthermore, 62% of the
complications in the 35 studies reviewed were found to be due to the relatively benign
condition of liponecrosis. Compared to the complication rate determined by Agha et
al., the complication rate exhibited by the cohort of this study was significantly higher
at 21.3%. Despite this inferior complication rate, the results of our study are
encouraging as a great deal of the complications reported were not significant. In fact,
23.1% of all complications were due to liponecrosis or oil cysts discovered in the
post-operative period. Therefore, this procedure can still be considered to have a
relatively favorable safety profile based upon the data.

In addition to surgical complications, many questions have arisen concerning the
oncological safety of lipofilling. Adipose tissue has previously been discovered to
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promote angiogenesis and create an inflammatory microenvironment, two actions that
are feared to promote tumorogenesis [13]. A recent study of adipose tissue harvested
from healthy human donors found that adipose derived stem cells stimulated the
metastasis of a tumor cell in a mouse host when compared to injection of tumor cells
only [14]. Due to these concerns and discoveries, multiple investigations have been
directed towards the oncological effects of fat grafting to breast tissue. In the review
by Agha et al., the incidence of new or recurrent breast cancer was determined to be
4.4% [12]. A recent study of 195 patients undergoing AFG for breast reconstruction
indicated a similar rate of oncologic occurrence of 5.1% [15]. The occurrence rate
determined in our patient population was found to be 10.5%. The oncological
occurrence determined in this study may be elevated due to the cohort investigated.
Of the patients included in this investigation 34.9% were afflicted with HER-2
positive or triple negative breast cancers, both poor prognostic indicators.
Additionally, 22 patients were found to have grade III carcinomas. Additionally, in
one large study focusing upon the oncological recurrence of breast cancer in 1027
patients with stage I and II disease, the locoregional recurrence rate was found to be
8% [16]. This recurrence rate is similar to that determined in our study, indicating an
acceptable oncological outcome for lipofilling in post-mastectomy patients.
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Chapter 6: Do Stem Cells Have an Effect When We Fat Graft?
Fat Versus Fiction

This section is based on an article published in Annals of Plastic Surgery and reproduced
here with permission of Wolters Kluwer Health Lippincott Williams & Wilkins©

Rinker BD, Vyas KS. Do Stem Cells Have an Effect When We Fat Graft? Ann Plast
Surg. 2016 Jun;76 Suppl 4:S359-63.

Summary: Fat grafting has become a widely accepted modality of soft tissue restoration
and has found applications in many areas of aesthetic and reconstructive plastic surgery.
Numerous claims have been made regarding the regenerative effects of fat grafting on the
recipient bed. The purpose of this paper is to survey the available literature to answer the
question of whether fat grafting has a positive effect on the surrounding tissues. It has
been convincingly demonstrated that fat grafts contain viable adipose-derived stem cells
(ASCs). The fate of these cells is determined by the microenvironment of the recipient
bed, but animal studies have shown that a large fraction of ASCs survive engraftment.
Numerous clinical studies have demonstrated the positive effects of fat grafting on
recipient tissues. Improvement in validated scar scores as well as scar stiffness
measurements have been documented after fat grafting of burn scars. Fat grafting has also
been convincingly demonstrated to improve the quality of irradiated tissues, as measured
by validated clinical scales and staged histology. It is ultimately unclear whether ASCs
are responsible for these effects, but the circumstantial evidence is weighty. Fat grafting
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is effective for volumizing and improving skin quality in the setting of radiation, burns,
and other scars. The observed effects are likely due to ASCs, but the evidence does not
support the routine use of ASC-enriched fat grafts.

Introduction: Autologous fat grafting has become a widely accepted method used by
plastic surgeons to correct soft tissue defects due to its simplicity, versatility, low donor
site morbidity, and biocompatibility. Fat grafts have been used as soft tissue filler to
improve function and aesthetic form after trauma (1), thermal or radiation damage (2),
the correction of congenital anomalies (3) or aging (4). In the aesthetic surgery arena,
they have been used for body and facial contouring (5,6) and breast augmentation.
However, the applicability of autologous fat grafting has been limited by variability in
long-term graft retention, with estimates of the survival rate by volume ranging from 20%
to 80% (7–10).

The recent discovery of multipotent mesenchymal adipose tissue-derived stem cells
(ASCs) in subcutaneous adipose tissue has encouraged the study of their role in
enhancing fat grafts for applications in soft tissue augmentation, tissue engineering, and
wound healing (11). The objective of this review is to evaluate the role of ASCs in
clinical applications of fat grafting, to answer the question, “Do stem cells have an effect
when we perform fat grafting?” Applying the deductive nomological model of logicians,
this question can be addressed by reducing it to its 3 component parts, which are: (1)
Does fat grafting transfer viable stem cells? (2) Does fat grafting induce tissue
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regeneration? (3) Are the stem cells responsible for the observed regenerative effects?
Does Fat Grafting Transfer Viable Stem Cells?

In 2000, Halvorsen et al (12) described the osteogenic differentiation of ASCs, and in
2001, Zuk et al (13) demonstrated adipose tissue as an easily accessible and abundant
source of adult mesenchymal stem cells with multilineage potential. Although ASCs
share many of the characteristics of other mesenchymal stem cells (14), including selfrenewal and multipotency, they can be obtained much more easily and with higher
cellular yield. The ASCs are isolated from the stromal vascular fraction (SVF) of
collagenase-digested adipose tissue. Adipose harvested through direct excision or with
the Coleman technique with centrifugation has been shown to yield the most SVF cells
and ASCs (15). The SVF is a heterogenous population of cells and rich source of ASCs,
preadipocytes, vascular progenitors, fibroblasts, pericytes, macrophages, mast cells, and
lymphocytes (16). Culture of SVF on a tissue culture surface with growth media yields an
adherent and more homogenous population of ASCs that can be expanded in vitro and
differentiated into cells of ectodermal and endodermal lineages, including adipocytes,
osteoblasts, chondrocytes, endothelial cells, neuron-like cells, myocytes, and
cardiomyocytes (12, 17–19).

Factors influencing ASC populations include donor age (20), sex, harvesting and
processing technique, harvest site (21), and other variables; this contributes to
heterogeneity among results and influences complicates direct comparison of studies. The
studies of ASCs in fat grafting must take into consideration patient variability, volume of
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lipoaspirate and recipient site, and the number of SVF and ASCs in the lipoaspirate,
which may account for the differences observed among studies. Some studies conclude
that the lower abdomen or inner thigh are the preferable donor sites for adipose tissue
harvesting due to the relative ease of access and high yield of ASCs (22), although the
current literature does not support a significant difference in the volume or weight of
grafted fat among donor sites (23). A recent systemic review of the literature revealed no
significant difference in outcomes of grafted fat obtained from different donor sites,
donor site preparations, harvesting technique, harvesting cannula size, centrifugation
speed, or when tumescent technique was used. Clinical studies favored fat processed by
centrifugation compared to sedimentation and higher retention was observed with slower
reinjection in less mobile areas (24).

Fat grafting has been used clinically for over 100 years, but the underlying cellular and
molecular mechanisms of the engraftment process remain to be elucidated. Avascular fat
grafts rely on diffusion for survival until revascularization occurs; this results in cell
death with subsequent volume loss, fibrosis, and the development of oil cysts. The cell
survival theory (25) and host replacement theory were the predominant hypotheses of the
engraftment process until Eto et al (26) described the fate of adipocytes based on 3 zones
defined by the local microenvironment and distance from the surface. Within the
peripheral/regenerating zone, adipocytes and ASCs within 300 μM from the surface
survive. Although viability may be preserved in the intermediate/ inflammatory zone,
adipocytes in the central/necrotic zone die within the first 24 hours due to lack of
nutritional diffusion, severe ischemia, necrosis, and graft resorption. The ASCs are more
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resistant to hypoxic conditions (27), however, and survive for up to 3 days to regenerate
the adipose tissue through adipogenesis, angiogenesis, and paracrine effects. More recent
models suggest that recipient adipocytes may be more significant in replacing the
necrotic adipocytes (28). A study using green fluorescent protein mice reveal that
regenerated adipocytes mostly originate from ASCs within the grafted tissue, although
only ASCs located adjacent to the necrotic adipocytes differentiated directly into
adipocytes (29). In contrast, a recent transcriptional analysis of ASCs within grafted fat
transplants demonstrated no changes in adipogenic differentiation, challenging the belief
that ASCs contribute to regenerating adipocytes (30).

Revascularization of the free fat graft is essential to graft survival and is influenced by
ASCs. The ASCs differentiate into endothelial cells in vitro and were once thought to
directly contribute to vasculogenesis after fat transfer (31). Studies of transgenic mice
demonstrate that the neovasculature of fat grafts is derived from the recipient animal,
refuting the direct contribution of ASCs in revascularization (28). The current
predominant hypothesis is that ASCs promote revascularization of ischemic free fat
grafts through the release of proangiogenic paracrine growth factors, including vascular
endothelial growth factor (VEGF), basic fibroblast growth factor, hepatocyte growth
factor, and insulin-like growth factor-1 (32,33). Lipoaspirate supplemented with ASCs
has been shown to improve angiogenesis and long-term graft retention through the
release of these factors (34,35). Thus, ASCs are observed to survive after grafting, and in
fact play a major role in adipocyte survival and differentiation.
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Does Fat Grafting Induce Tissue Regeneration?
Fat grafting was pioneered by Neuber and Czerny, working separately in Germany in the
1890s (36,37). It was used enthusiastically by Gillies, who observed that the
subcutaneous application of “fat parcels” improved the quality of scars. Autologous fat
grafting fell from favor until the 1990s, when Coleman38 developed the technology of
structured fat grafting and observed positive effects on the skin, even in the presence of
severe atrophy and scarring.

Wound repair is a process of inflammation, angiogenesis, tissue development, and
remodeling. Fat grafting has been used as a treatment modality for complex wounds,
burns, and scars due to its influence on the wound healing process, including stimulation
of angiogenesis (39), release of cytokines and growth factors such as transforming
growth factor-β, granulocyte colony-stimulating factor, and VEGF, recruitment of
endogenous stem cells to thewound bed, and by direct differentiation into cells. Fat
grafting has been shown to reduce inflammation and fibrosis, decrease hypertrophic
scarring, and decrease healing time (40–42). Several applications of autologous fat
grafting provide direct evidence for the regenerative effects of the technique.

Scars
Adult stem cells are important for the mobilization and coordination of cells during the
healing process (43). The discovery of ASCs and refinement of the fat grafting and cellbased therapy processes permitted the introduction of large numbers of ASCs into
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targeted treatment areas to improve healing. Local injection of ASCs in a pig model has
been shown to decrease scar size and pliability and improve color through the inhibition
of TGF-β against fibroblasts, decrease activity of mast cells, and increase expression of
matrix metalloproteinases that all contribute to scar remodeling (44). Pallua et al (45)
reported decreased pain, improved scar color, quality, pigmentation, stiffness, and
pliability in patients with facial scars treated with lipofilling.

Radiation-Induced Injury
Fat grafting can reverse chronic skin changes secondary to radiation, and these effects are
likely mediated by ASCs. In an irradiated mouse model, human fat grafts were injected
into the subcutaneous plane of the scalp, resulting in attenuated dermal thickness and
collagen deposition and increased vascularity in the irradiated tissue compared to the
non-irradiated tissue (46). In 2007, Rigotti et al (47) demonstrated improved tissue
wound healing with neovessel formation and significant clinical improvement in breast
cancer patients undergoing repeated transplantation of purified autologous lipoaspirates
for radiationinduced wounds. In 2009, Panettiere et al (48) investigated the effects of fat
grafting on the functional and aesthetic aspects of irradiated reconstructed breasts
compared to control. A significant improvement in all clinical symptoms and aesthetic
scores was achieved in the fat grafting group compared with the control group.

Burns
Fat grafting has also been successful in the management of thermal injury (49) and burn
scars (41). Bruno et al (50) treated half of a scar area with processed lipoaspirate and
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collected biopsies before treatment and at 3 and 6 months after the treatment.
Immunohistochemical evaluation revealed a marked improvement in vascularity, dermal
papillae, and increased collagen organization and elastic fibers with lipofilling. Klinger et
al (51) reported on lipoaspirate treatment in 3 adult patients with hemifacial hypertrophic
scars and keloids from severe burns. The scar was examined through punch biopsy before
and after treatment and at 6-month follow-up revealed new collagen deposition, local
hypervascularity, and dermal hyperplasia with a significant improvement in skin texture
and thickness. Several other clinical studies have reported similar success with the use of
lipoaspirate in the management of burn scars for not only filling soft tissue voids (52) but
also for the resolution of pain and functional improvement. In a study by Klinger et al
(42) of 20 patients with retractile and painful burn scars restricting normal daily activity
and joint mobility, autologous fat graft led to a significant improvement in joint mobility
and scar appearance. Baptista et al (53) described the benefits of autologous fat grafting
for the management of painful burn scars and noted improvement of symptoms in the
majority of patients with no reported complications. Patients with severe burns may
require serial transplantation to overcome underlying structural defects of the fibrotic
tissue.
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Figure 6-1. SVF in cell assisted lipotransfer or tissue culture. Liposuction of
subcutaneous adipose tissue followed by centrifugation yields lipoaspirate. The oil layer
is discarded to reduce the incidence of oil cysts. The SVF, which contains cells such as
pre-adipocytes and adipose-derived stem cells, can be obtained through collagenase
digestion and centrifugation of lipoaspirate. The SVF can be utilized in cell-assisted
lipotransfer or can be cultured in vitro. Adipose-derived stem cells are multipotent and
demonstrate plasticity in culture; these cells can be induced to differentiate into
adipocytes, myocytes, osteoblasts, chondrocytes, endothelial cells, hepatocytes,
hematopoietic cells, and other cell types by exposure to growth factors.
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Figure 6-2. Conventional lipotransfer compared to cell-assisted transfer. In conventional
lipotransfer, preinjection processing is limited to cleansing and centrifugation. In cellassisted lipotransfer, a portion of the lipoaspirate is subjected to enzymatic digestion and
centrifugation to isolate the stromal vascular fraction, which contains adipose-derived
stem cells and other cells thought to improve graft retention. These cells are added to
lipoaspirate to yield a stem cell enriched lipograft.
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Are the Stem Cells Responsible for the Observed Regenerative Effects?
It has not been definitively proven that ASCs are the causative agent for the observed
regenerative effects after fat grafting, rather than the trauma of injection or inflammatory
mediators. However, the circumstantial evidence for ASCs is compelling. The ASCs have
been shown to support tissue regeneration by differentiating to replace defective cells or
through the release of paracrine factors that directly accelerate tissue repair via hostderived cells (54). For example, ASCs secrete several growth factors in response to
hypoxia, including the proangiogenic factor VEGF and anti-inflammatory cytokine
interleukin (IL)-10 (54). The growth factors brain-derived growth factor, glial-derived
growth factor, and nerve growth factor have been shown to augment nerve regeneration.
The secretion of growth factors, such as VEGF, hepatocyte growth factor, insulin-like
growth factor-1, granulocyte colony-stimulating factor, IL-6, and IL-8 can affect
processes such as angiogenesis, wound healing, and/or immunomodulation. These
paracrine effects of ASCs are likely responsible for the observed tissue regeneration after
fat grafting for complex wounds, burns, scars, and radiation-induced skin injury.

Additional circumstantial evidence for ASCs as the regenerative agent in fat grafting is
provided by the observed effects of cell-assisted lipotransfer (CAL) (Fig. 1). Enrichment
of fat grafts with concentrated ASCs through CAL significantly enhances volume
retention (55) and neovascularization and reduces the adverse effects of lipoinjection,
such as fibrosis and cyst formation (31). The CAL been heralded by some as superior to
conventional lipoinjection (31, 56, 57). The specific mechanisms contributing to
improved fat graft volume retention with CAL are not well understood, but it is debated
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thatASCs can differentiate directly into adipocytes and contribute to tissue regeneration
and secrete antiapoptotic factors to reduce the loss of adipocytes (Fig. 2). A more
evidence based hypothesis affirms the role of ASCs in the release of angiogenic growth
factors that promote improved graft vascularization in the hypoxic graft environment
(30). This process has been successful in cosmetic breast augmentation and soft tissue
reconstruction (56, 58–61), facial contouring (62,63) and facial lipoatrophy (56,57,64).

In a clinical trial of patients with craniofacial microsomia, CAL enhanced fat volume
retention for facial recontouring compared with conventional lipoinjection (65). Kølle et
al (66) conducted the first clinical study to assess the effect of lipofilling with fat grafts
enriched with ex vivo expanded ASCs. This triple-blinded placebo-controlled clinical
trial of 10 healthy adults demonstrated improved volume retention in fat grafts enriched
with ex-vivo expanded ASCs compared to conventional fat grafts. However, not all
clinical studies have reported improved graft survival rates with CAL. In 2 studies of
women undergoing breast augmentation with CAL, there was no significant advantage of
CAL over conventional techniques when measured by magnetic resonance imaging at 6
months postoperatively (59,67).

Conclusions
Autologous free fat grafting is a safe and dynamic procedure used by plastic surgeons to
improve functional and aesthetic form for volume loss or deformity for a variety of
indications, including trauma, burn or radiation damage, scars and complex wounds,
congenital anomalies, aging, body and facial contouring, and breast augmentation and
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reconstruction. Current practice for autologous fat grafting for soft tissue reconstruction
or augmentation has been limited by variability in long-term graft retention, resulting in
suboptimal outcomes and repetitive procedures. Evidence-based research suggests that
the SVF and ASCs may improve fat graft survival, largely through angiogenic properties,
although superiority of cell-assisted lipotransfer over conventional lipotransfer has not
been unequivocally demonstrated. The tissue regenerative properties of fat grafts in the
setting of radiation, burns, and scars are likely due to ASCs. High-quality clinical trials to
demonstrate safety and efficacy are necessary to guide the development of protocols for
clinical practice.
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Chapter 7: Profile of Adipose Derived Stem Cells in Obese and Lean Environments:
A Review
Summary
Introduction: Due to the demand of stem cells for applications in regenerative medicine,
new methods of isolating these cells are highly sought. Adipose tissue is a readily
available and non controversial source of multipotent stem cells with low risk to potential
donors. However, donor Body Mass Index (BMI) over 25 has been associated with
altered cellular microenvironment and thus has implications for stem cell efficacy in
recipients. This systematic review explores the existing literature on adipose-derived
stem cells (ASCs) and the effect of donor obesity on cellular function.

Methods: The search term “obesity on adipose derived stem cells” was used to search
Pubmed database. 243 papers were retrieved. Of those, 4 were meta-analyses and 31 were
reviews.
Results: There is agreement on reduced ASC function in response to obesity in terms of
angiogenic differentiation, proliferation, migration, viability and on an altered and
inflammatory transcriptome. Osteogenic differentiation and cell yield do not show
reasonable agreement. Finally, weight loss partially rescues some of the aforementioned
features.
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Conclusions: Generally, obesity reduces ASC stem cell qualities and may have an effect
on their therapeutic value. As weight loss and some biomolecules have been shown to
rescue these qualities, further research should be conducted on methods to return obese
derived ASCs to baseline.

Introduction
The growing field of modern regenerative medicine requires the development of a
reliable source of stem cells for tissue engineering and other medical applications. Stem
cells are characterized by the ability to self-regenerate and also to form multiple types of
terminally differentiated cells. While embryonic stem cells are totipotent in their
differentiation potential, adult stem cells have been found to be multipotent and much
less controversial in their origin. In fact, adipose tissue, which is commonly discarded
after procedures such as liposuction, is an easily accessible and cost effective source of
adult stem cells. These adipose-derived stem cells (ASCs) can then be used in multiple
therapeutic avenues, including healing bone defects, organ repair, vascular regeneration
and increasing fat tissue survival rate [1, 2].

The exploration of adipose derived stem cells (ASCs) as a source of material in
regenerative medicine has raised concerns as to the optimal donor environment. Studies
have shown previously that age adversely affects ASC proliferation and differentiation
potential [3-7]. In addition, gender and anatomic location of extraction play a role in
differentiation capability [6-8]. However, it is important to note that the viability of
adipocytes does not differ between obese and lean individuals in fat taken from the flank,
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inner thigh and lower abdomen [9]. ASCs from fat taken from the omentum also showed
no difference in proliferation as compared with those taken from subcutaneous fat in one
study [7]. However, Cleveland-Donovan et al.10 suggests that subcutaneous ASCs have a
greater capacity for proliferation, differentiation and survival as compared with omental
ASCs due to impairment of the AKT pathway. In addition, according to three studies,
body mass index (BMI) does not influence the concentration of processed lipoaspirate
cells [2, 11, 12]. However, Yu et al [13] suggest a positive correlation between BMI and
yield while van Harmelen et al [14] and Aust et al [15] suggest a negative correlation.
The variable results could partially be explained by the error prone, high subject
variability and protocol dependent nature of quantifying ASCs, as noted by Bakker et al.
[16]. Clinically, the totality of these results suggests age is a strong prognostic factor of
ASC graft usefulness while donor site and gender may also play a role. However, the
effect of BMI on graft utility is clearly an area of contention, especially with respect to
lipoaspirate yield.

Given the fact that many ASCs are extracted from the excess adipose tissue of
overweight (BMI > 25) or obese (BMI > 30) donors, the potential influence of this
microenvironment has become an area of clinical relevance. Healthy adipose tissue is
increasingly seen not only as an energy reservoir, but also as an endocrine organ with a
role in normal metabolic regulation. On the other hand, adipocytes in obese patients have
been proven ‘dysfunctional’ due to their induction of a hypoxic and mildly inflammatory
cellular microenvironment [17, 18].
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The WHO estimates over one billion overweight (BMI > 25) and 300 million obese (BMI
> 30) individuals worldwide. In addition, the prevalence of obesity is increasing, with
over 20% of the United States already falling under that category [19]. With a significant
part of the prospective donor population ASCs experiencing the environment produced
by obesity, substantial efforts have been made to characterize that environment’s effects.

Altered Environment
An important first step in understanding obesity’s effects on ASCs is characterizing the
obesity microenvironment. Obesity is one of the conditions, along with diabetes and
aging, that induces cellular stress in the form of low-level inflammation and storage of
excess lipids [17]. Generally, this is through adipocyte hypertrophy, coinciding with
decreased angiogenesis and lipogenesis [20]. Interestingly, ASCs have been found to not
only promote the generation of inflammatory macrophages, but also to directly
differentiate into these cells [21]. Therefore, the presence of inflammatory cells and
cytokines in the adipose tissue of obese patients may be in large part due to site-specific
mesenchymal ASCs [22, 23]. In addition, obesity increases the level of local and
systemic circulating inflammatory cytokines which encourages migration of macrophages
into the subcutaneous adipose tissue, adding another source to the inflammatory cells
[24]. One of the upregulated cytokines potentially thought to increase this localization of
inflammatory cells is osteopontin [25]. NFkB is shown to be heavily upregulated in obese
ASCs responding to hypoxia, providing another mechanism for the increased
inflammatory response [26].
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Hypoxia has been noted in the white adipose tissue of obese mice, indicated by a 1.7 fold
increase in lactate and an increase in bound pimonidazole, which forms adducts with thiol
in hypoxic environments [18]. The hypoxia is partly due to a decrease in perfusion.
Expectedly, as HIF1A is thought to be a key mediator in the hypoxia response, affecting
cell survival and metabolism, it is decreased in obese ASCs [27].
One study showed that even after bariatric surgery-induced weight loss, the ASCs
isolated from a formerly obese individual’s adipose tissue still showed negative effects on
mitochondrial function. These formerly obese ASCs also remained more pro-adipogenic
despite normal BMI, potentially through epigenetic mechanisms, which may explain the
reason why weight loss is difficult to maintain for many obese patients [20].

Altered Transcriptome Profile
Superficially, many of the surface markers on obese-derived vs lean-derived ASCs are
similar, such as CD29, CD44, CD90 and CD105 [28]. Upon further investigation,
obesity-induced inflammation can in fact cause lasting functional differences in ASCs
from obese donors. One study showed increased mRNA expression of pro-inflammatory
cytokines such as TNF-alpha and IL-6 by obese ASCs, which further caused no clinical
improvement when used in murine models of multiple sclerosis [29]. Additionally, a
study showed strong upregulation of NFkB in response to hypoxia [26].

These results were bolstered by another study in domestic pigs fed an atherogenic diet vs
normally fed controls for 16 weeks. At the end of the study, ASCs in the obese pigs
expressed higher amounts of TNF-alpha, which further correlated in vitro with enhanced
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adipogenic and osteogenic differentiation [30]. Lee et al [31] also showed the
overexpression of chemokines MCP-1 and MIP-1 alpha, and adhesion molecules
fibronectin that respectively attract and retain macrophages to tissue. Further, Nair et al.
showed an upregulation of various inflammatory genes, including IL-8 and CD53 in
ASCs isolated from obese Pima Indian individuals [32]. Finally, several microRNAs
implicated in differentiation and cell senescence are upregulated in obese ASCs [33]. It is
important to note that IL-6, mentioned previously, and IL-8 in high levels are also a cause
of cell senescence [34]. Thus, the preponderance of evidence points to ASCs not only
being influenced by, but contributing to the low grade inflammatory environment
observed in obesity.

Differentiation Potential
ASC, as multipotent cells, have the potential to revolutionize reconstructive surgery by
increasing availability of high demand tissue types. For example, the reconstruction of
craniomaxillofacial defects, whether inherited or acquired, is often limited by the scarcity
of available bone tissue. In one study, ASCs derived from lean human subjects showed an
increased propensity towards osteogenic differentiation as compared to those derived
from obese individuals, both in vitro and in vivo [35]. When the obese ASCs were
supplemented with estradiol, they regained their osteogenic propensity. This contradicts
the previously mentioned Zhu et al study using porcine models of obesity, which showed
increased osteogenic differentiation in obese-derived ASCs that correlated with increased
TNF-alpha expression [30]. The finding also contradicts Yang et al., which showed an
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increase in osteogenic differentiation potency with increasing BMI in human derived
ASCs [12].
Obese-derived ASCs also showed reduced overall differentiation and angiogenic
differentiation potential compared to their lean-derived counterparts, limiting their
efficacy as regenerative tools. [14, 36, 37]. Roldan et al showed that this reduction in
differentiation capacity was associated with dysregulation of Sonic Hedgehog, Wnt and
Notch signaling pathways [33]. Isakson et al. [38] also showed dysregulation of Wnt and
increased TNF-a led to a proinflammatory, macrophage-like phenotype which limited the
normal differentiation capacity of ASCs. Studies also show that obese-derived ASCs
exhibit decreased expression of genes essential to embryogenesis, wound repair and
angiogenesis such as the HOX and T-box genes [28].

Migration Potential
In order to effectively aid wound healing and other regenerative processes, ASCs must be
able to migrate to injured tissue with the aid of chemotactic factors such as SDF-1,
CXCL16 and CXCR4 [39]. Reliably reproducible chemotaxis would potentially even
allow the intravenous delivery of ASCs to distant injury sites within the body [40]. Oñate
et al showed that obese-derived ASCs had significantly lower expression of SDF1 as
compared to lean controls, indicating that obesity may affect the delivery of ASCs to
injured tissue [28]. In contrast, a study showed that when responding to stimuli like
MCP1 and HMGB1, obese human derived ASCs doubled their migration capacity.
However, it was also found that under basal conditions that population has a reduced
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migration capacity as there is no dose dependent response in migration to chemotactic
factors like TNF-A, SDF-1 or IL-8 [37].

Proliferation Potential
The preponderance of studies show ASCs from obese populations display impaired
proliferation potential and decreased cell survival [26, 27, 41]. One study however
showed no significant correlation between BMI and proliferation [2]. Perez at al found a
significantly increased population doubling time in obese derived ASCs as opposed to
lean ASCs in mice and humans [27]. The study also found an increased fraction of preapoptotic cells in obese ASC populations. This could potentially be due to the reduced
telomerase activity and upregulation of p21, increasing DNA instability and apoptosis,
respectively [27].
Obese individuals do not all have the same microenvironment in their tissues; but the
presence of metabolic syndrome is indicative of a certain subset of cells. Oñate et al
reported that only ASCs from patients with metabolic syndrome had a significantly
higher population doubling time than ASCs from normal weight or metabolically healthy
obese patients [36]. Another study by the same group was able to differentiate increasing
degrees of impairment between healthy lean, healthy obese and metabolic syndrome
obese individuals [28]. Metabolic derangement also limits the lifespan of ASCs derived
from obese subjects; in a porcine model of obesity, ASCs showed increased senescence
compared to ASCs from lean pigs [30].
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Weight Loss
As mentioned previously, ASCs isolated from previously obese individuals have been
reported to be pro-adipogenic and maintain negative mitochondrial function. Thus, as
previously obese individuals may be an important source of ASCs, it is important to
characterize ASCs isolated from this environment. Some studies have shown a significant
decrease in inflammatory cytokines [42] and inflammatory cell infiltration [43] in
subcutaneous adipose tissue following weight loss. However, effects on ASCs themselves
have been less encouraging. Mitterberger et al [44] found no change in ASCs isolated
from previously obese populations. Indeed, ASCs from the previously obese group
achieved an adipocytic phenotype faster than those isolated from lean patients [44, 45].
However, Petrangeli et al. [26] noted obese ASCs recover differentiation potential
features after hypoxia and Perez et al. noted that ASCs from formerly obese mice
partially recovered viability [46]. A study also showed ASCs from previously obese
patients had the same osteogenic potential as those from controls [45]. In Perez et al.,
formerly obese ASCs showed partial recoveries to non-obese baseline in proliferation,
cell morphology and migration potential but not live cell fraction or angiogenic potential
[46]. More generally, in a study examining the effects of bariatric surgery in women,
ASCs from previously obese individuals showed the most lipid accumulation and
secreted more MCP-1, an inflammatory cytokine [47]. The data would suggest that
though inflammation is generally reduced following weight loss, ASC differentiation
potential and transcriptome profile do not completely return to baseline.
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Discussion
Metabolic health seems to play a larger role in predicting the performance of ASCs than a
strict BMI cutoff. The presence of this metabolic derangement due to obesity results in an
inflammatory cellular microenvironment, which reduces the proliferation potential of
ASCs. In terms of angiogenic differentiation potential, obesity appears to play a negative
role while in osteogenic potential there is less of a clear relation. This may be an
important distinction for ASCs used in scaffolds and other bone grafts. Additionally,
studies show that obesity may decrease ASC therapeutic value by altering the cell
transcriptome, impairing migration, slowing doubling time and hastening senescence.

Many of these studies rely heavily on animal models of diet-based obesity for a set
amount of weeks. Further research should attempt to more accurately model human
obesity, which is also dependent on stress level, genetics and amount of exercise. This
would more accurately predict the effect of donor obesity on ASCs and thus, the efficacy
of using these cells in regenerative medicine. Further research should also further
elucidate methods by which obese-derived ASCs may be returned to their healthy state,
as some studies found using estradiol, TNF-alpha and weight loss. Based on the current
body of knowledge, it can be assumed that ASCs derived from obese, metabolically
unhealthy donors do not exhibit the same properties and are potentially less
therapeutically valuable as those derived from lean, healthy donors. This should be taken
into account when the ASCs are used for clinical purposes.
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Chapter 8: The Effect of Obesity on Adipose Stem Cell Functionality and Fat Graft
Retention

ABBREVIATIONS:
ADQ: adiponectin
ARS: Alizarin red staining
ASC: Adipose tissue-derived stem cell
BMI: Body mass index
BMSC: Bone marrow-derived stem cell
CFU: Colony-forming unit
DMEM: Dulbecco’s modified Eagle’s medium
FACs: Fluorescence-activated cell sorting
FBS: Fetal bovine serum
HIF-1α: hypoxia inducible factor
LPL: lipoprotein lipase
MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
ORO: Oil-red-O
P/S: penicillin/streptomycin
RT-PCR: real time polymerase chain reaction
RUNX-2: runt-related-transcription factor 2
SVF: stromal vascular fraction
TIE2: tyrosine kinase 2
VEGF: vascular endothelial growth factor
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Summary
Purpose: Fat grafting has become a widely accepted modality of soft tissue restoration
and has found applications in many areas of plastic surgery, such as in breast
reconstruction; however, current practice is plagued by tremendous variability in longterm retention, resulting in suboptimal outcomes and repetitive procedures. Anecdotally,
we have experienced reduced graft retention in obese patients when compared to lean
patients. Adipose-derived stem cells (ASCs) within adipose tissue are thought to
contribute to fat graft survival; this has led to questions about donor conditions, such as
obesity, on ASC function. Our study will determine the impact of obesity on ASC
function as it relates to fat graft retention.
Methods: ASCs were isolated and cultured from the lipoaspirate of female patients who
were undergoing autologous fat grafting at the time of secondary breast reconstruction
and grouped into lean (BMI<30) and obese (BMI>30). ASC yield, viability, growth
kinetics, and capacity for multi-lineage differentiation into adipogenic and osteogenic
lineages were compared in vitro. Adipogenic differentiation was assessed at 1 week of
differentiation with Oil Red O staining and photometric quantification. Early osteogenic
differentiation was assessed at 1 week of differentiation with alkaline phosphatase
staining and quantification. Late osteogenic differentiation was assessed at 2 weeks of
differentiation with Alizarin Red stain in with photometric quantification and
quantification of calcium content. Clinical correlation with serial photographs and
questionnaires from the patients and surgeons were performed to assess retention over
time.
Results: ASCs derived from obese donors exhibited a significantly decreased ability to
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proliferate when compared to ASCs derived from non-obese subjects. Obese patients
were more likely to have graft resorption at the 3 month (p=0.046), 6 month (p=0.003)
and 12 month (p=0.002) visits when compared to non-obese patients. Fat graft retention
also positively correlated to ASC proliferation (r=0.49, p=0.03).
Conclusion: Altered ASC behavior of the obese subcutaneous adipose depot may
contribute to reduced long-term graft retention in obese patients due to diminished
proliferation potential. In addition to other ASC properties, the compromised ability of
ASCs to proliferate in obese subjects should be considered in applications of cell-based
technologies and therapies such as tissue engineering, stem cell banking and fat grafting.

Introduction
Autologous fat grafting is a dynamic and widely accepted modality of soft tissue
restoration in plastic and reconstructive surgery that is used to improve functional and
aesthetic form (1-3) due to its easy accessibility, abundance, and benefits of nonimmunogenicity. Fat grafting refers to the procedure in which fat is harvested by
liposuction from a part of the body where it is unwanted and injected into an area where
it can be used to add volume or correct a contour deformity. Advantages of the technique
include using autologous fatty tissue rather than a foreign body (such as a filler or
implant) and the added benefit of having liposuction to remove fat from an undesirable
location. The concept of fat grafting has been of interest since the inception of whole-fat
grafts in 1893 and became more popular with the advent of liposuction in the 1980s (4),
which enabled the recovery of significant volumes of fat that could be reintroduced into
patients as grafts (5). Since then, hundreds of reports have highlighted the benefits of fat
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transfer for the management of soft tissue defects and contour deformities from trauma
(4), disease (5), congenital defects (6), wound and scars (7), breast reconstruction (8, 9),
and other reconstructive and aesthetic purposes.

In the year 2013 alone, over 95,000 reconstructive breast procedures were performed and
the number of patients seeking breast reconstruction is greatly increasing (1, 10-13).
From 1998 to 2008, the Nationwide Inpatient Sample database registered 178,603
mastectomies and 51,410 immediate breast reconstructions. Breast reconstruction
following mastectomy has benefits on body image, sexuality, self-esteem and quality of
life. Along with implants, fat grafting is a widely utilized modality in breast
augmentation and reconstruction (Figure 8-1). In a recent national survey of plastic
surgeons, 88% who performed fat grafting to the breast reported using it in breast
reconstruction. Autologous fat grafting can modify the size, shape and contour of the
breasts (10, 11), improve the quality of irradiated breast skin (12), and alleviate postmastectomy pain syndrome (13). Fat grafting is a valuable adjunct to other methods of
tissue augmentation and reconstruction, such as implants or complex microvascular tissue
flap procedures (14-17). Ideally, fat grafting could become an alternative to implants in
breast reconstruction (11-13).

Despite the long history of fat grafting, the adoption of autologous fat as the ideal soft
tissue filler is plagued by tremendous variability in long-term graft retention, resulting in
unpredictable results, suboptimal outcomes and repetitive procedures (14-17). In fact,
only about 20-80% of grafted fat remains. The mechanisms contributing to long-term fat
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graft survival and resorption are not well understood. Previous research has attempted to
identify factors that may contribute to variability in fat grafting outcomes, including the
role of adipose-derived stem cells (ASCs), which survive after grafting and promote the
regeneration of adipocytes (Figure 8-2). Several ongoing clinical trials are exploring the
potential of enriching fat grafts with ASCs to promote long-term graft survival,
particularly to the breast. While there is significant interest to understand the role of
ASCs in fat grafting, little is known about the impact of obesity on ASC functionality.
Understanding how obesity affects ASC function may help us to understand why
anecdotally that lean patients have better fat graft retention compared to obese patients.

Obesity (BMI > 30 kg/m2) is a growing epidemic in the United States, affecting more
than 33% of adults. The effects of obesity on the intrinsic cellular properties of ASCs are
still largely unknown, and no study has correlated these variables to fat graft retention
(15-24). We aim to determine the effect of obesity on ASC function (yield, proliferation,
and differentiation) and to correlate in-vitro ASC function with fat graft retention. We
hypothesize that obesity is associated with compromised ASC function and reduced fat
graft retention. Our results may help to define which patients will benefit most from fat
grafting procedures, leading to more predictable fat grafting outcomes and refinement of
future cell-based therapies and regenerative applications utilizing ASCs.

Methods

Donor Selection and Informed Consent
All protocols were reviewed and approved by the University of Kentucky Institutional
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Review Board prior to tissue collection and all subjects provided informed consent.
Patients who had a scheduled consultation for secondary breast reconstruction with fat
grafting with a University of Kentucky plastic surgeon and who were identified by study
personnel as candidates for the study were informed of the opportunity to donate
otherwise discarded lipoaspirate and to participate in the study. Patients were informed
that participation in the study was completely voluntary and that refusal to participate in
the study would not affect medical care. Demographic data on each subject was limited to
age, ethnicity, sex, height, weight, body mass index, medical history and comorbidities,
history of breast cancer, chemotherapy or radiation, operative technique, fat harvest
volume and fat graft volume.

Donor Demographics
Lipoaspirate was obtained with informed consent from subjects undergoing elective
liposuction (n=19). Inclusion criteria comprised female patients ranging in age from 1865 years with a BMI <30 (non-obese) or BMI >30 (obese) who have scheduled
autologous fat grafting using subcutaneous abdominal tissue for secondary breast
reconstruction between January 1, 2012 and January 1, 2016. These criteria were selected
to minimize variables such as sex, age and depot site that may contribute to lipoaspirate
variability. Furthermore, harvesting and processing techniques were standardized. Due to
potential impact on adipose tissue function, we excluded patients with a history of
diabetes mellitus, those on insulin or immunosuppressive drugs such as corticosteroids,
with autoimmune disease, connective tissue disease, hematologic abnormalities, prior or
scheduled chemotherapy and/or radiotherapy, current smokers, pregnant women, and
those with abnormalities of adipose tissue (e.g., lipodystrophy).
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Lipoaspirate Harvesting
Lipoaspirate was harvested by liposuction performed under general anesthesia and sterile
conditions. In all cases, subcutaneous adipose tissue was harvested from the lower
abdominal region utilizing the Coleman technique with a standard harvest cannula on a 5ml syringe under manual suction. The harvested fat was centrifuged in the operating
room (G force-1,006g) to obtain approximately 75 cc of purified fat from each patient
(Figure 8-3). The tissue was sent directly to the research laboratory for stem cell
isolation following centrifugation.

ASC Isolation and Culture
ASCs were processed from fresh human subcutaneous adipose lipoaspirate according to
previously published methods with minor modifications (19). Briefly, lipoaspirate was
rinsed with warm sterile phosphate-buffered solution to remove erythrocytes, followed by
removal of the oil and saline layers. The remaining fat layer was digested with
Dulbecco's Modified Eagle Medium–Low Glucose (DMEM, Life Technologies, Grand
Island, NY) containing 0.15% collagenase type I (Worthington Biochemical, Lakewood,
NJ) for 60 minutes at 37°C on a shaker. After centrifugation (300g) for 5 minutes at room
temperature, the supernatant was aspirated and discarded. The cellular pellet was
resuspended in DMEM with 10% fetal bovine serum (FBS, Walkersville, MD), 1%
Antibiotic/Antimycotic and 1% Penicillin-Streptomycin, then filtered through a 100- and
40-µm strainer and centrifuged at 300g for another 5 min. The supernatant was again
discarded. The cell pellet was then re-suspended in red cell lysis buffer and centrifuged
before re-suspending the SVF in complete medium and cultured in plates that were
maintained in a humid atmosphere of 5% carbon dioxide/95% air at 37°C. Cultures were
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washed every day with warm PBS and maintained in stromal medium until 90%
confluent. Primary isolated ASCs derived from each individual donor were compared
before the first passage. ASCs were evaluated under phase contrast microscopy (Olympus
CKX41) after primary isolation. The adherent population was then harvested by digestion
with trypsin (0.05%)/EDTA (1 mM) at 37°C for five minutes, washed in stromal medium
and replated at 5 × 103 ASCs per sq cm (Passage 1) or cryopreserved for future use.

Cell Yield and Viability
The trypan blue exclusion assay (Sigma, SA, 200-786-7) was used to count the number of
viable cells. A fresh solution of 10 uL trypan blue (0.05%) in water was mixed with 10
uL of each cell suspension for 5 minutes. Non-viable cells stain blue. Non-viable and
viable cells were counted in a hemocytometer using light microscopy (Olympus CKX41).

Growth Kinetics and Proliferation Assay
To measure proliferation, cells were seeded in at a density of 5,000 cells/well and then
cultured in ASC plating medium for 72 hours at 37°C and 5% CO2. Proliferation was
measured using the MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) assay according to manufacturer’s instructions and fluorescence intensity was
measured using a micro-plate reader. Cell number was calculated and the percentage
increase in cell proliferation was calculated based on existing and seeding cell count
number.

Colony Forming Unit Assay
To examine differences in ASC growth, colony forming unit (CFU) assays were
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performed. ASCs were plated in 6 well plates and cultured in a 37°C incubator with
humidified 5% CO2. After 14 days of culture, the media was removed and the plates were
washed with 3 mL PBS. 3% crystal violet in 100% methanol was added and the plates
were incubated for 10 minutes at room temperature. The plates were washed with dH20
until the background was clear. The stained colonies were examined under a microscope
and the numbers of colonies greater than 2 mm in diameter were counted. Percent CFU
was defined as the number of colonies per plate divided by the number of cells plated x
100.

Adipogenic Differentiation Assay
Adipogenic differentiation was assessed at 1 and 2 weeks with Oil Red O (ORO) staining
and photometric quantification. Briefly, cells were seeded in triplicate into standard tissue
culture plates at 3 x 104 cells/cm2 per well and maintained at 37°C in a 5% carbon
dioxide incubator under 95% humidity, and adipogenic differentiation medium (ADM)
(consisting of Dulbecco’s Modified Eagle’s (DMEM)-Ham’s F-12 medium, 10% fetal
bovine serum (FBS), 15 mM HEPES at pH 7.4, 33 µM biotin, 17 µM pantothenate, 100
nM human recombinant insulin, 1 µM dexamethasone, 0.5 mM isobutylmethylxanthine,
5 µM rosiglitazone, 1% penicillin/streptomycin, 1% antibiotic/antimycotic) was added
after cell attachment for three days before being converted to adipocyte maintenance
medium (identical to adipogenic differentiation medium but without
isobutylmethylxanthine and rosiglitazone) for the remaining nine days. The medium was
replaced every other day for up to 14 days before fixation. Cultures were photographed
under phase contrast microscopy to monitor morphological changes. Adipogenic
differentiation was identified by the formation of lipid droplets in the cytoplasm. The
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percentage of differentiated ASCs producing lipid droplets was assessed by percentage of
intracytoplasmic incorporation of Oil Red O (ORO) into monolayers at day 7 and day 14
of adipogenesis using phase contrast microscopy at 10x and 40x magnification and then
extracted with isopropanol and quantified by absorbance spectrophotometry at 520 nm.

Osteogenic Differentiation Assay
To measure osteogenic differentiation, the extent of extracellular calcium deposition was
assessed by Alizarin Red S stain with photometric quantification. Briefly, cells were
seeded in triplicate into standard tissue culture plates at 3 x 104 cells/cm2 per well and
maintained at 37°C in a 5% carbon dioxide incubator under 95% humidity until at least
80% confluence. Confluent cultures of ASCs were subjected to Osteogenic
Differentiation Medium (DMEM/Hams F-12, 10% FBS, 1% antibiotic/antimycotic, 1%
penicillin/streptomycin, 10 mM β-glycerophosphate, 50 µg/ml sodium 2-phosphate
ascorbate, 10−8 M dexamethasone) and maintained in culture for 14 days with medium
changes every third day. The cultures were rinsed three times with 150 mM NaCl, fixed
in 70% ethanol, and stained with Alizarin Red in order to assay extracellular
mineralization. Briefly, cells were fixed with 4% paraformaldehyde at room temperature
for 10 minutes. After washing two times with deionized water, 1 ml of alizarin red S
solution (2%, pH 4.2) was added to each well. Each well was then washed with deionized
water four times. The plate was dried at room temperature. The amount of matrix
mineralization was determined by dissolving the cell-bound Alizarin Red S in 20%
methanol and 10% acetic acid with gentle shaking for 15 minutes at room temperature
and quantifying spectrophotometrically at 415 nm. Stains were performed in triplicate
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and all measurements were normalized to the total protein content of a well seeded at
equal density.

RNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was harvested and processed by means of RNeasy Mini Kit (Qiagen;
Valencia, CA) according to the manufacturer’s instructions. cDNA was synthesized from
extracted RNA with TaqMan Reverse Transcription Reagents Kit (Invitrogen). An ABI
Prism 7900HT Sequence Detection System (Applied Biosystems; Foster City, CA, USA)
was used to perform quantitative real-time polymerase chain reaction (qRT-PCR) with
Power SYBR Green PCR Master Mix (Applied Biosystems) as the reporter. qRT-PCR
analysis was conducted to detect gene expression levels of the adipogenic differentiation
marker lipoprotein lipase (LPL) and adiponectin (ADQ) was determined in a subset of
samples. Each sample was run in duplicate and the mean values of the duplicates were
used to calculate the transcript level. Gene expression values were normalized to 18S
ribosomal RNA as internal control in the corresponding samples and the quantity of 18S
did not vary between the two groups (p=0.31). Gene expression of early osteogenic
marker runt-related-transcription factor 2 (RUNX-2) was analyzed and assessed in a
manner identical to that described above by qRT-PCR in a subset of samples. The mRNA
expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor (HIF)1α, and endothelium-specific receptor tyrosine kinase 2 (TIE2) under normoxic
conditions were determined with real-time RT-PCR. Specific primers for the genes
examined are based on their PrimerBank sequences (Table 1).
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Clinical Evaluation
Patient photographs were taken serially at 2 weeks, 3, 6 and 12 months to evaluate fat
graft retention clinically. The serial two-dimensional photographs and clinical evaluation
were used to objectively evaluate breast contour based on percent fullness. Patients in
both groups were monitored for the occurrence of adverse events of any type,
logoregional cancer recurrences, fat necrosis, oil cysts, infection or skin necrosis. The
patient and two reconstructive breast surgeons were asked to rate the fullness of the fat
graft at each of the aforementioned time periods, specific issues such as nodularity,
irregular shape/contour, dimpling, over or underfilling), complications (pain or infection)
and time to resolution of these issues or complications). Patients were asked to rate their
satisfaction of the procedure with questions such as whether the results were as expected,
whether they would have this procedure again, and whether they would recommend this
procedure to a family member or friend. During each clinic visit or through telephone
follow-up, the patient reported by what quantity the fat graft had decreased from baseline.

Statistical Analysis
Data are shown as mean, median and percentage. Statistical analyses were performed
using GraphPad Prism software (GraphPad Prism Software v5.01 (GraphPad Software,
San Diego, CA). Numerical data are presented as means ± SDs. Statistical comparisons
between the lean and obese groups were made using student’s t-tests. Pearson r and pvalues were obtained through correlation analysis. Regression analysis with least fit
ordinary squares for proliferation and differentiation and the R2 coefficients were
evaluated. Results were reported as a positive or negative correlation depending on the
relationship of R2 to 0 (weakest correlation) or 1 (strongest correlation). The statistical
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significance was set at p< 0.05.

Results
This prospective study included 19 women who underwent fat grafting for secondary
breast reconstruction. The two groups were significantly different in body mass index
(mean lean=26.4, mean obese=33.7; p<0.0001). Analysis of the satisfaction assessment
questionnaire revealed that both groups were satisfied with the aesthetic result of the fat
grafting procedure. In both groups, the majority of patients would undergo the fat
grafting procedure again and would recommend the fat grafting procedure to a friend. At
12-month follow-up, the obese group had less fat graft retention than lean group as
determined by self (p=0.04) and surgeon (p=0.01) questionnaires and clinical evaluations
(Figure 8-4). The interrater reliability for the raters was found to be Kappa = 0.68, 95%
CI (0.50, 0.89). Obese patients were more likely to have graft resorption at each followup at the final (12 month) outcome when compared to lean patients (Figure 8-5). There
was no difference in the rates of complications such as fat necrosis or oil cysts between
the two groups (p=0.32). No patients reported locoregional cancer recurrence following
AFG during the follow-up period.

Obesity does not impact cell yield
Obesity had no impact on cell yield (Figure 8-6). The mean yield achieved was 364 ±
126 x 103 cells/mL of lipoaspirate. No significant difference was found when comparing
the mean cell yield ratios between the lean (0.331 [0.07-0.575]) and obese (0.420 [0.2330.679]) groups (p>0.05).

140

Obesity impacts ASC kinetics
Non-obese ASCs displayed significantly faster growth kinetics (Figure 8-7) and
proliferation (Figure 8-8) than those from obese environments. Obese subjects (0.3834 ±
0.0265) demonstrated reduced proliferative potential when compared to lean subjects
(0.2665 ± 0.04195); p<0.003 as measured by MTT assays.

Obesity reduced CFU potential in vitro
Lean ASCs formed a significantly higher percentage of colonies (33.2 ± 2.93) than obese
ASCs (23.2 ± 2.67), p=0.04 (Figure 8-9).

Obese ASCs demonstrated reduced adipogenic differentiation potential in vitro
After one week of adipogenic differentiation, Oil Red O staining was performed. Less
lipid droplet formation was observed in obese ASCs compared to lean ASCs (Figure 810 and 8-11, p=0.04). However, the expression levels of LPL and ADQ were not
significantly different between the lean and obese cohorts (Figure 8-12 and Table 8-1).

Obese ASCs demonstrated reduced osteogenic differentiation potential in vitro
To measure osteogenic differentiation, the extent of extracellular calcium deposition was
assessed by Alizarin Red S stain at 14 and 21 days. Obesity reduced early and late
osteogenic differentiation potential (Figure 8-13, p=0.04). However, the expression
levels of the early osteogenic gene RUNX2 were not significantly different between the
lean and obese cohorts (Figure 8-12).
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Correlation with retention

Fat graft retention varied between lean and obese phenotypes (p<0.01) at each visit and at
the 12-month follow-up (Figure 8-4 and 8-5). Correlation analysis of age, satisfaction,
proliferation, colony formation, and adipogenic differentiation between lean and obese
donors was performed. No statistically significant difference in graft retention for age
(p=0.8) or satisfaction (p=0.2) was identified. There was a positive trend for retention and
satisfaction (Figure 8-14). There was a statistically significant relationship between
proliferation and retention (p=0.03, r=0.4996). There was an upward trend toward colony
formation and retention, but this did not reach statistical significance (p=0.12, r=0.4363).
There was no relationship between adipogenic differentiation and retention as assessed
by oil red O stain and retention (p=0.51, r=-0.109) (Figure 8-15).

Discussion
ASCs are prominent tools in regenerative medicine due to their abundance, ease of
isolation and multipotent capacity. Due to the dynamic use of fat grafting across clinical
applications, much effort has been taken to understand the impact of patient
characteristics on fat graft viability. In this study, we demonstrate that an obese
environment modulates in vitro properties of ASCs. There is accumulating evidence of
decreased proliferation and differentiation potential with increased age, radiotherapy, and
diabetes, although this is not consistent among all studies. In this study, ASCs derived
from obese donors exhibited compromised properties. In this study, cell yield did not
differ between the lean and obese groups. However, non-obese ASCs displayed
significantly faster growth kinetics and proliferation compared to obese ASCs and had
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increased proliferation when measured by the MTT assays. Clonogenic ability as
measured by colony forming potential was also significantly reduced in obese subjects.
When measuring adipogenic differentiation of ASCs by Oil Red O staining with
spectrophotometric quantification, the obese cohort had a significantly lower rate of
adipogenesis when compared to the non-obese group. Adiponectin, a protein hormone
and anti-inflammatory cytokine that modulates glucose and lipid metabolism, was not
statistically significant between the lean and obese cohorts, but inversely correlated to
BMI and had a weak upward trend toward increased retention. Obesity also reduced early
and late osteogenic differentiation potential as measured by alizarin red staining.
RUNX2, a marker for early osteogenic differentiation, demonstrated a weak downward
trend with BMI, suggesting impaired osteogenic potential for the obese. ASC
proliferation potential and fat graft retention were significantly reduced in the obese.
Therefore, it is possible that the ability of ASCs to proliferate may impact graft retention.
Although our adipogenic staining revealed a statistically significant difference between
the lean and obese cohorts, there was no statistically significant difference when related
to retention. Adiponecin, a protein hormone and anti-inflammatory cytokine that
modulates glucose and lipid metabolism, was inversely correlated to BMI. RUNX2, a
marker of early osteogenic differentiation, showed a weak downward trend with BMI and
retention. Hypoxia-inducible factor-1 (HIF1a) is a transcription factor that accumulates
during hypoxia and increases the mRNA expression of several variety of genes that
stimulate angiogenesis and other pathways. HIF1a showed a slight trend upwards with
increased retention. The major inducer of angiogenesis is vascular endothelial growth
factor (VEGF) and ASCs secrete this cytokine that contributes to their angiogenic
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properties. There was a downward trend for VEGF products with increasing BMI and no
trend with retention. The TEK tyrosine kinase (TIE2) is an angiopoietin 1 receptor that is
involved in the pathway for angiogenesis and vascular maturation. The data show an
upward trend of TIE2 with increased BMI and increased retention.

Our results are in agreement with that of groups who previously reported that ASCs from
obese individuals were compromised differentiation potential (20). Perez et al. reported
reduced proliferative abilities of obese ASCs and also changes in telomerase activity and
DNA telomere length, suggesting decreased self-renewal capacity. In addition, metabolic
analysis demonstrated impaired mitochondrial content and function in obese ASCs (21).
This same group has also demonstrated impaired differentiation and migration properties
in ASCs derived from obese patients (22, 23). Perez reported decreased cell proliferation,
viability, and adipogenic capacity in obese mice (24). Roldan noted that human omental
ASCs derived from morbidly obese individuals were capable of initiating the adipogenic
differentiation process, but maturation was impaired after two weeks; the group also
observed decreased cell proliferation, premature senescence, and increased cytokine
secretion (25). The plasticity of preadipocytes and inverse relationship between lipid
storage and proinflammatory capacity have also been noted (26). Van Harmelen et al
found that the adipogenic differentiation capacity of subcutaneous mammary adipose
tissue is decreased in obese women (27). Furthermore, Onate et al. showed diminished
adipogenic and angiogenic differentiation (28) and an upregulation of inflammatory
genes in ASCs derived from obese patients (29). ASCs are currently being used in cellassisted lipotransfer techniques in breast reconstruction. Notably, if ASCs derived from
ex-obese patients have adipogenic memory of the obesity phenotype, then it reasonable to
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assume that an altered inflammatory memory also exists, thus potentially worsening
tumor progression. Obesity is a chronic inflammatory state and therefore future studies
should evaluate inflammatory genes that may contribute to diminished ASC function.
While there is much variability in outcomes among studies, this could be partially
explained by differences in harvesting technique or in vitro methodologies.

Understanding ASCs after massive weight loss has tremendous implications for
regenerative medicine. ASCs promote tissue repair and regeneration by indirectly
producing soluble factors or by directly differentiating into ASCs. For example, if ASCs
are isolated from ex-obese patients, the regenerative potential may be modified and
distinct from those derived from non-obese patients. Understanding the impact of obesity
and other patient characteristics is scarce, but is crucial for surgeons when considering
the amount of lipoaspirate to inject, to improve patient selection, and to counsel patient
expectations with regards to outcomes and the need for repeat procedures.

Limitations
This study has many limitations; first, the in vitro methodologies may not correspond to
what occurs in vivo. The cohort of patients included in the study may not be
representative of the general population, which may limit the generalizability.
Furthermore, none of our patients were morbidly obese, diabetic, or with metabolic.
Future research should include subgroup analysis of these populations and consider the
influence of massive weight loss on ASC memory and function. Furthermore, it will be
important to assess other properties of the SVF, such as macrophages and T cells, to
better understand their role in fat graft survival both in vitro and in vivo.
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This study is limited by absence of a standardized metric to evaluate graft stability.
Current evaluation of fat grafts is limited to clinical evaluation, ultrasound (US),
magnetic resonance imaging (MRI), computerized tomography (CT), and threedimensional (3-D) imaging. Although most of the currently published clinical outcome
studies rely on patient and surgeon reported outcomes, ideally, graft volume retention
should be quantified with a more objective and validated assessment tool such as with 3D imaging or MRI to monitor fat graft outcomes over time. However, MRI confers both
cost and risk to the patient and 3-D imaging is not a readily available methodology for
volumetry. Two-dimensional clinical photographs and clinician assessment with
questionnaires are standard methods for assessing fat graft retention. The kappa
coefficient showed substantial agreement among raters; the evaluation of aesthetic results
was overall positive, suggesting that contour irregularities were improved by the fat
grafting procedure. Lim et al. utilized 2D photographic analysis in their 2012 study
assessing patients with craniofacial microsomia and Treacher Collins Syndrome (30).
Therefore, we utilized serial photographs, clinical evaluations and a questionnaire to
assess fat graft volume over time.

Conclusions
ASCs derived from obese donors (BMI>30) have impaired cell function. This suggests
ASCs in adipose tissue of obese patients have impaired capacity for spontaneous or
therapeutic repair than ASCs from non-obese metabolically normal individuals. Although
many factors contribute to fat graft retention, altered adipose cell behavior of the obese
subcutaneous adipose depot may contribute to reduced long-term graft retention in obese
patients. Of all measured variables, ASC proliferation was most related to retention.
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Nonetheless, the results discussed here should be considered for all applications
involving ASCs, including in cell-based therapies, tissue engineering and stem cell
banking.
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Figure 8-1. Fat harvesting and preparation. (A) Markings on the donor site. (B)
Markings on the donor site, oblique view. (C) Harvesting with the cannula fitted directly
on to the 10-mL Luer Lock syringe. (D) Centrifugation of the syringes in batches of 6
for 20 minutes. (E) Centrifugation separates the fat into 3 layers. Only the middle layer
of purified fat is retained. (F) Transfer from one syringe to another, using a 3-way tap to
obtain 10-mL syringes containing pure fat.
Reprinted from Delay E, Guerid S. The Role of Fat Grafting in Breast Reconstruction.
Clin Plast Surg. 2015 Jul;42(3):315-23, vii., with permission from Elsevier.
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Figure 8-2. The fate of nonvascularized fat grafting is controversial. Long-term
retention of fat graft occurs both due to adipocyte survival within transplanted fat and by
ASC adipogenesis. Eto et al. found that transplanted fat grafts can be divided into three
zones. The outer 300 μm forms the peripheral zone and survives through plasma
imbibition. The central zone represents the innermost zone of the graft where all
adipocytes and progenitor cells die. In the intermediate zone, adipocytes still die, but
ASCs are able to survive and regenerate, contributing to long-term tissue remodeling and
fat retention. Therefore, ASCs are better able to endure ischemic insult and therefore play
a major role in fat graft survival.
With permission, from:
Mashiko T, Yoshimura K. How does fat survive and remodel after grafting? Clin
Plast Surg. 2015 Apr;42(2):181-90. doi: 10.1016/j.cps.2014.12.008. Epub 2015 Jan
29. Review. PubMed PMID: 25827562.
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Figure 8-3. Lipoaspirate processing. Lipoaspirate (whole fat tissue derived from
liposuction) is obtained through a liposuction cannula and centrifuged. The upper (oil)
and lower (serous) layers are decanted. The middle fatty layer is injected into the patient
in the process of fat grafting. A portion of the lipoaspirate is saved and is subjected to
washes, collagenase digestion, and centriguation. The stromal vascular fraction (SVF) is
separated from the mature adipocytes. The SVF is plated and grown to confluence.
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Figure 8-4. Surgeon and Patient-Reported Graft Retention Outcomes. At 12-month
follow-up, the obese group had less fat graft retention than lean group as determined by
self (p=0.04) and surgeon (p=0.01) questionnaires and clinical evaluations. The interrater
reliability for the raters was found to be Kappa = 0.68, 95% CI (0.50, 0.89).
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Figure 8-5. Volume retention vs. obesity over time. Obese patients were more likely to
have graft resorption at the 3 month (t-test, p=0.046), 6 month (t-test, p=0.003) and 12
month (t-test p=0.002) visits when compared to lean patients.
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Figure 8-6. Cell yield did not differ between the lean and obese groups. The mean
yield achieved was 364 ± 126 x 103 cells/mL of lipoaspirate. No significant difference
was found when comparing the mean cell yield ratios between the lean (0.331 [0.070.575]) and obese (0.420 [0.233-0.679]) groups (p>0.05).
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Figure 8-7. Obesity reduces ASC kinetics. Proliferation was measured by cell counting.
Data represent mean ± SEM. Non-obese ASCs displayed significantly faster growth
kinetics and proliferation than those from obese environments.
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Figure 8-8. Obesity affects ASC proliferation as measured by MTT assays. Cell
growth was measured by MTT assays. Obese subjects (0.3834 ± 0.0265) demonstrated
reduced proliferative potential when compared to lean subjects (0.2665 ± 0.04195);
p<0.003. Values are reported as mean ± SEM.
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Figure 8-9. Clonogenic ability as measured by colony forming potential is reduced in
the obese population. ASCs were plated in 6 well plates and cultured for 14 days,
washed with PBS, and stained with 3% crystal violet in 100% methanol for 10 minutes.
The plates were washed with dH20 until the background was clear. The stained colonies
were examined under an inverted microscope and the numbers of colonies greater than 2
mm in diameter were counted. %CFU was defined as the number of colonies per plate
divided by the number of cells plated x 100. When grouped, the lean group formed a
significantly higher percentage of colonies (33.2 ± 2.93) compared to the obese (23.2 ±
2.67); p=0.04. Values are reported as mean ± SEM.
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Figure 8-10. Adipogenic differentiation of ASCs was assessed by in vitro staining with
Oil Red O and measured by spectrophotometric quantification. Even accounting for
differences in cell proliferation, the obese cohort had a significantly lower rate of
adipogenesis compared to the lean cohort; p=0.04.

Figure 8-11. Unstained (left) and stained (right, with Oil Red O) lipid droplets during
adipogenesis at 40X magnification.
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Figure 8-12. Obesity reduces early and late osteogenic differentiation potential as
measured by alizarin red staining. Higher alizarin red staining intensity represents
more osteogenic differentiation. More osteogenic differentiation was observed in both
early (day 14) and late (day 21) osteogenesis in the lean group compared to the obese
group.

Gene
LPL
ADQ
RUNX2
HIF-1a

Primer forward sequence (5’-3’)
GCTCGTGCTGACTCTGGCCG
GGCCGTGATGGCAGAGAT
TGGTTACTGTCATGGCGGGTA
CAGAGCAGGAAAAGGAGTCA

Primer reverse sequence (3’-5’)
TCTTCTTTGGTCGGCGGCGG
TTTCACCGATGTCTCCCTTAGG
TCTCAGATCGTTGAACCTTGCTA
AGTAGCTGCATGATCGTCTG

VEGF

CTCTACCTCCACCATGCCAAG

AGACATCCATGAACTTCACCACTTC

TIE2
18S

CGCATAACCAGTGAAACAGC CCCTGTGCTCAGACAGAAATGAGA
ATTGC
AAACGGCTACCACATCCAAG
CCTCCAATGGATCCTCGTTA
Table 8-1. Primers used for qRT-PCR. 25 nmole DNA Oligo from IDT
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Figure 8-13. Comparison of mRNA expression of LPL, ADQ, RUNX2, HIF1a,
VEGF and TIE2 in the ASCs of lean and obese donors. When grouped, there was no
statistically significant difference between these factors assessed by unpaired t-test; LPL,
p=0.5; ADQ, p=0.9; RUNX2, p=0.6; HIF1a, p=0.8; VEGF, p=0.8 and TIE2, p=0.9.
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Factor

LPL

r
pr
pcoefficient value coefficient value
Retention
BMI
0.0268
0.9159
0.2368
0.3291

ADQ

-0.2799

0.2605

0.0455

0.8532

RUNX2

-0.05828

0.8183

-0.05828

0.8183

HIF1a

0.01722

0.9459

0.1574

0.5198

VEGF

-0.1076

0.6708

0.01962

0.9365

TIE2

0.433

0.0727

0.2944

0.2212

Table 8-2. Correlation analysis of factors LPL, ADQ, RUNX2, HIF1a, VEGF and
TIE2 between lean and obese donors. There was trend toward lower levels of ADQ and
VEGF and higher levels of TIE2 with increased BMI, although these did not reach
statistical significance. There was a trend toward higher levels of LPL, HIF1a, and TIE2
with increased retention, although these did not reach statistical significance.
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Figure 8-14. Correlation analysis of age and satisfaction between
lean and obese donors. There was no statistically significant difference
in graft retention for age (p=0.8) or satisfaction (p=0.2). There was a
positive trend for retention and satisfaction.
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Figure 8-15. Correlation analysis of proliferation, colony formation and adipogenic
differentiation between lean and obese donors. There was a statistically significant
relationship between proliferation and retention (p=0.03, r=0.4996). There was an
upward trend toward colony formation and retention, but this did not reach statistical
significance (p=0.12, r=0.4363). There was no relationship between adipogenic
differentiation as assessed by oil red O stain and retention (p=0.51, r=-0.109).
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Chapter 9: Adipose Graft Enrichment Strategies: A Systematic Review
Summary

Purpose: Autologous fat grafting is a dynamic modality used in reconstructive surgery as
an adjunct to improve functional and aesthetic form. However, current practices in fat
grafting for soft tissue augmentation are plagued by tremendous variability in long-term
graft retention, resulting in suboptimal outcomes and repetitive procedures. This
systematic review identifies and critically appraises the evidence for various enrichment
strategies that can be used to augment and improve the viability of fat grafts.

Methods: A comprehensive literature search of the Medline and PubMed databases was
conducted for animal and human studies published through October 2015 with multiple
search terms related to adipose graft enrichment agents encompassing growth factors,
platelet-rich plasma, adipose-derived and bone marrow stem cells, gene therapy, tissue
engineering, and other strategies. Data on level of evidence, techniques, complications,
and outcomes were collected.

Results: A total of 1064 articles were identified of which 132 met inclusion criteria. The
majority of enrichment strategies demonstrated positive benefit for fat graft survival,
particularly with growth factors and adipose-derived stem cell enrichment. Platelet-rich
plasma and adipose-derived stem cells had the strongest evidence to support efficacy in
human studies and may demonstrate a dose-dependent effect.
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Conclusions: Improved understanding of enrichment strategies contributing to fat graft
survival can help to optimize safety and outcomes. Controlled clinical studies are lacking,
and future studies should examine factors influencing graft survival through doubleblinded, randomized controlled clinical trials in order to obtain consistent outcomes and
to establish recommendations.

Introduction
The concept of fat grafting was initially pioneered by Neuber in 1893, and transitioned
into popularity almost a century later with the advent of liposuction. Lipoplasty enabled
the recovery of significant volumes of fat that could be reintroduced to patients as grafts
[1]. Since then, autologous fat grafting has evolved to become a dynamic modality used
in reconstructive surgery as an adjunct to improve functional and aesthetic form. There is
tremendous clinical interest in the utilization of fat grafting for soft tissue reconstruction
and augmentation with thousands of cases performed each year in the treatment of
patients with volume loss due to trauma, disease, congenital defects, or the natural
process of aging. However, current practice is plagued by tremendous variability in longterm graft retention, with some studies estimating a volume survival rate of 20-80%,
resulting in suboptimal outcomes and repetitive procedures [2-4]. Furthermore, the Food
and Drug Administration (FDA) released guidelines changing the regulation of human
cells, tissues, and cellular-or-tissue-based-products in December 2014. These products
would be considered as biologic drugs by the FDA and surgeons would need to apply for
premarket FDA approval and licensure prior to their use. The American Society of Plastic
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Surgery has drafted a response to explicate why these FDA regulations are misguided [5].
This systematic review critically appraises the level of evidence for adipose graft
enrichment agents, including growth factors, platelet-rich plasma, adipose derived and
bone marrow stem cells, gene therapy, tissue engineering, and other strategies.

Methods
A systematic literature review of the PubMed database was performed using the
following search algorithm:
(Fat AND ("transplantation" OR "transplantation" OR "grafting" OR "transplantation"
OR "grafting” AND ((fat AND ("transplantation"[Subheading] OR "transplantation"[All
Fields] OR "transplantation"[MeSH Terms] OR "transplantation"[All Fields] OR "organ
transplantation"[MeSH Terms] OR ("organ"[All Fields] AND "transplantation"[All
Fields]) OR "organ transplantation"[All Fields])) OR lipofilling[All Fields] OR
lipostructuring[All Fields] OR lipografting[All Fields]) AND (("intercellular signaling
peptides and proteins"[MeSH Terms] OR ("intercellular"[All Fields] AND
"signaling"[All Fields] AND "peptides"[All Fields] AND "proteins"[All Fields]) OR
"intercellular signaling peptides and proteins"[All Fields] OR ("growth"[All Fields] AND
"factors"[All Fields]) OR "growth factors"[All Fields]) OR ("vascular endothelial growth
factor a"[MeSH Terms] OR "vascular endothelial growth factor a"[All Fields] OR
"vegf"[All Fields]) OR FGF[All Fields] OR IGF[All Fields] OR EGF[All Fields] OR
PDGF[All Fields] OR EPO[All Fields] OR ("platelet-rich plasma"[MeSH Terms] OR
("platelet-rich"[All Fields] AND "plasma"[All Fields]) OR "platelet-rich plasma"[All
Fields] OR ("platelet"[All Fields] AND "rich"[All Fields] AND "plasma"[All Fields])
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OR "platelet rich plasma"[All Fields]) OR ("Pharmacol Res Perspect"[Journal] OR "prp"
OR "genetic therapy" OR ("genetic" AND "therapy"[All Fields]) OR "genetic
therapy"[All Fields] OR ("gene"[All Fields] AND "therapy"[All Fields]) OR "gene
therapy"[All Fields]) OR (("adipose tissue"[MeSH Terms] OR ("adipose"[All Fields]
AND "tissue"[All Fields]) OR "adipose tissue"[All Fields]) AND ("engineering"[MeSH
Terms] OR "engineering"[All Fields])) OR (("adipose tissue"[MeSH Terms] OR
("adipose"[All Fields] AND "tissue"[All Fields]) OR "adipose tissue"[All Fields]) AND
derived[All Fields] AND ("stem cells"[MeSH Terms] OR ("stem"[All Fields] AND
"cells"[All Fields]) OR "stem cells"[All Fields]))). A total of 1064 studies were identified
on this preliminary search (Figure 1). Relevant articles were selected through assessment
of titles and abstract as well as the reference lists of related articles. Pertinent articles
were selected and reviewed. 932 studies were unrelated to fat grafting enrichment.
Among the remaining articles, 109 were animal studies and 23 were human studies. With
regards to human studies, there were no reports on Vascular Endothelial Growth Factors
(VEGF), Fibroblast Growth Factor (FGF), Insulin-Like Growth Factor (IGF), or
Epidermal Growth Factor (EGF) in enrichment strategies. There was one study on
Platelet-Derived Growth Factor (PDGF), one study on erythropoietin (EPO), 11 studies
on Platelet-Derived Growth Factor (PRP), and ten studies Adipose Tissue-Derived Stem
Cells (ASCs). With regards to animal or in vitro studies, there were 12 reports on VEGF,
11 for FGF, one for IGF, one for EGF, one for PDGF, one for EPO, six for PRP, and 33
for ASC. Other enrichment strategies characterized 43 studies. Neutral, negative, or
positive results from these studies are summarized in Figures 2 and 3.
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Figure 9-1. Search Strategy
A comprehensive literature search of the Medline and PubMed databases was conducted
for animal and human studies published through October 2015 with multiple search terms
related to adipose graft enrichment agents encompassing growth factors, platelet-rich
plasma, adipose-derived and bone marrow stem cells, gene therapy, tissue engineering,
and other strategies. Data on level of evidence, techniques, complications, and outcomes
were collected.

Legend: Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF),
Insulin-like Growth Factor (IGF), Epidermal Growth Factor (EGF), Adipose-derived
Stem Cells (ASCs), Platelet Derived Growth Factor (PDGF), Erythropoietin (EPO),
Platelet-Rich Plasma (PRP)
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Figure 9-2. Systematic Review of Adipose Graft Enrichment in Animal Models. The
majority of enrichment strategies demonstrated positive benefit for fat graft survival,
particularly with growth factors and adipose-derived stem cell enrichment.
*Not included in graphs: 43 studies related to other enrichment factors and methods

Legend: Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF),
Insulin-like Growth Factor (IGF), Epidermal Growth Factor (EGF), Adipose-derived
Stem Cells (ASCs), Platelet Derived Growth Factor (PDGF), Erythropoietin (EPO),
Platelet-Rich Plasma (PRP)

167

Figure 3. Systematic Review of Adipose Graft Enrichment in Humans. Platelet-rich
plasma and adipose-derived stem cells had the strongest evidence to support efficacy in
human studies and may demonstrate a dose-dependent effect.
*Not included in graphs: 43 studies related to other enrichment factors and methods

Legend: Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF),
Insulin-like Growth Factor (IGF), Epidermal Growth Factor (EGF), Adipose-derived
Stem Cells (ASCs), Platelet Derived Growth Factor (PDGF), Erythropoietin (EPO),
Platelet-Rich Plasma (PRP)
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Factors that influence fat graft survival
Autologous fat grafting has become a dynamic modality used in reconstructive surgery as
an adjunct to improve functional and aesthetic form. However, the factors leading to
successful long-term outcomes in fat grafting are not fully understood. Until fully
understood, producing consistent results will continue to be a challenge. Kato et al. used
animal models to show that a process of dynamic tissue remodeling occurs over a period
of three months following fat grafting [6-9]. During this time, varying degrees of
adipogenesis and macrophage mediated replacement of fat with scarring and oil cyst
formation occurs. Several groups have attempted to identify which factors contribute to
the variability in outcomes in autologous fat grafting. These factors may influence the
process of dynamic tissue remodeling. One of the initial aspects reviewed was fat donor
site and volume of fat used for grafting.

In a recent retrospective study, Small et al. looked at patients who underwent autologous
fat injection to reconstructed breasts and used three-dimensional imaging to find that the
choice of donor site (anterior abdomen versus lateral thigh), radiated versus non-radiated
breast tissue, and volume of fat injected did not play a significant role in volumetric
retention of the fat graft at 20 weeks post-revision [10], although previously published
studies described that patients receiving higher volumes of injected fat had slower
volume loss and greater total volume retention [11].

Pressure and shear have previously been described as important variables that should be
taken into consideration during the harvesting and preparation of fat grafts. In order to
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determine the role of pressure and shear on ultimate fat graft viability, Lee et al.
performed liposuction on fresh human panniculectomy specimens, subjected the
lipoaspirates to negative pressure, positive pressure, or shear stress and injected them into
nude mice and examined the samples at four weeks [12]. Only the samples subjected to
shear stress via fast injection versus slow injection showed a significant decrease in graft
weight and unfavorable changes in histology. The authors concluded that shear stress
plays a more important role in fat graft viability than pressure. In contrast, Cheriyan et al.
showed that low-pressure abdominal lipoaspiration resulted in greater cell viability at
seven days post-operation than high-pressure abdominal lipoaspiration. They hypothesize
that this difference in findings may be attributable to differences in harvesting and
processing between the two studies, given that multiple factors play a role in the success
of autologous fat grafting [13].

A less appreciated yet promising tool in fat grafting is the graft-to-capacity (GC) ratio,
which looks at the volume of fat injected relative to the volume of the recipient site.
Using 3D imaging, del Vecchio et al. looked at 30 cases of women who underwent breast
augmentation with autologous fat grafting and calculated an average GC ratio of 117
percent +/- 22 percent [14]. They found that there was an inverse relationship between
the GC ratio and the percentage volume maintenance of fat at 12 months postaugmentation. If the ratio was more than one standard deviation above the mean, there
was lower percentage volume maintenance of fat. This can occur if the volume of fat
injected is excessive, if the volume of the recipient site is not adequate to accommodate
the volume injected, or a combination of both. In contrast, if the ratio was more than one
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standard deviation below the mean, there was higher percentage volume maintenance of
fat. One effective method employed in the study was to use tissue expansion to increase
the capacity, or volume of the recipient site, to accommodate the desired amount of fat to
be grafted while still maintaining an appropriate GC ratio. It is interesting to note that the
correlation coefficient between the GC ratio and percentage volume maintenance was
0.62, suggesting that other factors also contribute to the long term success of autologous
fat grafts. For example, a variety of harvesting techniques were used which could have
had an effect on percentage volume maintenance, such as shear stress as described above
by Lee et al. [12, 14]. Another factor that must be taken into account is the intrinsic
compliance of the recipient site tissue. The breast tissue of a multiparous healthy woman
may accommodate a greater volume of fat than the breast tissue of a woman with a
history of radiation treatment to the breast [14]. While many factors contribute to fat graft
survival, this systematic review focuses on evidence for enrichment strategies.

Growth Factors in Fat Graft Enrichment
Growth factors comprise a set of proteins or steroid hormones whose function is to
stimulate the growth of specific tissues and to facilitate cellular division and
differentiation (Figure 4). Generally, growth factors serve as intercellular signaling
molecules that bind with particular cell surface receptors to impart their influence. Brief
descriptions of various growth factors are articulated below, as well as their potential
impacts on the enrichment and survivability of fat grafts.
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Figure 9-4. Growth Factor Signaling. Growth factors comprise a set of proteins or
steroid hormones whose function is to stimulate the growth of specific tissues and to
facilitate cellular division and differentiation. Generally, growth factors serve as
intercellular signaling molecules that bind with particular cell surface receptors to impart
their influence.

Legend: Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor
(PDGF), Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF) and
respective receptors.
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Vascular Endothelial Growth Factors (VEGF) are involved with angiogenesis and
enhanced vascularization. While no studies have been performed to examine the effects
of VEGF enrichment of fat in humans, VEGF enrichment has universally demonstrated
positive effects in rodent models (Table 1). Numerous methods, including VEGF-loaded
microspheres and nanospheres, transfected Adipose-Derived Stem Cells (ASCs), Bone
Marrow Derived Stem Cells (BMSCS), and gene therapy, have demonstrated
significantly improved fat graft neovascularization, enhanced survival, and quality of
adipose tissue.

Kakudo et al. described techniques for adipose-derived regenerative cell (ADRC)enriched fat grafting. ADRCs comprise a heterogeneous assortment of cells (e.g.,
vascular smooth muscle cells, adult stem cells, leukocytes, endothelial cells, endothelial
progenitor cells) that are resident in adipose tissue subjected to collagenase digestion [15,
16]. Recent studies suggest that fat grafts enriched with cultured ADRCs might result in
augmented graft viability [17, 18]. Lu et al. suggested that ADRC fat grafts transfected
with VEGF exhibited the highest density of capillaries and graft longevity [17].

Fibroblast Growth Factors (FGF) comprise a group of heparin-binding proteins that
are involved with the propagation, differentiation and survival of a broad range of cells
and tissues, embryonic development, angiogenesis, wound healing, and endocrine
signaling. β-FGF is involved in the process of vasculogenesis and angiogenesis. While no
studies have been performed to examine the effects of FGF enrichment of fat in humans,
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enrichment has demonstrated universally positive effects in animal models, including
enhanced graft volume vascularization, viability, and retention compared to control
(Table 2). Hong et al. investigated the effects of transfer media that consisted of β-FGF
and insulin to the viability of fat grafts that were introduced to rabbit models. Enhanced
quality and viability of transplanted adipose tissue was noted [30]. It was determined that
β-FGF has the capacity to directly (as a mitogen for mesenchyme-derived cells) and
indirectly (serving as an angiogenic factor) stimulate pre-adipocytes to augment the mass
of fat grafts [31].

Insulin-Like Growth Factors (IGF) comprise proteins that are closely akin to insulin
and engaged in an intricate system that facilitates cell communication. These growth
factors also promote cell proliferation and inhibit apoptosis. IGF-1 has the capacity for
initiating preadipocyte differentiation. A study by Boney et al. suggests that IGF-binding
proteins may have a critical role in modulating the activity of IGF-1 in adipogenesis [42].
Cervelli et al. described the use of activated autologous platelet-rich plasma (PRP),
derived from blood centrifugation, as a strategy for releasing multiple growth factors,
including IGF-1, which are thought to be significant in facilitating fat graft survival [4345]. No studies have been performed to examine the effects of IGF enrichment of fat in
humans. Yuksel et al. delivered sustained doses of basic FGF, as well as insulin and IGF1 to rats using poly(lactic-coglycolic acid)-polyethylene glycol microspheres. It was
discovered that each of these growth factors served to increase the fat graft mass and
volume in contrast to control blank microspheres (Table 3) [31, 46].
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Epidermal Growth Factor (EGF) is a low-molecular-weight polypeptide that is found
in a number of human tissues with functionality encompassing angiogenesis, keratinocyte
and endothelial chemotaxis, mitogenesis of epithelial and mesenchymal cells, and
fibroblasts, and control of collagenase secretion [47]. No human studies have been
conducted to assess the affects of EGF, but a study by Park et al. demonstrated increased
survival rate and neovascularization in fat grafts placed within rabbits ears. In vitro, EGF
has augmented propagation and differentiation of ASCs (Table 4). [48-51].

Platelet-Derived Growth Factor (PDGF) is a dimeric glycoprotein that is a potent
mitogen for fibroblasts and angiogenisis that can form capillary tubes in adipose tissuederived stem cells [52]. It is created and stored in platelet α-granules and released
subsequent to platelet activation, and is also generated by a number of other cell species,
including endothelial cells, macrophages, and smooth muscle cells. Above a certain
dosage threshold, PDGF exhibits an inhibitory effect on human preadipocyte
differentiation in vitro [53]. Although an animal study by Craft et al. demonstrated
encouraging results, a double blind clinical trial by Fontdevila et al. demonstrated no
statistical advantage to using PDGF over controls (Tables 5 and 6). This study involved
autologous human fat grafting to a patients face and carried a level of evidence of 2b [54,
55]. Craft et al. bound PDGF to 20-160 µm gelatin microspheres and demonstrated its
capability for the preservation of adipose weight and structural integrity in mouse model
xenografts [55].
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Erythropoietin (EPO) is a glycoprotein hormone and a cytokine that mediates the
generation of red blood cells (erythropoiesis) [56]. It is involved in responding to
neuronal injuries [57]. In wound healing processes it promotes cellular propagation and
differentiation, has cytoprotective properties, and is pro-angiogenic and functions to
inhibit apoptosis [58]. Although no in vivo human trials have been conducted, one in vitro
human study by Sabbatini using a three-week EPO treatment regimen demonstrated
sustained revascularization and reduced inflammation (Tables 7 and 8). [59]
Furthermore, Hamed et al. observed that EPO-treated human fat grafts within mice had
increased volume and weight, exhibited elevated microvascular density and angiogenic
factor expression, and decreased inflammation [60].

Platelet Rich Plasma (PRP)
Platelet-Rich Plasma (PRP) consists of blood plasma enriched with approximately a fivefold concentration of platelets in comparison to ambient plasma, and is typically prepared
via whole blood centrifugation. It contains numerous growth factors including IGF-1,
EGF, VEGF (A and C), PDGF (-AA, -AB, and –BB) and transforming growth factor
(TGF-ß1 and -ß2), which are released by PRP via α-granules on their activation by blood
resident collagen [61]. These growth factors promote proliferation of endothelial cells,
angiogenesis, and proliferation of adipocyte progenitor cells [47, 61]. PRP has been used
to help augment wound healing, bone regeneration, and autologous fat grafting [62].

PRP enrichment demonstrates positive effects in both human and animal models,
including enhanced graft volume vascularization and retention compared to control.
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However, several studies yielded no benefits over controls (Tables 9 and 10). Li et al.
used animal models to demonstrate that fat grafts treated with PRP prior to
transplantation into nude mice had a significantly lower necrosis area ratio and higher
number of micro-vessels than control [63]. Sadati et al. explored the utilization of PRP to
augment autologous fat graft volume retention over a 30-month timeline involving 2033
grafts. Most of the 580 patients involved in the study demonstrated greater graft volume
retention and survival with PRP over extended durations, in contrast to control subjects
[64]. Gentile et al. showed that patients treated with PRP-enriched autologous fat grafting
for breast reconstruction had a significantly greater percentage maintenance of contour
and volume compared to the control group at one year follow-up [65]. On the contrary,
Salgarello retrospectively reviewed 42 women receiving breast fat grafting; this analysis
of clinical outcomes per surgeons and patients, rate of liponecrosis, and necessity of
further fat grafting offered little support for PRP enhancement [66].

Adipose Tissue-Derived Stem Cells (ASCs)
Adipose Tissue-Derived Stem Cells (ASCs) are distinguished by their
immunosuppressive attributes and low immunogenicity; hence, they may be applied to
impart graft tolerance while averting autoimmunity [82]. Both human and animal models
have almost universally exhibited positive results using ASCs, including minimal atrophy
and increased vascularization (see tables 12 and 13). Kølle et al. undertook a triple-blind
placebo-controlled trial that included 13 subjects to elucidate the survival of fat grafts
that were enriched with ASCs (20 x 106 ASCs per mL of fat - 2000 times the nominal
physiological level) as compared to non-enriched fat grafts. The results revealed that the
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ASC-enriched fat grafts exhibited considerably higher residual volumes (>80% after four
months) than the controls. The ASC enriched fat grafts contained higher volumes of
adipose and new connective tissue and less necrotic tissue [83]. Sterodimas et al.
established that patients receiving ASC-enriched fat grafts achieved results in fewer
sessions compared to controls and had significantly higher satisfaction after 6 months,
although by 18 months the groups were not significantly different [84]. In patients with
craniofacial microsomia, ASC-enriched fat grafts demonstrated an 88% retention volume
compared to 54% for controls [85].

Gene Therapy
Angiogenesis plays a key role in maintaining the long-term viability of autologous fat
grafts. Neovascularization is vital for graft survival beyond 48 hours [62]. VEGF is one
of the most important growth factors involved in this process. As discussed previously,
PRP provides multiple growth factors, including VEGF, which may improve fat graft
survival. However, PRP is not the only source of VEGF. A new modality being explored
is the use of adenovirus vectors containing the VEGF gene. The goal would be to
increase the levels of VEGF to promote neovascularization and enhance graft survival. Yi
et al. showed that when adenovirus vectors containing the VEGF gene were mixed with
adipose tissue and subsequently transplanted into mice, there was greater capillary
density, and less cyst formation and fibrosis when compared to the control groups at 15
weeks post-transplantation [28]. Using a similar approach, Lu et al. used adenovirus
vector containing the VEGF gene to transfect adipose-derived stem cells, which were
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then mixed with human adipose tissue and transplanted into mice. At six months posttransplantation, there was a significant increase in graft survival, capillary density and
significantly less fat necrosis and fibrosis relative to control [17]. These adenovirus
vectors can be used to introduce other genes for growth factors that could augment fat
graft viability too. However, due to the integrating nature of many viral vectors, more
research is moving towards non-viral transfecting systems. One promising example is
minicircle DNA vectors, which do not integrate into genomic DNA, have low levels of
immunogenicity due to intracellular degradation of the bacterial components of the
plasmid, and offer high intracellular expression levels of genes. Studies are needed with
fat grafting to determine effects of this modality, but it appears to be very promising
[126-129].

Adipose Tissue Engineering
Adipose Tissue Engineering may facilitate the enrichment and subsequent survival of
fat grafts. Wang et al. combined human adipose-derived stem cells (hASCs) with a
decellularized human adipose tissue extracellular matrix (hDAM), including VEGF,
collagen, and sulfated glycosaminoglycan. These subcutaneously implanted engineered
grafts in rat models sustained their volume at eight weeks. They did not initiate an
immune response, and proceeded to undergo remodeling as evidenced by adipose tissue
formation, host cell infiltration, and neovascularization [100]. Lequeux et al. investigated
the seeding of autologous ASCs onto collagen substrates to enhance fat-enriched
hypodermal tissue in a porcine wound model. Subsequent to culturing for ten days, the
ASC scaffolds and controls were implanted in adult porcine models. It was shown that
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the vascularized ASC scaffolds possessed an augmented layered connective/extracellular
tissue matrix within the subcutaneous tissue in comparison with controls [130].

Other Studies
The enhancement of fat grafts is not exclusive to the methods represented above. Rather,
autologous fat grafting represents a rapidly emerging technique and investigations into
many enhancement methods exist. These include but are not restricted to the inclusion of
traditional eastern remedies such as salvia miltiorrhiza, employment of biological
scaffolds, and a variety of harvesting and injection techniques (Table 13).

Discussion
Autologous fat grafting is a widely utilized procedure by plastic surgeons to augment
functional and aesthetic form. However, unpredictability of volume retention and other
complications leaves providers with the inability to determine the optimal technique.
Multiple donor sites can be utilized in autologous fat grafting without a significant effect
on outcomes. However, careful planning should be undertaken when determining the
volume of fat to be grafted in relation to the volume of the recipient site, which can be
assessed using the GC ratio. The authors suggest that there may be a positive correlation
between a lower GC ratio and long-term percentage volume maintenance, as
demonstrated by del Vecchio et al. [14] In addition, the intrinsic compliance of the
recipient tissue must be taken under consideration when determining the optimal amount
of fat to be injected for the desired outcome. If the volume of the recipient site cannot
meet the patient’s expectations, then the surgeon should consider employing tissue
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expansion to optimize safety, long-term percentage volume maintenance, and patient
satisfaction.

Inconsistent study designs and methodologies create an obstacle in determining an
optimal fat grafting technique. The authors suggest that 3D imaging should be used as the
gold standard to monitor volume retention in future studies, which would allow for more
accurate comparison of results among different studies. In addition, there have been
conflicting results among studies on the effects of aspiration pressure. Lee et al.
concluded that harvest pressure did not affect graft viability while Cheriyan et al. showed
that lower harvest pressure led to greater fat graft viability. [12,13] Performing large
double-blind randomized controlled studies need to be performed should allow for a
consensus to be reached. However, both studies demonstrated that slow fat injection,
resulting in lower sheer stress than fast fat injection, resulted in greater fat graft viability.
Currently, the authors propose that low-pressure aspiration and slow fat injection should
be employed to increase fat graft viability.

In addition to harvesting techniques and donor/recipient site considerations, studies have
indicated that varying adjunct strategies augment fat graft survival. A process of dynamic
tissue remodeling occurs after fat grafting, particularly in the first three months postoperatively [6]. During this time, different degrees of adipogenesis, liponecrosis,
scarring, oil cyst formation, and differentiation and proliferation of ASC transpires. Of
central importance to this process is angiogenesis as it provides long-term graft viability.
Several growth factors contribute to angiogenesis, in addition to other vital processes
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involved in incorporation of the graft into the recipient site, including VEGF, IGF, EGF,
PDGF, FGF, and EPO. Enrichment of fat grafts through VEGF activated autologous
stromal vascular fraction and adipose-derived regenerative cells may assist with the
improvement of fat graft viability. FGF has been shown to increase fat graft mass,
volume, quality and viability, but their effects on these fat grafts were only examined in
animals. β-FGF has the capacity to directly and indirectly stimulate pre-adipocytes to
augment the mass of fat grafts and support metabolic requirements for enhancing their
vascular structure. Although universally backed by affirmative results, the large number
of animals studies provides a wanting level of evidence. The authors recommend
performing an FDA approved double-blind randomized controlled studies in humans to
determine the utility of VEGF and FGF for adipose graft enhancement in humans.
According to new regulations, all fat grafting procedures should obtain FDA approval
prior to initiation.

IGF has the capacity to initiate preadipocyte differentiation and modulate activity in
adipogenesis. The authors found only one study examining IGF in animals [31]. The
results, although beneficial, raised a few questions. Yuksel et al. utilized microspheres
with no IGF only control. Furthermore, the deficient level of evidence indicates the need
for further studies in animals and humans with and without microspheres to determine the
appropriate usage of IGF.

EGF has been shown to increase the proliferation of hASCs and adipogenesis-related
mRNAs as well as hasten the propagation and hASC differentation. However, only one
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animal study has been conducted and the authors recommend further studies before a
conclusion can be made [51].

PDGF exhibits an inhibitory effect on human preadipocyte differentiation in vitro and
demonstrated preservation of adipose weight and structural integrity in mouse model
xenografts. Fontdevila et al. indicated the PDGF alone provided negative results, but
Craft et al. suggested PDGF with microsphere administration provided some benefit. [54,
55] These studies reveal that further research should pursue the use of PDGF use with
microspheres.

The EPO-treated fat grafts had increased volume and weight, exhibited elevated
microvascular density and angiogenic factor expression, and decreased inflammation and
apoptosis in a dose-linear fashion. However, there is only one in vitro study with human
tissue involving EPO [59]. A randomized control study is recommended before EPO may
be used in a clinical setting.

The use of PRP, which contains multiple growth factors, can be incorporated with fat
grafts to increase survival and long-term viability [73, 65]. However, optimal platelet
concentration and preparation methods must be determined and standardized so that
results of subsequent larger-scale studies can be compared. [65,66,78] The authors find
this discrepancy worrisome and further studies involving breast tissue are necessary to
settle the discrepancy between several PRP human studies.
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Considerable advances have also been established in stem cell technologies, gene
therapy, and adipose tissue engineering. ASC-enriched fat grafts exhibited considerably
higher residual volumes of adipose and new connective tissue compared to controls.
Rodent studies involving adenovirus vector-containing VEGF genes mixed with adipose
tissue demonstrated greater capillary density, and less cyst formation and fibrosis when
compared to the control groups. In a similar rodent study, VEGF transfected ASCs
demonstrated significantly increased graft survival and capillary density, and
significantly less fat necrosis and fibrosis relative to the control groups at six months
following transplantation. Engineered grafts implanted in rat models undergo adipose
tissue formation, host cell infiltration, and neovascularization without rejection. Many
human studies with varying levels of evidence have demonstrated good functionality in
humans. The decreased immune activity in fat grafts, decreased atrophy, decreased
number of procedures and the good levels of evidence indicate that ASC-enriched fat
grafts have great potential for future use in human fat grafts. Further use of nonintegrating DNA technology like minicircle vectors may also augment current strategies
[126].

Future Directions
Improved understanding of variables contributing to adipose graft survival will optimize
lipofilling procedures, making them safer and more effective. Safety should remain a
priority in experimental therapies such as ASCs and gene therapy. Novel methods in gene
therapy and the use of stem cells are currently under investigation to improve fat graft
viability and long-term survival (Figure 5, 6). Controlled clinical studies are lacking, and
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future studies should examine factors influencing graft survival through double-blinded,
randomized control clinical trials in order to obtain consistent outcomes and to establish
recommendations.
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Figure 9-5. Discussion and Future Direction
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PRP
ASC

Figure 9-6. Future Directions for adipose graft enrichment strategies in humans.
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Table 9-1. VEGF Animal Studies
PMID, Title

Jun-Jiang,
2015

25812001
Vascular
endothelial
growth factor
165-transfected
adipose-derived
mesenchymal
stem cells
promote
vascularizationassisted fat
transplantation
[19]

Ding, 2014

25180953
Effect of
Calcium
Alginate (CA)
Microsphere
Loaded with
Vascular
Endothelial
Growth Factor
on Adipose
Tissue
Transplantation
[20]

Li, 2014

24740717
Improvement in
autologous
human fat
transplant
survival with
SVF plus VEGFPLA nanosustained
release
microspheres
[21]

Model

In vitro

Mice

Nude
mice

Donor site

N/A

Subcutaneous
abdominal fat
from a
healthy,
young
woman

Byproduct of
skin grafting
surgery on 30
yr old human
female

Recipient
site

N/A

Dorsum

LOE

Technique

5

Group 1: VEGF165
recombinant gene
incorporated into the
adenovirus pAdEasy-1
system and transfected
into ASCs
Group 2: Blank
adenovirus pAdEasy-1
system transfected into
ASCs
Control: No virus
transfected into ASCs

5

Group 1: adipocytes +
VEGF-enriched CA
microspheres
Group 2: adipocytes +
free VEGF
Control: adipocytes +
empty CA microspheres
Control: adipocytes

Followup

NA

3, 6,
and 12
weeks

Group 1-4 were
implanted
subcutaneously into the
dorsum of each mouse
(n=96)

3
random
sites

5

Group 1: fat + SVF +
VEGF-PLA (polylactic
acid) nano-sustained
release microspheres
Group 2: fat + SVF
Control: fat + DMEM
Groups 1-3 were injected
subcutaneously into 3
random sites on each
mouse (n=18)

2
months

Result

Conc

The VEGF165
adenoviral vector
induced greater
proliferation of ASCs
compared to the blank
virus and control
groups

+

Mass and
microvascular
density of grafts in
the group with CA
microspheres loaded
with VEGF were
statistically higher
than that of other
groups in a timedependent manner

+

Mean wet weight of
fat was higher in
SVF+VEGF-PLA
versus SVF cells
alone and control
graft. SVF+VEGF-PLA
were composed of
adipose tissue, had
greater capillary
density and VEGF
expression, more
capillaries, less fat
necrosis and less
fibrosis compared to
the control

9
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Author,
Year
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the survival of
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in rats using
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endothelial
growth factor
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mesenchymal
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(BMSCs) [24]
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mice

Lipoaspirate
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subcutaneous
abdominal fat
of a healthy
young
woman

Dorsum

5

Chitosan nanospheres
loaded with VEGF were
mixed with adipocytes
and injected
subcutaneously into the
dorsa of mice at four
points, with each mouse
carrying four different
grafts

3, 6,
and 12
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SpragueDawley
Rat

Mouse
epididymal
region

Rat inguinal
fat

Forehead

Back

5

5

Metabolic activity and fat
graft volume were
measured with PET and
CT scans. Histologic
analysis was also
performed
Each rat (n=36) received
all 3 fat mixtures at
randomly selected sites:
Group 1: BMSCs with
VEGF165 gene
transfected
Group 2: BMSCs without
transfection
Control: low glucose
DMEM

+

4 and
12
weeks

VEGF-A therapy
enhanced the
survival and capillary
density of the
transferred fat after
surgery. Both groups
showed higher
glucose metabolism
in the transplanted
fat than in the fat
before
transplantation

+

30, 90
and
180
days

Group 1 had a
significantly higher
survival rate and
higher capillary
density. Both groups
1 and 2 had
significantly less fat
fibrosis and necrosis
than the control

+

Group 1: fat + VEGF-A
(n=9)
Control: fat (n=9)
Mice

The weight and
vascularization of
treated-grafts were
signiﬁcantly higher
than controls in a
time-dependent
manner

0

Tervala,
2014

24150116
Analysis of fat
graft metabolic
adaptation and
vascularization
using positron
emission
tomographycomputed
tomographic
imaging [23]
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Zhang,
2014

24559057
Effect of
chitosan
nanospheres
loaded with
VEGF on
adipose tissue
transplantation:
a preliminary
report [22]

Group 1: adipocytes +
chitosan nanospheres
with VEGF
Group 2: adipocytes +
free VEGF
Control: adipocytes +
empty chitosan
nanospheres
Control: adipocytes only

Lu, 2009

20009828
Improvement of
the survival of
human
autologous fat
transplantation
by using VEGFtransfected
adipose-derived
stem cells [17]

Lei, 2008

18230293
Effect of rhVEGF
gene
transfection on
survival of
grafts after
autologous free
granular fat
transplantation
in rats [27]

Wistar
rat

Human
lipoaspirate

Inguinal
adipofascial
flap

Flank

Dorsal
interscapular
region

5

5

Group 1: VEGF prior to
fat graft (n=6)
Group 2: VEGF with the
graft (n=6)
Control: empty
microsphere with graft
(n=6)
Control: fat graft only
(n=6)

5

Each mouse (n=72) was
injected at one of four
locations with the
following:
Group 1: VEGFtransfected ADSCs
Group 2: ADSCs
Group 3: 10 mmol/L
insulin
Control: DMEM

201

Topcu,
2012

22351845
Increasing the
viability of fat
grafts by
vascular
endothelial
growth factor
[26]

Nude
mice

Nude
mice

SpragueDawley
rat

Lipoaspirate
from human
thigh

Inguinal fat
pads

Four
locations
on each
mouse

Back

Group 1: VEGF-loaded
PLGA were injected in a
lipoaspirate scaffold into
mice microspheres (n=6)
Control: empty
microspheres (n=6)
Control: lipoaspirate
(n=6)

5

Group 1: fat + plasmid
cDNA with gene encoding
rhVEGF (n=16)
Control: fat + blank
plasmid (n=16)
Control: fat + normal
saline (n=16)

3 and 6
weeks

VEGF-loaded PLGA
injections had a
higher mass, volume
and vascularization
compared to
injections without
VEGF

+

90
days

Graft viability of
groups 1-3 was
significantly higher
than control. Groups
1 and 2 had higher
relative adipocyte
index compared to
control and group 3.
Rats preconditioned
with VEGF had a
significantly higher
microvascular
density than other
experimental groups

+

6
months

Group 1 showed the
highest survival
percent (74.1 +/12.6), with less fat
necrosis and fibrosis
and significantly
higher capillary
density compared to
control

+

Day 7,
15 and
30

Weights of the two
control groups were
significantly lower
than the group
injected with the
rhVEGF gene. The
expression of VEGF
and micro-vessels
was significantly
higher in the group
injected with the
rhVEGF gene

+

1

Chung,
2012

22772067
VEGF
microsphere
technology to
enhance
vascularization
in fat grafting
[25]

Nishimura,
2000

10942136
Microvascular
angiogenesis
and apoptosis in
the survival of
free fat
grafts [29]

Nude
mice

Human
breast

Rats

Inguinal fat
pads

Scalp

Back

5

Group 1: human breast fat
treated with adenovirusmediated VEGF (AdVEGF) (n=10)
Group 2: adenovirusmediated green fluorescent
protein gene (GFP) (n=10)
Control: normal saline
(n=10)

15
weeks

5

Free fat grafts enhanced
with VEGF and grafted
tissue was examined for
necrosis and signs of
vascularization (n=25)

Day 7,
30, 90
and
180

Revascularization of
the graft around day
7

+

+

2
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Yi, 2007

17293285
VEGF gene
therapy for the
survival of
transplanted fat
tissue in nude
mice [28]

Fat survival volume,
weight, and capillary
density were
significantly higher
in the group treated
with Ad-VEGF,
compared to groups
2 and 3. There was
less cyst formation
and fibrosis in the
group treated with
Ad-VEGF. Mice
treated with AdVEGF also had
significantly higher
VEGF protein levels
after the fat injection,
compared to groups
2 and 3

Table 9-2. FGF Animal Studies
PMID, Title

Model

Donor site

Recipient
site
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Jiang,
2015

25695105
Improvement of the
survival of human
autologous fat
transplantation by
adipose-derived
stem-cells-assisted
lipotransfer
combined with bFGF
[32]

Nakamu
ra, 2011

21210502
Increased survival
of free fat grafts and
vascularization in
rats with local
delivery of fragmin/
protamine
microparticles
containing FGF-2
[33]

Fisher
344 rat

Hong,
2010

19556175
Enhancing the
viability of fat grafts
using new transfer
medium containing
insulin and betafibroblast growth
factor in autologous
fat transplantation
[30]

New
Zealand
White
rabbits

Inguinal
region

Dorsum

Kuramo
chi,
2008

18837800
Matrix
metalloproteinase 2
improves the
transplanted
adipocyte survival
in mice [34]

Mice

Inguinal
region

Randomly
chosen
different
areas

Immunocompromised
nude
mice

Human fat
tissue

Inguinal
region

Back

Dorsal side
pockets

LOE

Technique

Followup

5

Human fat tissues were
mixed with ASCs, ASCs plus
100 U of bFGF, or medium as
the control.

12 weeks

5

Group 1: fat combined with
fragmin/protamine microparticles containing FGF-2
(n=48)
Group 2: grafts containing
only FGF-2, only fragminprotamine micro-particles,
or only PBS

30 and
120 days

5

5

Group 1: modified DMEM
(n=6)
Group 2: modified DMEM
with insulin (n=6)
Group 3: modified DMEM
with insulin and beta-FGF
(n=6)
Control: saline

Transplants were combined
with bFGF in the presence of
MMP-2 (group 1) or with
MMP-2 inhibitor (group 2)

1, 3, 6 and
12 months

4 weeks

Result
Mixtures with ASCs
significantly
increased the
weight and volume
of fat grafts, ASCs
and ASCs with bFGF
showed less fibrosis
but more
microvasculature
density. Higher
survival and
vascularization in
bFGF treated
implants.
Control fat grafts
were significantly
resorbed after 30
days, while the
group with
fragmin/protamine
micro-particles
containing FGF-2
experienced
minimal resorption
and higher graft
volume retention.
Groups 2 and 3
showed
significantly greater
viability of fat grafts
than the saline
control. There were
more mature
adipocytes and
reduced cyst
formation and
fibrosis in groups 2
and 3
Transplant with
MMP-2 had faster
fat accumulation,
higher PPAR
gamma mRNA
levels, and faster
glucose uptake.

Conc

+

+

+

+

3

Author,
Year

Tamura,
2007

18349632
FGF-2 enhances
vascularization for
adipose tissue
engineering [35]

17917834
Adipose tissue
formation in
response to basic
fibroblast growth
factor [36]

Nude
mice

Beagle
dogs

Human
abdomen

Subcutaneous
fat

Back

Vocal
cords

5

Recurrent laryngeal nerve
paralysis was prepared in 12
beagle dogs. Fat was injected
into the ipsilateral and
contralateral vocal cord for
experimental and control
groups.
Group 1: Mixture of fat with
bFGF, gelatin microspheres,
and collagen sponge
Control: Autologous fat

5

Silicone substrate was
coated with gelatin
containing FGF, then
transplanted into the dorsal
subdermal layer in a rabbit.
After 2-4 weeks, autologous
fat was transplanted into the
capsule (n=13)

4 weeks

In groups
pretreated with
growth factors,
proliferation of
blood vessels was
observed, while
overall necrosis was
observed in
untreated controls

5

A collagen sponge acted as a
cell scaffold and contained
preadipocytes and gelatin
microspheres (containing
bFGF).
Group 1: Sponge with
preadipocytes and
microspheres with bFGF
(n=6)
Group 2: Sponge with
preadipocytes and free bFGF
(n=6)
Group 3: Sponge + bFBF
microsphere (n=6)
Group 4: Sponge +
preadipocytes (n=6)
Group 5: Preadipocytes +
microspheres of bFGF (n=6)

6 weeks

Group 1 presented
the most viable fat
growth
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5

Control: preadipocytes
without FGF-2 (n=5)
Group 2: preadipocytes with
FGF-2 loaded microspheres
(n=5)

Yazawa,
2006

Kimura,
2003

17014671
Influence of
vascularized
transplant bed on
fat grafting [37]

12695078
Adipose tissue
engineering based
on human
preadipocytes
combined with
gelatin
microspheres
containing basic
fibroblast growth
factor [38]

Rabbit

Mice

Posterior
neck

Human
adipose
tissue from
breast

Dorsal
subdermal
layer

Back

14 days

Vascularization was
significantly
enhanced with FGF2 loaded
microspheres

+

8 weeks
and 24
weeks

In vocal cords
injected with bFGF
and fat mixture,
immature
adipocytes were
found at 8 weeks
after injection.
Vocal cords with
untreated fat
showed a significant
decrease in volume
over time

+

+

+

4

Marra,
2008

Eppley,
1992

1374121
Autologous facial fat
transplantation:
improved graft
maintenance by
microbead
bioactivation [40]

Eppley,
1991

1897414
A physiochemical
approach to
improving free fat
graft survival:
preliminary
observations [41]

Rat

Rat

Rats

Inguinal
region

Inguinal
region

Inguinal fat
pad

Back

Face

Lateral
face

5

Bioactive fat grafts were
created by the addition of
basic fibroblasts via dextran
beads. There were 4 grafts
for each animal: FGF and
beads, free fat alone, free fat
plus beads, and beads plus a
control solution (n=40).

1 and 12
months

5

Fat grafts are either mixed
with either bFGF alone or
dextran beads pretreated
with bFGF. Grafts were
compared by weight and
histology at one and 6
months after the transplant
(n=20)

1 and 6
months

5

Bioactive free fat grafts were
made using bFGF carried on
positively charged,
hydrophillic, dextran beads.
The bioactive fat grafts were
compared with contralateral
free fat grafts (n=15).

90 days

Complete retention
of the bioactive fat
grafts was observed
after 90 days, while
the free fat grafts
lost nearly half their
original weight

+

+

5
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Eppley,
1992

1280367
Bioactivation of
free-fat transfers: a
potential new
approach to
improving graft
survival [39]

The growth factor
grafts maintained
nearly their entire
weight 1 year after
the transplant. The
free fat group lost
more than half of
the original graft
weight after 1 year.
There were more
small-sized
adipocytes among
the larger
adipocytes in the
growth factor
treated group.
The grafts were
very similar after 1
month, but after 6
months the beadcontaining grafts
maintained nearly
complete weight
and had better
overall graft form

+

Yuksel,
2000

PMID, Title

10809102
Increased free fatgraft survival with
the long-term, local
delivery of insulin,
insulin-like growth
factor-I, and basic
fibroblast growth
factor by PLGA/PEG
microspheres [31]

Model

Rats

Donor
site

Inguinal
fat

Recipient
site

Subdermal
pockets in
the dorsolumbar
region

LOE

5

Technique

Group 1: fat + insulin
microspheres (n=6)
Group 2: fat + IGF-1
microspheres (n=6)
Group 3: fat + basic FGF
microspheres (n=6)
Group 4: fat + insulin and IGF-1
microspheres (n=6)
Group 5: fat + insulin, IGF-1, and
basic FGF microspheres (n=6)
Control: fat + blank
microsphere (n=6)
Control: untreated fat (n=6)
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Follow-up

Result

Conc

12 weeks

All growth factor
treatments
significantly
increased fat graft
weight and volume in
comparison with the
untreated and blank
microsphere-treated
controls. Treatment
with insulin and IGF1, alone or in
combination, was
found to increase the
adipocyte area
percentage in
comparison with fat
grafts treated with bFGF alone or in
combination with
other growth factors

+

6

Table 9-3. IGF Animal Studies
Author,
Year

Author,
Year

Park, 2011

PMID, Title

21461630
The effect of
epidermal growth
factor on
autogenous fat graft
[51]

Model

New
Zealand
rabbits

Donor
site

Inguinal
region

Recipient
site

Ear

LOE

5

Technique

Group 1: fat + EGF (n=24)
Control: fat + normal saline
(n=24)

Follow
-up

3
month
s

Result

Concl.

The EGF fat graft had a
significantly higher
survival rate compared
to the control group.
There was also an
increase in
neovascularization and
maintenance of fat cell
morphology observed
in the EGF group

+

207

7

Table 9-4. EGF Animal Studies

Author,
Year

PMID, Title

Craft, 2009

18178534
Effect of local, longterm delivery of
platelet-derived
growth factor
(PDGF) on injected
fat graft survival in
severe combined
immunodeficient
(SCID) mice [55]

Model

Donor
site

Mice
with
SCID

Human
subcuta
neous
adipose
tissue
from the
abdome
n

Recipient site

Pericranial region

LOE

Technique

5

Group 1: fat + PDGF
bound to
microspheres (n=8)
Group 2: fat + free
PDGF (n=8)
Control: fat + blank
microspheres (n=8)
Control: fat graft
(n=8)

Followup

12 weeks

Result

Concl.

The group with
PDGF bound to
microspheres had an
increased weight
maintenance and
preservation of
adipose tissue
architecture, as
compared to the
control groups

+

208

8

Table 9-5. PDGF Animal Studies

Author, Year

Fontdevila,
2014

PMID, Title

25068344
Double-blind clinical
trial to compare
autologous fat grafts
versus autologous fat
grafts with PDGF: no
effect of PDGF [54]

Model

Human

Donor
site

Various
dependi
ng on
patient

Recipient site

Face

LOE

2b

Technique

Group 1: fat + PDGF
Control: fat

Followup

2 and 12
months

209

Result

Concl
.

Both groups
exhibited
significant
increase of volume
in the facial area
and improvement
in clinical facial
atrophy grade
after
treatment. There
was no statistically
significant
difference in the
volume gain
between the
groups.

-

9

Table 9-6. PDGF Human Studies

Author, Year

Hamed, 2010

PMID, Title

210

21085572
Erythropoietin improves
the survival of fat tissue
after its transplantation
in nude mice [60]

Model

Nude
mice

Human
thigh

Recipient site

Scalp

LOE

5

Technique

Experimental: lowdose EPO + fat graft
(n=10)
Experimental: highdose EPO + fat graft
(n=10)
Control: VEGF + fat
graft (n=10)
Control: PBS + fat
graft (n=10)

Follow-up

15 weeks

Result

Conc

The weight
and volume
of EPOtreated
grafts were
higher than
PBS-treated
and VEGFtreated
grafts. EPO
treatment
increased
the
expression
of
microvascul
ar density
and
angiogenic
factors,
while
reducing
inflammatio
n and fat
cell
apoptosis in
a dosedependent
manner

+

0

Table 9-7. EPO Animal Studies
Donor
site

Author, Year

Sabbatini, 2015

PMID, Title

26034645
Effects of erythropoietin
on adipose tissue: a
possible strategy in
refilling [59]

Model

In vitro

Donor
site

Anterior
midface

Recipient site

N/A

LOE

5

Technique

211

Fat graft was seeded
on culture dishes for
24 hours and then
treated for 3 weeks
with either 0.15 μg/ml
of EPO, 0.30 μg/ml of
EPO, or 0.60 μg/ml of
EPO. After staining
with CD31 and CD68,
quantification of cell
infiltration in fat grafts
was estimated.

Follow-up

3 weeks

Result

Conc

EPO
increased
the number
of CD31positive
microvessel
s and CD31positive
small
lymphocyte
s in the fat
grafts. EPO
decreased
the number
of CD68positive
cells and
macrophage
s in the fat
grafts.

+

1

Table 9-8. EPO Human Studies

Table 9-9. PRP Animal Studies
PMID, Title

Li, 2015

25805284
Improved fat graft
survival by
different volume
fractions of
platelet-rich
plasma and
adipose-derived
stem cells. [67]

Por, 2009

18550460
Platelet-rich
plasma has no
effect on
increasing free fat
graft survival in
the nude mouse
[68]

Nakamura,
2010

20548232
Platelet-rich
plasma (PRP)
promotes survival
of fat-grafts in rats
[69]

Model

Donor
site

Nude
mice

Human
fat
tissue
and
blood

Nude
mice

Human
lipoaspi
rate
from
subcuta
neous
abdomi
nal
adipose
tissue

Rats

Inguinal
region

Recipie
nt site

Subcuta
neous
(mouse)

Scalp

Subcuta
neous
dorsal
pockets

LOE

Technique

Follo
wup

Result

Conc

20% (v/v) PRP and
ASCs had higher
residual volumes and
improves graft survival.
No significant difference
between 20% and 30%
PRP in terms of
retaining fat grafts and
histology.

+

5

Lipoinjection of granular fat, PRP
(0%, 10%, 20%, and 30%;
volume/volume [v/v]) and ASCs

10,
30,
60
and
90
days

5

Group 1: fat + PRP (n=12)
Control: fat + normal saline
(n=12)

16
week
s

The mean weight,
volume and histological
parameters between the
experimental and
control groups were not
statistically significant

10,
20, 3,
120
days

The control group was
significantly resorbed
by day 30. The PRP
group showed little
resorption from day 30120. The number of
normal adipocytes in
the control group
decreased after day 20
but the PRP group
sustained normal
adipocytes. PRP had
more granulation tissue
and capillary formation.
PRP increased
angiogenesis and viable
adipocytes

5

Fat transplants prepared with PRP
and without PRP (control) were
transplanted into subcutaneous
dorsal pockets on the right and
left sides of 64 rats
Group 1: fat + PRP + fat graft
Control: fat

no sig
diff

2
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Author,
Year

+

New
Zealand
rabbits

Scapula
r area

Ear

RodriguezFlores,
2011

21184066
Influence of
platelet-rich
plasma on the
histologic
characteristics of
the autologous fat
graft to the upper
lip of rabbits [71]

New
Zealand
rabbits

Groin
fat pad

Upper
lip

Oh, 2011

21492303
Activated plateletrich plasma
improves fat graft
survival in nude
mice: a pilot study
[72]

Nude
mice

Abdome
n

Scalp

5

Group 1: fat + PRP (n=15)
Control: fat + normal saline
(n=15)

6
mont
hs

PRP group had a
significantly higher fat
survival weight, number
of adipocytes and blood
vessels. There was more
necrosis and fibrosis in
the control group

5

One side of the rabbit's upper
lip was injected with fat + PRP
while the other side was
injected with fat alone (n=8)

8
and
12
week
s

PRP group had less
inflammatory reactions
and fewer oil cysts
compared to control

+

10
week
s

Increase in weight,
volume, and vascularity;
reduced cysts, vacuoles,
and fibrosis; no
difference in the cellular
integrity and
inflammation between
the two groups

+

5

Group 1: fat + PRP
Control: fat + normal saline

+

3
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Pires Fraga,
2010

20708988
Increased survival
of free fat grafts
with platelet-rich
plasma in rabbits
[70]

Table 9-10. PRP Human Studies
PMID, Title

Model

Tajima,
2014

25287591
Direct and indirect
effects of a
combination of
adipose-derived
stem cells and
platelet-rich
plasma on bone
regeneration[74]

Gentile,
2013

22964262
Breast
reconstruction with
autologous fat graft
mixed with plateletrich plasma [65]

PRP

Keyhan,
2013

22883321
Use of platelet-rich
fibrin and plateletrich plasma in
combination with
fat graft: which is
more effective
during facial
lipostructure? [75]

PRP and
platelet
rich
fibrin
(PRF)
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Sasaki,
2015

26335660 The
Safety and Efficacy
of Cell-Assisted Fat
Grafting to
Traditional Fat
Grafting in the
Anterior Mid-Face:
An Indirect
Assessment by 3D
Imaging. [73]

Human

Rat

Donor
site

Anterior
mid face

Inguinal
fat pads

Abdome
n

Inner
side of
the knee

Recipie
nt site

Site
specific
dependi
ng on
patient

Calvaria
l defect

Breast

Face

Follo
wup

LOE

Technique

3

On the voluntary principle,
candidates selected one of four
techniques for volumization of
their mid-face: conventional fat
grafting; PRP-assisted fat
grafting; SVF-assisted fat
grafting; and PRP/SVF- assisted
fat grafting. For comparison
data, comparable fat volumes,
SVF volumes and nucleated
cells, and PRP volumes and
platelet concentrations were
injected into each designated
group.

Up to
one
year

5

ASCs were isolated from
inguinal fat pads of F344 inbred
rats, while PRP was prepared
from these rats. The ASC/PRP
admixture was transplanted
into the rat calvarial defect.

4
and
8
week
s

2b

Group 1: fat + PRP (n=50)
Control: fat (n=50)

1b

Patients underwent bilateral
facial lipostructure: one side
was treated with PRP and the
other side was treated with
PRF. Each patient was
evaluated for fat resorption
(n=25)

1
year

1
mont
h
and
1
year

Result
PRP, SVF, and PRP/SVF
cell supplementation of
processed fat resulted in
statistically significant
percent mean graft
retention over their
baseline control at 12
months (p < 0.01). The
use of either PRP or SVF
alone resulted in almost
equal outcomes.
Combining cell
populations provided no
additional advantage
over single cellular
therapy.
Transplantation of the
ASC/PRP admixture had
dramatic effects on bone
regeneration overtime
in comparison with rats
that received other
transplants.
Furthermore, some ASCs
directly differentiated
into osteogenic cells

Conc

+

4

Author,
Year

+

69% maintenance of the
contour restoring and
volume after 1 year in
the PRP group
compared with 39% in
the fat only group

+

After 1 year, the
hemiface treated with
PRP showed greater fat
resorption compared to
the side treated with
PRF

+

Niţă, 2013

24398999
The synergy
between lasers and
adipose tissues
surgery in
cervicofacial
rejuvenation:
histopathological
aspects [76]

Cervelli,
2012

22182435
Treatment of
traumatic scars
using fat grafts
mixed with plateletrich plasma, and
resurfacing of skin
with the 1540 nm
nonablative laser
[77]

PRP

Gentile,
2012

23197813
A comparative
translational study:
the combined use of
enhanced stromal
vascular fraction
and platelet-rich
plasma improves fat
grafting
maintenance in
breast
reconstruction [78]

PRP, eSVF
(enhance
d stromal
vascular
fraction)

PRP,
adipolase
r
rejuvenat
ion

Flanks
or
abdome
n

Face

2b

Adipolaser rejuvenation was
compared in two zones of the
inferior abdomen in patients
(n=50) preparing for
abdominoplasty. The histology
of fat alone (area A) or
stimulation of fat graft with
fractional CO2 laser and
activated PRP (area B) were
compared

10
days
and
4
mont
hs

+

Group 3 was the most
effective treatment
(11% increase of wound
healing vs. Group 2 and
22% increase of wound
healing vs. Group 1)

+

After 1 year, the e-SVF
fat grafts had a 63%
maintenance of contour
restoring and volume;
PRP-enhanced fat grafts
had a 69% maintenance;
non-treated fat grafts
had a 39% maintenance

+

5

215

Significant histological
difference between
stimulated and nonstimulated fat grafts
with regard to number
of young adipocytes
present, pre-adipocytes,
local cell growth,
neovascularization, and
dermal matrix
remodeling. CO2 with
PRP prolonged the life
and take of the facial fat
graft, increased collagen
formation, and led to
better remodeling of the
dermal matrix

Abdome
n

Abdome
n

Trauma
tic scars
of
differen
t body
parts

Breast

1b

3b

Group 1: fat + PRP (n=20)
Group 2: nonablative laser
(n=20)
Group 3: treated with both
procedures 1 and 2 (n=20)

3
and
6
mont
h
inter
valfo
r up
to 24
mont
hs

Group 1: fat + e-SVF (n=10)
Group 2: fat + PRP (n=13)
Control: fat (n=10)
1
year

Cervelli,
2009

19156458
Regenerative
surgery: use of fat
grafting combined
with platelet-rich
plasma for chronic
lower-extremity
ulcers [80]
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Cervelli,
2010

20489388
Tissue regeneration
in loss of substance
on the lower limbs
through use of
platelet-rich plasma,
stem cells from
adipose tissue, and
hyaluronic acid [79]

PRP

PRP

PRP

Abdome
n

Abdome
n

Breast

Inferior
limbs
ulcers
or loss
of
substan
ce

Lower
limb
chronic
ulcers

3b

3b

2b

Group 1: fat + PRP (10%)
(n=17)
Control: fat (n=25)

Fat + PRP (n=30)

Group 1: fat + PRP (n=20)
Control: fat + hyaluronic acid and
collagen (n=10)

3
and
6
mont
hs

0, 1,
2,
and
3
week
s; 1,
3,
and
6
mont
hs;
and
1
year
2
and
5
week
s; 3,
6,
and
12
mont
hs;
then
annu
al

Fat graft enriched with
PRP (10%) was not
better than Coleman fat
graft using parameters
of clinical outcomes
(from surgeons and
patients), rate of
liponecrosis, and
necessity for further fat
graft

no
sig
diff

Wound healing
improvement after 3
weeks in 100% of
patients; healing in less
than 6 weeks in 47% of
patients; complete
wound healing within 3
months of 57% patients

+

16/20 patients had
ulcers re-epithelialize
during an average of 9.7
weeks compared with
2/10 treated with
hyaluronic acid and
collagen based
treatment

+

6

Salgarello,
2011

21617451
Breast fat grafting
with plateletrich plasma: a
comparative
clinical study and
current state of
the art [66]

Abdome
n, flanks,
trochant
er
regions,
inner
thigh,
and
medial
aspect
of the
knees

PMID, Title
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Jung, 2015

26207545
Improvement of Fat
Transplantation: Fat
Graft With
Adipose-Derived
Stem Cells and
Oxygen-Generating
Microspheres [86]

Kashimura
, 2015

26375247
The Effect of
Mature AdipocyteDerived
Dedifferentiated Fat
(DFAT) Cells on a
Dorsal Skin Flap
Model [87]

Loder,
2015

25185931
Wound Healing
after thermal injury
is improved by fat
and adipose-derived
stem cell isografts
[88]

Zhu, 2015

24172865
Adipocyte
regeneration after
free fat
transplantation:
Promotion by
stromal vascular
fraction cells [89]

Model

Donor
site

Rat

Inguinal
fat pads

SpragueDawley
rat

Intraperi
toneal
adipose
tissue
from
male SD
rat

C57BL/6
mice

BALB/c‐
nu/nu
mice

Inguinal
fat pads

Human
abdomin
al
lipoaspir
ate

Recipie
nt site

Back

Back

Burn
sites

Back

LOE

Technique

5

Group 1: Fat transplantation
only
Group 2: Fat transplantation
with oxygen-generating
microspheres
Group 3: Fat transplantation
with ASC’s
Group 4: Fat transplantation
with oxygen-generating
microspheres and ASC’s

5

Group 1: Flap base injection
where DFAT cells injected 2 cm
from the flap base
Group 2: Flap center injection
where DFAT cells injected in
flap center

5

5

Group 1: processed adipose
Group 2: ASCs
Group 3: mixed adipose
(adipose and ASCs)
Group 4: saline

Group 1: fat with SVF cells
Control: fat with DMEM

Followup

Result

Conc

2 weeks

Compared to control
group, weight and
volume increased
significantly in group
3 and 4; group 3 and
4 had the largest
survival distance of
fat cells from
transplanted tissue.
Group 3 had the most
FGF-2 at 14 days and
Group 4 had the most
FGF-2, IGF-1, EGF at
14 days.

+

14 days

Connective tissue
thickened in the flap
base injection group
of rats. The survival
rates for flap base
injection group were
the highest.

5 and
14 days

No significant
changes in
proliferation or
vascularization were
seen at 5 days
between groups. All
groups showed
improved healing
over controls.

1, 4, 7,
14, 30,
60, 90
days

Adipose tissue mixed
with SVF cells
showed a higher
retention rate, new
vessels on graft at
day 3, neonatal
adipocytes
surrounding new
vessels, and higher
levels of VEGF and
bFGF compared to
the control group
(adipose tissue with

+

no sig
diff

+

7

Table 9-11. ASC Animal Studies
Author,
Year

Mice

Abdomi
noinguinal
fat pads
from
GFP+
mice

Koellensp
erger,
2014

24703751
Intracutaneously
injected human
adipose tissuederived stem cells in
a mouse model stay
at the site of
injection [91]

Immuno
deficient
BALBc/n
ude mice

Human
abdomin
al
lipoaspir
ate

Kono,
2014

24300011
Phenotypic and
functional
properties of feline
dedifferentiated fat
cells and adiposederived stem cells
[92]

Animal

Feline
omental
fat tissue

Tian, 2014

25608789
Effects of rat
allogeneic adiposederived stem cells

SpragueDawley
rats

Inguinal
region

Parasca
pular
region

5

Group 1: whole fat graft (n=6)
Group 2: ASC + peptide
hydrogel carrier (n=6)
Control: Contralateral side

8 weeks

5

Group 1: MSC injected (n=21)
Control: Culture medium
injected

4
weeks,
6
months
12
months

5

Mature adipocyte-derived
dedifferentiated fat (DFAT)
cells were compared to ASCs for
growth kinetics, colony-forming
unit fibroblast (CFU-F)
frequency, immunophenotypic
properties, and multilineage
differentiation potential

5

A = allogeneic adipose granule
(AG) group;
B=autologous adipose granule
group;

Back

N/A

Back

N/A

DFAT cells and ASCs
had similar
immunophenotypes.
CFU-F's were
significantly higher
in DFAT and both
cells exhibited
multipotent activity
in vitro

7 days

Groups C and D had
higher wet weights
and more
surrounding cells

+

+

8
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Derby,
2014

24334307
Adipose-derived
stem cell to
epithelial stem cell
transdifferentiation:
a mechanism to
potentially improve
understanding of fat
grafting's impact on
skin rejuvenation
[90]

culture medium and
no SVF cells).
Both whole fat and
ASC groups have
increased dermal
vessels. GFP+ cells
express p63.
Significantly higher
levels of p63 were
expressed in ADSC +
hydrogel group
versus gel alone and
control
MSCs move deeper in
subcutaneous tissue
and exhibit partial
differentiation to
adipocytes,
successfully stay at
the injection site and
survive up to one
year. Some
differentiate into
adipocytes with no
inflammation,
ulceration, or tumor
induction

No
sig diff

+

C= autologous
ADSCs+autologous AG group;
D= allogeneic
ADSCs+autologous AG group
Group 1: rounded-tip cannula
with a length of 170 mm, a
diameter of 3 mm, and a single
elliptic suction port on the side
near its distal end (port
diameter: 3 × 9 mm)

on the early
neovascularization
of autologous fat
transplantation [93]

Trivisonno
, 2014

24687265
Harvest of
superficial layers of
fat with a
microcannula and
isolation of adipose
tissue-derived
stromal and vascular
cells [94]

Mice

Abdome
n and
hip of
human
females
(n=6)

N/A

5

Group 2: rounded-tip
infiltration cannula with a
length of 170 mm, a diameter of
2 mm, and 5 round ports placed
spirally along the sides of the
distal cannula shaft (each port
diameter: 1 mm)

with positive CD31
than groups A and B.

Several
weeks

Number of cells
collected by
microcannula were
significantly higher
and cells implanted
into the mice
survived multiple
weeks in areas
experiencing
neovascularization

+

1, 4, 7
and 14
day

SVF cells contained
blood-derived cells,
adipose-derived
stromal cells
(ADSCs), and
endothelial cells.
ADSCs moved to the
periphery of the
implant

+

3
months

Survival rate of ASC
treated grafts after 3
months was 23.56
+/- 2.49%, while the
survival rate of the
untreated control
grafts was 11.06 +/2.10%.

+

Dong,
2013

He, 2013

24260375
The survival
condition and
immunoregulatory
function of adipose
stromal vascular
fraction (SVF) in
the early stage of
nonvascularized
adipose
transplantation [95]

23210496
Effect of ASCs on
the graft survival
rates of fat particles
in rabbits [96]

Nude
mice

Rabbit

Human
abdomin
al
lipoaspir
ate

Inguinal
regions

Flank

Dorsal
midline

5

Mice (n=28) were injected on
contralateral sides with:
Group 1: human lipoaspirate
mixed with marked SVF cells
Control: human lipoaspirate
mixed with PBS

5

Experimental: SVF containing
ASC transplanted with fat graft
into one side of rabbit's dorsal
midline; Control: untreated fat
graft transplanted into the
other side of the dorsal midline

9

219

ASCs expressing firefly
luciferase were injected into
immunosuppressed mice

Liu, 2013

220
Philips,
2013

Wang,
2013

Zamperon
e, 2013

22681647
The adjuvant use of
stromal vascular
fraction and
platelet-rich fibrin
for autologous
adipose tissue
transplantation [98]
23783061
Prevalence of
endogenous CD34+
adipose stem cells
predicts human fat
graft retention in a
xenograft model
[99]

23816649
Combining
decellularized
human adipose
tissue extracellular
matrix and adiposederived stem cells
for adipose tissue
engineering [100]
23777308
Isolation and
characterization of a
spontaneously
immortalized
multipotent
mesenchymal cell
line derived from
mouse subcutaneous
adipose tissue [101]

Rabbits

Human
orbital
adpiose
tissue

Rabbit

Scapular
region
(rabbit)

Nude
mice

Human
lipoaspir
ate

Fischer
rats

Human
abdomin
al
lipoaspir
ate

Mice

epididy
mal/par
ametrial
fat pads
of mice

Rabbit
orbit

Rabbit
Ear

4
weeks,
8
weeks,
and 12
weeks

+

Weekly
up to 24
weeks

Group 4 had a higher
microvessel density
at 4 weeks postimplant and the
resorption rates
were the lowest of all
the groups

+

8 weeks

High correlation
between SVF
percentage of CD34+
progenitors and high
graft retention

+

+

+

5

Group 1: injection with
hyaluronic acid gel (HAG);
Group 2: injection wtih HAG +
human orbital stromal vascular
fraction (hoSVF); Group 3:
injection with HAG + hoADSCs

5

Group 1: adipose granules
(AG)+saline; Group 2:(AG)+SVF;
Group 3: (AG+PRF); Group 4:
(AG+SVF+PRF).

5

Lipoaspirate from human
subjects (n=8) were injected
into mice. The fat was evaluated
for SVF percentage and relevant
markers.

5

Group 1: engineered fat grafts
(ASCs with hDAM
microparticles and fresh fat)
Control: fresh fat grafts
harvested via the Coleman
technique

1, 2, 4,
and 8
weeks

Engineered fat grafts
maintained their
volume for 8 weeks
and the ASCs
contributed to
adipose tissue
formation

5

NOD/SCID-gnull male mice
were treated with monocrotalin
and the next day, 2x10^6 GFPm17 ASCs were
infused

Daily ,
varying
1 week
up to 6
weeks

Despite exposure to
pro-tumor agents,
this cell line was
non-tumorigenic and
immortalized as it
was found stable
after 180 passages.

0

Lee, 2013

23471894
Orbital volume
augmentation after
injection of human
orbital adiposederived stem cells
in rabbits [97]

Group with
HAG+hoADSCs had
the largest
exophthalmometric
value difference from
injection to 4 weeks
at 2.43 mm and 2.56
at 12 weeks. Specific
inflammation at
week 4 but went
away 8 weeks after
injection (all groups).

Flank

Back

Intrasple
nic
injection

Zografou,
2013

23636118
Autologous
transplantation of
adipose-derived
stem cells enhances
skin graft survival
and wound healing
in diabetic rats
[103]

Rabbit

Porcine
fat tissue

Rats

Pannicul
us
carnosus
tissue
from the
midline
of the
back

Butler,
2012

22655687
Cotransplantation of
adipose-derived
mesenchymal
stromal cells and
endothelial cells in a
modular construct
drives
vascularization in
SCID/bg mice [104]

Mice

Abdomi
nal fat
samples
(human)

Venugopal
, 2012

22374846
Adipogenesis on
biphasic calcium
phosphate using rat
adipose-derived
mesenchymal stem
cells: in vitro and in
vivo [105]

Sprague
Dawley
rat

Subcuta
neous
fat pad

Rabbits

Musclefascial
layer of
midline
of the
back

Dorsum

Dorsal
muscle

5

Rabbits with acute-on chronic
liver failure (ACLF) received
either ASC transplantation or
the same volume of saline

2, 7, 14,
21, and
28 days

5

A full thickness skin graft model
was used with ASCs (n=10) or
without ASCs (n=10) in diabetic
mice. The stem cells were
derived from the same rat's
inguinal fat pad. The grafts
were assessed after 1 week

1 week

5

Group1: modules coated with
EC, without
embedded adMSC; Group 2:
modules embedded with adMSC
and coated with EC; Group
3:modules with embedded
adMSC, without EC

3, 7, 14,
21, 30,
60, and
90 days

5

Cell-ceramic-engineered
construct with ASCs and BCP
implanted into rat dorsal
muscle

3 weeks

Increased survival,
angiogenesis and
epithelialization in
the ASC group. In
addition, the ASC
group had less
necrosis and
increased capillary
density, collagen
intensity, VEGF and
TGF-beta expression
Vessel number
increased up to day
14, then decreased
afterwards (pointing
to maturation of
vessels). Vessel
perfusion was
confirmed (day 21).
Implant volumes
decreased over time
but HMEC+adMSC
implants were larger
than control (adMSC
without HMEC
coating).
Histology of
implanted tissue
construct showed
chicken wire net-like
adipose cells within
the construct

+

+

1
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Zhu, 2013

23392800
Effects of
xenogeneic adiposederived stem cell
transplantation on
acute-on-chronic
liver failure [102]

ASC transplantation
were found in the
periportal region of
the liver, improved
survival rate,
biochemical
parameters, and
there was less
histomorphological
scoring

+

+

Rabbits

Nude
mice

Fu, 2010

21046778
Experimental study
of the effect of
adipose stromal
vascular fraction
cells on the survival
rate of fat
transplantation.
[108]

Rabbit

Moyer,
2010

20842001
Alginate
microencapsulation
technology for the
percutaneous
delivery of adiposederived stem cells
[109]

Jiang,
2009

19873723
Proliferation of the
mesenchymal stem
cells in a delayed fat
flap: an
experimental study
in rabbits [110]

Back

Human
adipose

Subcuta
nous
injection
over the
skull

Autologo
us fat
tissue

Back

5

1 week

5

Single donor ADSC were mixed
with fat that had been
cryopreserved at -70c for 8
weeks. This mixture was
injected subcutaneously into
nude mice.

4 and
15
weeks

5

Fat graft mixed with SVFs
(Group A), ASCs (Group B), or
untreated (Group C)

6
months

222

Ko, 2011

21448310
Effects of expanded
human adipose
tissue-derived
mesenchymal stem
cells on the viability
of cryopreserved fat
grafts in the nude
mouse [107]

Human
fat

Random pattern skin flaps were
designed on the backs of rabbits
and then injected with either
ADSCs or medium (without
ADSCs) as a control on the
contralateral side.

Nude
mice

Human

Rabbit

Delayed
fat flap
in
inguinal
region of
rabbit

Dorsal
subcuta
neous
pocket

N/A

5

5

Experimental: Nude mice were
implanted with ADSC-treated
alginate microspheres; Control:
untreated microspheres

Expression rates of ASCs taken
from a delayed fat flap

side with ADSCs had
a significant increase
of flap survival and
significantly higher
capillary density
At 4 weeks posttransplantation, the
adipose-derived
stem cell group
showed significantly
improved fat cell
integrity as well as
greater volume and
weight. At 15 weeks
the two groups
showed no
significant difference
in size, weight or
histological
parameters.
Groups treated with
SVFs (Groups A) and
ASCs (Group B)
consisted of adipose
tissue with less fat
necrosis and fibrosis
and higher capillary
density as compared
to untreated fat
grafts (Group C).

+

+

2

Li, 2011

21774351
The effect of
adipose-derived
stem cells on
viability of random
pattern skin flap in
rabbits [106]

+

1 and 3
months

Microspheres
showed durability of
up to 3 months, and
ADSCs remained
viable and
demonstrated signs
of mitosis.

+

21 days

In the delayed fat
flap, CD29 and CD44
were higher but
CD14 and CD45 were
lower.

+

Human
liposucti
on

Back

5

6
months

+

8 weeks

Neovascularization
was seen in group A,
but very little in
group B. Group A had
a higher weight of
cambium. There
were regenerated
adipocytes and
partial capillary
endothelium in both
groups.

Lu, 2009

20009828
Improvement of the
survival of human
autologous fat
transplantation by
using VEGFtransfected adiposederived stem cells
[17]

Rabbits

Nude
mice

Neck

(Autoge
nous
ASCs
transpla
nt)

Liposuct
ion
aspirate
from
human
thigh

Four
random
locations
on the
mouse
(1 spot
per
group,
four
injection
s per
mouse)

5

Group A: muscle flap and
collagen protein scaffold to
encapsulate ADSCs; Group B:
dextral gluteus maximus fascial
flap with no specific vessel
pedicle

+

5

Group 1; VEGF transfected
ASCs; Group 2: stem cells;
Group 3: 10 micromol/liter
insulin; Group 4: Dulbecco's
modified Eagle medium.

6
months

Group 1 showed the
highest survival
percent (74.1 +/12.6) and
significantly higher
capillary density

+

3

Li, 2009

19275095
Comparison
between kinds of
myofascial flap
encapsulating
adipose-derived
stromal cells carrier
complex in terms of
adipogenic efficacy
in vivo [112]

Nude
mice

ASCs were harvested from
liposuction and differentiated
into adipogenic, chondrogenic
and osteogenic lines. These
stem cells were mixed with fat
and injected to group A. Group
B was insulin + fat and group C
was medium +fat. Each
preparation was injected
subcutaneously on the backs of
the 18 mice.
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Li, 2009

19558169
Experimental study
of the effect of
adipose tissue
derived stem cells
on the survival rate
of free fat
transplantation
[111]

Wet weight of the
transplant was
highest in group A
(165.97mg),
followed by
B(93.42mg) followed
by C(67.64mg). The
rate of fibrosis and
steatonecrosis was
significantly lower in
the ASC group than
either of the other
two. It was also
shown that some of
the remaining
adipose-derived
stem cells expressed
CD31 and FITC
suggesting the
differentiated into
Vascular endothelial
cells

Lu, 2008

18176205
Improved viability
of random pattern
skin flaps through
the use of adiposederived stem cells
[114]

Mizuno,
2008

17975300
In vivo adipose
tissue regeneration
by adipose-derived
stromal cells
isolated from GFP
transgenic mice
[115]

Nude
mice

Inguinal
fat pads
of GFP
mice

Matsumot
o, 2006

17518674
Cell-assisted
lipotransfer:
supportive use of
human adiposederived cells for soft
tissue augmentation
with lipoinjection
[116]

Mice
with
SCID severe
combine
d
immuno
deficienc
y

Abdomi
nal or
thigh
liposucti
on
(human)

ClavijoAlvarez,
2006

17016179
A novel
perfluoroelastomer
seeded with
adipose-derived
stem cells for softtissue repair [117]

Nude
mice

ICR mice

Nude
mice

Human
abdome
n

Dorsal
cranial
region

Inguinal
fat pads
of ICR
mice

Pedicle
base or
1.5 cm
distal to
the
pedicle

Human
abdome
n

Dorsum

Back

Back

5

Implants included ASCs and
micronized acellular dermal
matrix (Alloderm).

5

Skin flap was elevated, then
injected with either ASCs from
inguinal pads of ICR mice or a
combination of mature
adipocytes and bFGF (control
group).

1 week

5

ASCs isolated from inguinal fat
pads of GFP mice were
incubated in an induction
medium to induce adipogenesis.
These induced ASCs were
combined with fibrin glue and
injected subcutaneously into
the dorsum of athymic mice.

4 and 8
weeks

5

Experimental: Human aspirated
fat transplanted with vascular
stromal fractions containing
isolated ASCs; Control: Human
aspirated fat transplanted
without vascular stromal
fractions

5

One of two fluoropolymers that
differ in pore size (U48 and
P54) were mixed with human
adipose-derived stem cells, and
then implanted subcutaneously
in a nude mouse for 30 days.

2
months

ASCs differentiated
into adipocytes.

Addition of ADSCs
resulted in a
significant increase
in flap viability and
capillary density
compared to
untreated control
groups.
Regenerated tissue
was soft with slight
angiogenesis.
Fluorescence
microscopy revealed
strong emitted green
fluorescence,
suggesting the ASCs
contributed to
adipogenesis.

+

+

+

4
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Yoo, 2009

19270821
Tissue engineering
of injectable soft
tissue filler: using
adipose stem cells
and micronized
acellular dermal
matrix [113]

4 weeks

Injected fat
containing ASCs
survived better by
approximately 35%
and contained more
microvasculature
than untreated fat.

+

30 days

Fluoropolymer U48
increased the
adherence and
provided a superior
surface for
proliferation of
adipose-derived
stem cells.

+

Mice
with
SCID

Human
ASCs

Back

5

ASCs seeded on gelatin sponges
were exposed to adipogenic
differentiation medium and
then implanted into the backs
of mice with SCID.

4 weeks

+
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5

Hong,
2006

17108684
Adipose tissue
engineering by
human adiposederived stromal
cells [118]

Adipogenic
constructs turned
into fat tissue within
4 weeks after
transplantation. No
fat formation was
observed when
ADSCS were exposed
to a control medium
without
differentiation
factors.

Table 9-12. ASC Human Studies

Charlesde-Sá,
2015

Hanson,
2013
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Kølle,
2013

Marino,
2013

PMID, Title
25811565
Antiaging treatment
of the facial skin by
fat graft and
adipose-derived
stem cells. [119]
23908304
Comparative
analysis of adiposederived
mesenchymal stem
cells isolated from
abdominal and
breast tissue [120]
24075051
Enrichment of
autologous fat grafts
with ex-vivo
expanded adipose
tissue-derived stem
cells for graft
survival: a
randomised
placebo-controlled
trial [83]
23773718
Therapy with
autologous
adipose-derived
regenerative cells
for the care of
chronic ulcer of
lower limbs in
patients with
peripheral arterial
disease [121]

Model

Donor site

Human

Liposuction
from
abdomen

Human
cells

Human

Human

Recipient
site

Face

LOE

Technique

4

Preauricular areas on the
patient were injected with fat
and its stromal vascular
fraction or with fat and
expanded mesenchymal stem
cells.

Followup

Result

Conc

3
months

Modified reticular
dermis architecture and
evidence of a richer
microvascular bed

+

N/A

Between the two sets of
ASC they showed
similar cell surface
phenotype and both
showed multilineage
differentiation. The
ASCs taken from breast
tissue had a higher FGF
expression level versus
the ASCs taken from
abdominal tissue.

+

Abdomen
and Breast

N/A

5

Comparison of surface marker
expression, differentiation
capabilities, fibroblast growth
factor (FGF) and receptor
expression, and
immunophenotype of
macrophages between ASCs
taken from breast and
abdominal tissue.

Abdomen

Posterior
part of
right and
left upper
arms

2b

Fat grafts with or without ASCs
injected into upper arms

121
days

ASC-enriched fat grafts
had significantly higher
residual volume than
control grafts

+

ASCs were injected into edges
of lower limb ulcer

4, 10,
20, 60
and 90
days

With ASC injection there
was a decrease in
diameter, depth and
pain. Also, 6/10 patients
experienced total
healing of the ulcer

+

Abdomen

Lower
limb ulcer

4

6

Author,
Year

Doornaert,
2012

227
Koh, 2012

Sterodima
s, 2011

21813882
Autologous fat
transplantation
versus adiposederived stem cellenriched lipografts:
a study [84]

Human

Human

Human

Human

Abdomen

Abdomen

Abdomen

Autologou
s fat or
ASCs

Face

N/A

Face
(ParryRomberg
disease)

Face
(congenital
or
acquired
facial
tissue
defects)

2b

5

2b

2b

Patients with craniofacial
microsomia received a graft
with adipose-derived stromal
cells or without (control group).
They were assessed
preoperatively and 6 months
post-operatively.

CD34+ ASCs were co-cultured
with mature adipocytes.

Group 1: Received microfat
grafts with ASC enrichment
Control: Received microfat
grafts without ASCs

Ten patients were treated with
autologous fat transplantation,
and the other ten received
adipose-derived stem cellenriched lipografts.

6 months

88% of the original
fat volume suvived
for the patients
with ASC and only
54% fat volume
survived for the
control group.

+

N/A

CD34+ ASCs
proliferate and
differentiate into
adipose tissue upon
exposure to mature
adipose cells.

+

15
months

Fat graft survival
was better in the
patients with the
adipose-derived
stem cell
enrichment. Overall
resorption was
20.59% in ASC
group and 46.81 in
control group.

+

6, 12, and
18
months

The patients with
the adipose-derived
stem cell treatment
only needed one
treatment, while
only 3/10 control
patients achieved
the desired result in
one session. There
was significantly
higher patient
satisfaction in the
experimental group
after 6 months, but
by the 18 month
evaluation the
groups were not
significantly
different.

+

7

Tanikawa,
2013

23806916
Fat grafts
supplemented with
adipose-derived
stromal cells in the
rehabilitation of
patients with
craniofacial
microsomia [85]
22777036
Intrinsic dynamics
of the fat graft: in
vitro interactions
between the main
cell actors [122]
22907186
Clinical application
of human adipose
tissue-derived
mesenchymal stem
cells in progressive
hemifacial atrophy
(Parry-Romberg
disease) with
microfat grafting
techniques using 3dimensional
computed
tomography and 3dimensional camera
[123]

Yoshimura
, 2008

17763894
Cell-assisted
lipotransfer for
cosmetic breast
augmentation:
supportive use of
adipose-derived
stem/stromal cells
[125]

Human

Human

Various
sites

Thighs,
abdomen,
and lower
legs

"Hostile
recipient
areas"

Breast

4

4

Autologous ASCs were injected
into recently grafted sites.

Stromal vascular fraction
containing ASCs combined with
aspirated fat and injected into
breasts for cosmetic breast
augmentation (n=40)

Monitore
d over 3
years

Postoperative
atrophy was
minimal and did not
change after 8
weeks. This was
compared to
historical atrophy
rates of 20-80%.

+

2 months

Postoperative
atrophy of injected
fat was minimal and
did not change
drastically after 2
months. Cyst
formation was
detected in 4
patients. Almost all
patients were
satisfied with the
augmentation.

+

8
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Tiryaki,
2011

21487913
Staged stem cellenriched tissue
(SET) injections for
soft tissue
augmentation in
hostile recipient
areas: a preliminary
report [124]

Table 9-13. Other studies

Bae,
2015

PMID, Title

25899889
Effects of human
adipose-derived
stem cells and
stromal vascular
fraction on
cryopreserved fat
transfer. [131]

Model

Human
to nude
mice

Donor
site

Lower
abdomen
of human

Recipient
site

Back of
nude mice

LOE

Technique

Followup

8 weeks

5

Adipose-derived stromal
cells isolated from human
lipoaspirate were labeled
with green fluorescent
protein and luciferase. Fat
grafts enhanced with
adipose-derived stromal
cells were injected into the
scalp and bioluminescent
imaging was performed to
follow retention of adiposederived stromal cells within
the fat graft.

1,5, and
10 days

229

5

The cryopreserved fat grafts
were treated with ADSC,
SVF, or normal saline in 30
six-week-old male nude
mice to test whether ADSC
and SVF could improve the
survival of the transplanted
fat tissue.

Garza,
2015

25502860
Studies in fat
grafting: Part IV.
Adipose-derived
stromal cell gene
expression in cellassisted lipotransfer
[132]

Human
to
mouse

Flank,
thigh, and
abdomen
(Human)

Scalp
(Mice)

Result
There was no
difference between
the control and SVF
groups with respect
to weight, volume,
and histological
findings. However,
the ADSC group
showed a significant
increase in weight
and volume
compared with the
control and SVF
groups. Histological
examination
showed that the
ADSC
supplementation
improved the
quality of the
transplanted fat
grafts.
Although adiposederived stromal cell
survival in the
hypoxic graft
environment
decreases
significantly over
time, these cells
provide multiple
angiogenic growth
factors. Therefore,
improved fat graft
volume retention
with adiposederived stromal cell
enrichment may be
attributable to
improved graft
vascularization.

Conc

+

9

Author
, Year

+

Gillis,
2015

26218392
Effect of NAcetylcysteine on
Adipose-Derived
Stem Cell and
Autologous Fat
Graft Survival in a
Mouse Model [133]

Inguinal

Rat

Human
insulin
genemodified
umbilical
cord
mesench
ymal
stromal
cells
(hUMSCs)

Scalp

5

5

hUMSCs infected with Adeinsuline-EGFP were seeded
in silk fibroin 3D scaffolds,
cultured for 4 days in
adipogenic medium, and
transplanted. A control
group received the silk
fibroin 3D scaffolds with
untransfected hUMSCs. Both
groups were analyzed at 8
and 12 weeks.

3 months

+

8 and 12
weeks

More tissue
regeneration, more
fat-like cells with
larger volume, and
more degradation of
the scaffolds in the
group with hUMSCs
infected with Adeinsulin-EGFP in the
scaffolds.

+

0

230

Mouse

Inguinal fat pads were
harvested using tumescent
solution with or without Nacetylcysteine. NAcetylcysteine-treated or
control grafts were injected
under recipient mouse
scalps.

In vivo, Nacetylcysteine
treatment resulted
in improved graft
retention compared
with control NAcetylcysteinetreated grafts
demonstrated less
fibrosis and
inflammation, and a
33 percent increase
in adipocyte density
compared with
controls (p < 0.001)
that was not
associated with
increased
vascularity.

Li,
2015

23509085
Construction of
engineering
adipose-like tissue
in vivo utilizing
human insulin genemodified umbilical
cord mesenchymal
stromal cells with
silk fibroin 3D
scaffolds [134]

Under
dorsal skin

25675023

Luo,
2015

Coimplanted endothe
lial
cells improve adipos
e
tissue grafts' survival
by increasing
vascularization [135]

Human
to Mice

Human

Mice
(Subcutan
eous)

5

The isolated ECs were
labeled, then added to 0.5mL fat grafts at different
numbers (0.5 × 10(6), 1 ×
10(6), 2 × 10(6), and 4 ×
10(6) cells) before
subcutaneous implantation
in nude mice. Grafts were
harvested at 1 week, 1
month, and 2 months after –
transplantation.

1 week, 1
month
and 2
months

+

1

231

Stromal vascular
fraction-derived
vascular cells exhibi
ted typical EC
characteristics. The
observed
differences in
explanted graft
weight, vessel
density, vascular
gene expression,
and cell tracking
result indicated that
coimplantation with
ECs
accelerated vascular
ization that
increased
graft survival in a
concentrationdependent manner.

Osinga,
2015

26017597
Effects of
intersyringe
processing on
adipose tissue and
its cellular
components:
implications in
autologous fat
grafting [136]

Human
in vitro

Abdomin
al

NA

5

Lipoaspiration was
performed, followed by
shuffling the fat either zero,
five, or 30 times between
two 10-cc syringes.
Thereafter, fat was applied
through a 1.5-mm cannula
for autologous fat grafting.

N/A

The process of
shuffling changed
the macroscopic but
not the microscopic
structure. No
difference in cell
number, viability,
number of lipid
droplets, vascular
architecture, or
ratio of cell
composition was
found. Analysis of
the stromal vascular
fraction did not
show significant
changes.

+

Mouse

Inguinal

Scalp

1 month
and 3
months

5

Inguinal fat of donor
Tie2/LacZ mice was
infiltrated with sildenafil or
saline, harvested, and
transplanted onto the dorsa
of recipient FVB mice.
Additional donor mice were
perfused with intraarterial
trypsin.

12 and 24
weeks

232

5

Grafts from C57BL/6 mouse
inguinal fat pads were
supplemented with M2
macrophages generated by
intraperitoneal Brewer's
thioglycollate injection and
in vitro culture. Grafts with
saline or M2 macrophages
were injected under
recipient mouse scalps and
assessed by serial microcomputed tomographic
analysis.

Soares,
2015

25626795
Targeted protection
of donor graft
vasculature using a
phosphodiesterase
inhibitor increases
survival and
predictability of
autologous fat grafts
[138]

Mice

Inguinal

Dorsa

+

2

Phipps,
2015

25539302
Alternatively
activated M2
macrophages
improve autologous
Fat Graft survival in
a mouse model
through induction
of angiogenesis
[137]

One month after
graft injection, no
significant
difference was
noted between M2
macrophagesupplemented (105
± 7.0 mm) and
control graft
volumes (72 ± 22
mm). By 3 months
after injection, M2
macrophagesupplemented
grafts remained
stable, whereas
controls
experienced further
volume loss (103 ±
8 mm versus 39.4 ±
15 mm; p = 0.015).
Compared with
controls, targeted
sildenafil treatment
improved early
graft perfusion,
doubled graft
retention at 12
weeks (83 percent
versus 39 percent; p
< 0.05), ultimately
retaining 64 percent
of the original graft
volume by 24 weeks
(compared to 4
percent; p < 0.05)
with superior
histologic features.

+

Rabbit

Scapular
region

Dorsum of
the ear

2,4,and
12 weeks

5

MSCs were cultured on
human rotator cuff tendon,
human highly cross-linked
collagen membrane, porcine
non-cross-linked collagen
membrane, a human
platelet-rich fibrin matrix,
and a fibrin matrix based on
platelet-rich plasma and
then counted for adhesion,
proliferation and live/dead
stain.

N/A

5

Lipoaspiration samples
were obtained from five
donors, and cellular
viability, proliferation, and
lipolysis were evaluated
following injection using
either a modified coleman

233

5

Minced adipose tissue
harvested from the scapular
region was transplanted
into the dorsum of the ears
of New Zealand rabbits. The
experimental groups were
intra-peritoneally injected
with S. miltiorrhiza for a
total 4 weeks. Levels of
VEGF, CD31, perilipin and
cell survival were
monitored.

Beitzel,
2014

Chung,
2014

24581253
Properties of
biologic scaffolds
and their response
to mesenchymal
stem cells [140]

24622574
Studies in fat
grafting: Part I.
Effects of injection
technique on in
vitro fat viability
and in vivo volume

Human
rotator
cuff

Mice

Bone
marrow,
proximal
humerus

Not
specified
(Human)

Various
various
biologic
scaffolds

Scalp

4,6,8, and
12 weeks

In vivo fat volume
retention was
significantly greater
than with the
modified Coleman
technique

+

3

Yu,
2015

26446419
Traditional Chinese
Medicine: Salvia
miltiorrhiza
Enhances Survival
Rate of Autologous
Adipose Tissue
Transplantation in
Rabbit Model [139]

At 12 weeks, the
survival rates in the
experimental group
were statistically
greater than that in
the control group,
respectively
(p < 0.05). Plasma
levels of VEGF in the
experimental group
at different time
points were
significantly higher
than that in the
control group
(p < 0.05).
Histologically, grafts
in the experimental
group showed
better survival of
adipocytes and neovascularization. By
perilipin immunohistochemical
staining, the
experimental group
demonstrated
better adipocyte
survival.
More cells adhered
to both the noncross-linked porcine
collagen scaffold
and PRF-M. Cell
proliferation was
higher in the noncross-linked porcine
collagen scaffold
compared with PRFM and fibrin matrix.
based on plateletrich plasma

+

+
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Li,
2014

Saliba,
2014

24740717
Improvement in aut
ologous human fat t
ransplant survival w
ith SVF plus VEGFPLA nanosustained releasemicrospheres [21]

24307457
Growth factors
expression in
hyaluronic acid fat
graft myringoplasty
[142]

technique or an
automated,low shear device

Human
cells
into
mice

Guinea
pigs

Human

Nuchal
area of
guinea
pig

Mouse

Tympanic
membrane

5

5

SVF cells were harvested
and constructed VEGFPLA nanosustained releasemicrosphe
res in
vitro. Human fat tissues was
mixed
with SVF cells plus VEGFPLA, SVF cells alone or
Dulbecco's modified Eagle's
medium as the control.
These three mixtures were
injected into random sites
in 18 nude mice.

Hyaluronic acid fat graft
myringoplasty (HAFGM)
technique and levels of EGF,
IGF, TNFalpha, VEGF, and
KGF were investigated.

2 months

0,3,8, 21
days

The mean wet
weight of fat in
the SVF plus VEGFPLA, SVF alone, and
control transplants
were 0.18 ± 0.013 g,
0.16 ± 0.015 g, and
0.071 ± 0.12 g,
respectively; the
differences between
groups were
statistically
significant. More
vessels were
present in
the SVF plus VEGFPLA transplants
than in the other
two types.
Transplants mixed
with SVF cells also
had an acceptable
density of
capillaries.
HAFGM had higher
levels of all growth
factors tested
except KGF and the
tympanic
membrane closure
was
neovascularizaed
and scarless, versus
spontaneous
closure in the
control group.

+

4

retention [141]

+

Albino
rats

Inguinal
fat pad

Dorsal
area

5

24984784
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Willem
sen,
2014

Xu,
2014

The effects of
platelet-rich plasma
on recovery time and
aesthetic outcome in
facial rejuvenation:
preliminary
retrospective
observations [144]

25562157
Human breast
adipose-derived
stem cells
transfected with the
stromal cell-derived
factor-1 receptor
CXCR4 exhibit
enhanced viability
in human
autologous free fat
grafts [145]

Human

Human
to
mouse

Upper
legs

Breast
adiposederived
stem cells
(Human)

Face

Random
(Mice)

3a

5

The dorsal area was
preconditioned with
standard technique microneedling 1-week prior to fat
graft transfer in the study
group while the control
group did not undergo
micro-needling

For the first part of this
study, i.e., evaluation of
recovery time after surgery,
the following selection
criteria were used:
nonsmoking females, aged
35-65 years, with a
complete documented
follow-up. For the second
part of the study, evaluation
of potential differences in
aesthetic outcome, the
records of these 82 patients
were screened for the
presence of pre- and
postoperative standardized
photographs in three views.
Human breast adiposederived stem cells (HBASCs)
were expanded ex vivo for 3
passages, labeled with
green fluorescent protein
(GFP) and transfected with
CXCR4 or left untransfected.
Autologous fat tissues were
mixed with the GFP-labeled,
CXCR4-transfected HBASCs
(group A), GFP-labeled
HBASCs (group B), the
known vascularizationpromoting agent VEGF
(group C), or medium
(group D) and then injected
subcutaneously into 32
nude mice at 4 spots in a
random fashion.

15 weeks

+

N/A

Adding PRP to facial
lipofilling reduces
recovery time and
improves the
overall aesthetic
outcome of a MACSlift.

+

6 months

Our data
demonstrated that
HBASCs can
enhance the
survival and quality
of transplanted free
fat tissues.
Moreover, CXCR4
transfection of these
HBASCs could
augment this effect.

+

5

Sezgin,
2014

24529693
Improving fat graft
survival through
preconditioning of
the recipient site
with microneedling
[143]

Fat grafts in the
study group had
better integrity and
a higher level of
vascularity
compared to the
control group.
Volume analysis
demonstrated
higher graft survival
in the study group
in comparison to
the control group

Mouse

Inguinal

Back

5

Fat tissue and SVF
separated from luciferase
(Luc)-transgenic rats were
applied for bioimaging
analysis. The Luc-fat (0.2
mL) was subcutaneously
injected into the back of
nude mice with or without
SVFs from 0.2 mL wild type
rat fat

+

N/A

Each system (1)
PNC's Multi Station,
(2) CHA Biotech
Cha-Station, (3)
Cytori Celution
800/CRS System,
and (4) Medi-Khan's
Lipokit with
MaxStem yielded
stromal vascular
fraction cells but
there are
differences in the
viability, number,
and safety profiles
of the collections.

N/A

236

Up to 63
days

Arono
witz,
2013

24281640 Adipose
stromal vascular
fraction isolation: a
head-to-head
comparison of four
commercial cell
separation systems
[147]

Human

Abdomen

N/A

5

Comparison of
commercially available
systems for isolating
stromal vascular fraction
cells

6

Zhou,
2014

25405913
In vivo bioimaging
analysis of stromal
vascular fractionassisted fat grafting:
the interaction and
mutualism of cells
and grafted fat
[146]

The bioimaging
results showed that
fat tissues
transplanted with
SVFs had higher
survival ratio than
those transplanted
without SVFs
Stromal vascular
fraction-assisted fat
grafts had more
integral structure
and less necrosis
cysts. The results
showed that, with
the existence of
grafted fat,
transplanted SVF
survived for a
significantly longer
time and could
contribute to fat
graft survival and
regeneration by
differentiating into
structural cells.

237
Hamed,
2013

Luo,
2013

23897352
The chemokine
stromal cell-derived
factor-1α promotes
endothelial
progenitor cellmediated
neovascularization
of human
transplanted fat
tissue in diabetic
immunocompromis
ed mice [60]

23509085
Construction of
engineering
adipose-like tissue
in vivo utilizing
human insulin genemodified umbilical
cord mesenchymal
stromal cells with
silk fibroin 3D
scaffolds[149]

Human

Mice

Nude
mice

BMMNCs
from
bone
marrow
in
posterior
iliac
crest; fat
from
abdomen,
thighs,
flanks

Human
fat tissue

Human
thigh
liposuctio
n

Breasts

Scalps of
mice

Back of
nude mice

3b

BMMNCs and purified fat
mixture injected directly
into patient's breasts

5

Human fat tissue with
phosphate-buffered saline
or stromal cell-derived
factor-1α was injected into
the scalp of each mouse.

5

Mice received human ADSC
fat grafts with or without
esteridiol enrichment, or
culture medium alone.
Survival rate of the fat grafts
was calculated.

2 weeks,
4 weeks,
3 months,
6 months,
and 12
months

Postoperative
atrophy of injected
fat was minimal and
did not change
significantly after
12 months; patient
experienced
improvement in
circumferential
breast
measurement

+

18 days
and 15
weeks

After 18 days:group
with stromal cellderived factor-1α
treatment of the
grafts in the diabetic
mice expressed
higher levels of
VEGF, increased
VEGF receptor 2,
CXCR4, endothelial
nitric oxide
synthase, and
protein kinase B
expression levels,
and lower caspase 3
and cytochrome c
levels. After 15
weeks:that same
group had increased
vascularization and
prevented
resorption of the fat
graft.

+

12 weeks

Estradiol enriched
fat grafts had a
higher tissue
survival rate than
the ADSC alone
group (76.9% vs
55.5%). there was
also increased
capillary formation

+

7

Bulgin,
2013

24024064
Autologous bonemarrow-derivedmononuclear-cellsenriched fat
transplantation in
breast
augmentation:
evaluation of
clinical outcomes
and aesthetic
results in a 30-yearold female [148]

Human

Auricular
concha

Nasal/chin
area

Zhao,
2013
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Alghou
l, 2012

Butala,
2012

22745452
The effect of
hyaluronan
hydrogel on fat graft
survival [152]

22495210
Endogenous stem
cell therapy
enhances fat graft
survival [153]

Nude
mice

Rat

Mice

Inguinal
area

Groin

Abdomen
and thigh
(Human)

Paraverteb
ral

Dorsum

Tail

+

4 months

Fat graft survival
rates were .2052 in
group A
(mesenchymal),
.1761 in group B
(expanded
mesenchymal) and
.1350 in group C
(Dulbecco's)

+

2b

5

Three groups of nude mice
recieved transplants of cells
containing .3ml of adipose
granula and .2ml of cell
components. Group A
received mesenchymal stem
cells, group B received
expanded mesenchymal
stem cells, group C received
Dulbecco's medium. Four
months later the grafts were
harvested measured.

5

Two groups. Group 1: fat
alone; Group 2: fat and
hyaluronan hydrogel in a
1:1 mix. In vivo scans at 4,
12, and 20 weeks to
quantify fat-HA graft
volume and volume of fat
alone

4,12 and
20 weeks

5

Male 8-week-old FVB mice
were grafted with either
high density or low-density
human lipoaspirate. Half of
the mice receiving lowdensity fat were treated
with a stem cell mobilizer
for 14 days

2 and 10
weeks

24165597
Enhancement of fat
graft survival by
bone marrow-derived
mesenchymal stem
cell therapy[151]

1 to 5
years

Chondrofat tissue
was stable after 1-5
years, maintained
good shape, no
infections, 5.6%
absorption

Two-stage transplantation:
1st = abdomen for growth
(6 months), 2=nasal/chin
area for reconstruction

Fat-HA yielded
reduced fat necrosis
(statistical diff. at 12
and 20 weeks),
higher blood vessel
density (sig. at 12
weeks only) and
less volume loss (at
20 weeks).
Endogenous
progenitor cell
mobilization
enhances lowdensity fat
neovascularization,
increases
vasculogenic
cytokine expression,
and improves graft
survival to a level
equal to that of
high-density fat
grafts

8

Yanaga
, 2013

24281577
Two-stage
transplantation of
cell-engineered
autologous
auricular
chondrocytes to
regenerate
chondrofat
composite tissue:
clinical application
in regenerative
surgery [150]

+

+
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Lee,
2012

Ma,
2012

23094251
Facial Soft Tissue
Augmentation using
Autologous Fat
Mixed with Stromal
Vascular Fraction
[155]

21607534
Utilizing musclederived stem cells
to enhance longterm retention and
aesthetic outcome
of autologous fat
grafting: pilot study
in mice [156]

SCID
mice

Human

Mice

Grown on
microcarr
iers

Lower
abdomen,
hip and
thigh

Autologo
us

Under the
skin

Face

Intramusc
ular

5

3a

5

Mice received implantations
of human adipose tissue
derived stromal cells with
or without endothelial cells.
Another group of mice
received the particles in a
fibrin matrix with and
without endothelial cells.
The mice were harvested 12
days, 4 weeks and 4 months
and grafts analyzed.

SVF cells were freshly
isolated from half of the
aspirated fat and were used
in combination with the
other half of the aspirated
fat during the procedure.
Between March 2007 and
February 2008, a total of 9
SVF-assisted fat grafts were
performed in 9 patients.

MDSCs and fat were
transplanted
intramuscularly in mice.
The mice were assessed
after 3 months.

12 days,
4 weeks
and 4
months

1 time a
week up
to 12
weeks, 1
time a
month up
to 11
months

3 months

There was a limited
improvement in the
group with the
endothelial cells
after 4 weeks. There
were significantly
fewer necrotic
regions after 4
weeks and 4
months.

Scores of the left
facial area grafted
with adipose tissue
mixed with SVF
cells were
significantly higher
compared with
those of the right
facial area grafted
with adipose tissue
without SVF cells.

Group containing
MDSCs showed
higher fat signal,
intact fat cells, less
fibrosis, less fat
graft loss, and
higher capillary
density.

+

+

9

Frerich
, 2012

22023101
Comparison of
different fabrication
techniques for
human adipose
tissue engineering
in severe combined
immunodeficient
mice [154]

+

240
Yang,
2012

Keck,
2012

Koh,
2011

21629060
Role of anti-TNF-α
therapy in fat graft
preservation [158]

21964747
Coenzyme Q10 does
not enhance
preadipocyte
viability in an in
vitro lipotransfer
model [159]
21393582
Stromal vascular
fraction from
adipose tissue
forms profound
vascular network
through the
dynamic reassembly
of blood endothelial

Rat

Rat

In vitro

Mice

Subcutan
eous fat
(Human
and mice)

Autologo
us

Subcutan
eous
adipose

Epididym
al
adipose
tissue

Dorsal
subcutis of
rodents

Back

N/A

Flank
region

5

Groups: rat (rATE, allograft)
or human (hATE, xenograft)
derived ATE included in
implant to be injected into
rat through a hyaluronan
hydrogel (HA)

12 weeks
to 9
months

5

Two groups: Group 1:
antirat TNF-alpha
monoclonal antibody was
added to fat graft; Group 2:
fat graft on its own. 8 rats
were killed and assessed on
days 7, 14, 30 and 60

7,14,30,6
0 days

5

Preadipocytes were treated
with coenzyme Q10 or a
control and incubated with
lidocaine. FACS and western
blot were used to assess
viability and apoptosis.

5

Cells were mixed with
Matrigel or PBS, BSA, VEGF
or cartilage oligomeric
matrix protein-angiopoietin
and implanted into the flank
region

+

0

Sarkan
en,
2012

22738319
Bioactive acellular
implant induces
angiogenesis and
adipogenesis and
sustained soft tissue
restoration in vivo
[157]

ATE-HA implant
showed bioactivity,
compatibility,
sustainability,
microvessel
induction, adipose
tissue deposition
(starting at week
12), included
capillaries, nerve
bundles and healthy
connective tissue,
and had large fat
pads at the end of
the study.
Group 1 had a
higher preservation
ratio of tissue
compared to Group
2 at 60 days (no
significant
difference in days
before this). Group
1 had lower
numbers of
apoptotic cells at
each time point and
expression of TNF
alpha was lower in
Group 1 versus
Group 2 for days 7
and 14.

+

NA

Coenzyme Q10 did
not improve
viability or have any
impact on the
observed apoptosis
parameters

-

1 week

Freshly isolated SVF
can effectively
induce new vessel
formation through
the dynamic
reassembly of blood
endothelial cells

+

cells [160]

Nude
mice

Human
fat

Nude mice

5

241
Kamak
ura,
2011

CondeGreen,
2010

21533662
Autologous cellenriched fat grafting
for breast
augmentation [162]

20442104
Effects of
centrifugation on
cell composition
and viability of
aspirated adipose
tissue processed for
transplantation
[163]

Human

Human

Thighs,
hips,
buttocks,
or
abdomin
al

Abdomen

Breast

N/A

3b

5

After adipose harvesting
using syringe liposuction,
the tissue is processed in
the Celution 800 System.
tThe mean cell viability
measured using an
automated cell counting
system before graft delivery
was 85.3%.

Samples of adipose tissue
were centrifuged and
samples of adipose tissue
that were not centrifuged
were compared.

2 months

3 and 9
months

N/A

Free-cell grafts
were resorbed in
50% of the mature
adipose group and
60% of the ADSC
group. Purified
adipose tissue had
an 81.8% survival
rate. The remaining
weight was greater
in the Scaffold
groups, but the
difference was not
statistically
significant.
All patients
demonstrated
improvement in
circumferential
breast
measurement
(BRM) from their
baseline state, and
breast
measurements were
stable by 3 months
after surgery. T

The pellet in the
centrifuged sample
had the highest
concentration of
MSCs and
endothelial cells

no sig
diff

1

Mojalla
l, 2011

21590499
Stem cells, mature
adipocytes, and
extracellular
scaffold: what does
each contribute to
fat graft survival?
[161]

Preparations of purified
adipose tissue, isolated
mature adipocytes, cultured
adipose derived stem cellls
without scaffold, collagen
scaffold only, cultured
adipose-derived stem cells
in a collagen scaffold with
and without bioactive
factors and freshly isolated
adipose derived stem cells
in a collagen scaffold were
used. Each preparation was
grafted onto the nude mice

+

Zhu,
2010

242
Umeno,
2009

Zhong,
2009

20098110
Supplementation of
fat grafts with
adipose-derived
regenerative cells
improves long-term
graft retention [18]

19460200
Efficacy of
autologous fat
injection
laryngoplasty with
an adenoviral
vector expressing
hepatocyte growth
factor in a canine
model [165]

18162449
Improved fat graft
viability by delayed
fat flap with
ischaemic
pretreatment [166]

Human

Mice

Dogs

New
Zealand
rabbits

Subcutan
eous

Inguinal
fat pads

Dog

Inguinal
region

N/A

Skull

True vocal
cords

Dorsal
midline

5

5

5

5

Human preadipocytes were
isolated from subcutaneous
adipose tissue of 15 patients
and treated with
bupivacaine, mepivacaine,
ropivacaine,
articaine/epinephrine, and
lidocaine for 30 minutes.
Adipose-derived
regenerative cells and fat
was transplanted into mice
and compared to mice that
were injected with nontreated fat graft. Fat grafts
were analyzed at both 6 and
9 months after the
transplantation.
Autologous fat plus an
adenoviral vector
expressing hepatocyte
growth factor was injected
into the right vocal cord.
Harvested fat plus an
adenoviral vector with no
gene was injected into the
left vocal cord. One year
later a total laryngectomy
was performed one year
after the intracordal fat
injection.

U-shaped fat flap was raised
in the inguinal region to
induce ischaemia. Three
weeks later, fat flap was
transferred to a pocket next
to the dorsal midline of the
rabbit.

N/A

6 months,
9 months

There is a marked
influence of local
anesthetics not only
on the quantity but
also on the quality
of viable
preadipocytes as
determined by their
ability to
differentiate into
mature adipocytes.
At both 6 and 9
months, ADRCs
increased graft
retention by 2-fold,
enhanced the
quality of the fat
grafts, and had a
higher capillary
density.

+

+

1 year

The fat area was
significantly larger
and the number of
vasculoendothelial
cells surrounding
adipocytes was
significantly greater
in the intracordal
injection with
hepatocyte growth
factor.

+

Up to 12
months

VEGF protein in the
ischaemia treated
fat flaps was
significantly higher
than the controls at
12 hours after the
treatment. There
was no difference in
number of vessels,
fat graft size, and
weight at 1 and 3
months after
transplantation. The
fat grafts in control
group disappeared
after 6 months,

+

2

Keck,
2010

21042106
Local anesthetics
have a major impact
on viability of
preadipocytes and
their differentiation
into adipocytes
[164]

while the treated
group maintained
the fat graft up to 12
months.

Piaseck
i, 2008

19083503
Purified viable fat
suspended in
matrigel improves
volume longevity
[168]

Nude
mice

Mice

Various –
with
scaffoldin
g

Mice
(unspecifi
ed)

interscapul
ar

Mice
(Unspecifi
ed)

5

Preadipocytes were seeded
on collagen scaffolds and
then implanted. The other
group, adipose tissue taken
by the Coleman technique
was also implanted but in a
different site for
comparison. Grafts were
assessed after 8 weeks.

5

Purified fat cells were
suspended in GFR Matrigel
and then implanted. The
other experimental groups
were unpurified fat (group
2), and then a control of
GFR-Matrigel (group 3). The
grafts were then assessed at
1 week, 1 month and 3
months

8 weeks

The group with the
preadipocytes
showed adipose
appearance and
peripheral
neovascularization.

+

1 week, 1
month,
and 3
months

Fat in GFR Matrigel
grafts had a higher
fat volume at 3
months, whereas,
the unpurified fats
developed fibrosis.

N/A

3

243

Mojalla
l, 2008

19065020
Does adipose tissue
cultured with
collagen matrix and
preadipocytes give
comparable results
to the standard
technique in plastic
surgery? [167]

244

TorioPadron
, 2007

Shosha
ni,
2005

Yamag
uchi,
2005

17380359
Engineering of
adipose tissue by
injection of human
preadipocytes in
fibrin [170]

15731687
The effect of
interleukin-8 on the
viability of injected
adipose tissue in
nude mice [171]
16246901
Revascularization
determines volume
retention and gene
expression by fat
grafts in mice [172]

Mice

Mice
(unspecifi
ed)

Mice
(unspecifie
d)

Nude
mice

Subcutan
eous
(human)

Mice

Suctionassisted
lipectomy

Scalp

Mice

Epididym
al fat

Subcutane
ous

Back
(mouse)

5

PuraMatrix (peptide
hydrogel) with adipocytes
were compared against just
PuraMatrix and then against
syringe-harvested fat alone

1 week, 1
month
and 3
months

5

Different concentrations of
undifferentiated human
preadipocytes in fibrin were
injected into athymic mice,
while the control group was
injected with just fibrin.

1,3,6 and
9 months

5

Group 1: interleukin-8
(0.25ng) injected 24 hours
before fat graft with 25 ng
of interleukin-8 per 1 cc of
injected fat. Group 2: fat
without interleukin-8

15

5

Fat grafts were transplanted
into mice either with TNP470 (an inhibitor of
angiogenesis) or without.

PuraMatrix with
purified fat had
higher volume and
longer fat graft
survival

Within 4 weeks
after initial volume
reduction of the
implants, the
volume and shape
of the implants with
preadipocytes
remained stable.
The control group
implants with just
fibrin were
completely
resorbed within 3
weeks. The best
results were
observed after
implantation of 30
million
preadipocytes.
Group 1 had
significantly less
cyst formation. No
significant
difference between
the groups
concerning weight
or volume of graft,
adipose cell size.
Mice with TNP-470
had fat grafts with
lower weight and
smaller adipocytes
than mice without
inhibitor. VEGF and
leptin were also

N/A

4

Piaseck
i, 2008

19083542
Beyond the cells:
scaffold matrix
character affects the
in vivo performance
of purified
adipocyte fat grafts
[169]

+

+

+

lower in TNP mice.

Humanin vitro

Abdomen

N/A

5

Fat obtained
intraoperatively and by
lipectomy was digested
with collagenase to isolate
adipocytes. These cells were
exposed to lidocaine

10 days

Lidocaine potently
inhibited glucose
transport and
lipolysis in
adipocytes and their
growth in culture.

+

however, persisted
only as long as
lidocaine was
present
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5

Moore,
1995

7484471
Viability of fat
obtained by syringe
suction lipectomy:
effects of local
anesthesia with
liodcaine (173)

Chapter 10: Conclusions

Autologous fat grafting is a common surgical procedure that involves the transfer of fat
from one area of the body to another in order to improve contour deformities. There is
tremendous clinical interest in the utilization of fat grafting for soft tissue reconstruction,
with thousands of cases performed each year in the treatment of volume loss due to
trauma, scars, wounds, fistulas, disease, congenital defects, or the natural process of
aging. In the setting of breast reconstruction, fat grafting provides significant contour
improvement and improves patient satisfaction. Although fat could become the ideal soft
tissue filler, it is plagued by its tremendous variability in long-term graft retention, with
volume survival rates of 20-80%, resulting in suboptimal outcomes and repetitive
procedures. The goals of this dissertation were to generate and critically appraise
evidence for the safety and efficacy of fat grafting in the setting of breast reconstruction
and to provide evidence-based recommendations to guide future therapies.

While there is tremendous interest in the use of fat grafting for aesthetic and
reconstructive breast surgery, concerns have been raised regarding efficacy and safety of
adipose-derived stem cells and fat grafting in the setting of breast reconstruction. In light
of the recent FDA regulatory changes regarding the processing of fat, a systematic review
was undertaken to determine the safety, efficacy, satisfaction, and oncological outcomes
of fat grafting to the breast. Based on our review of the literature and the data collected
from our institution, fat grafting appears to be oncologically safe in breast reconstruction.
Several adipose graft enrichment strategies encompassing growth factors, platelet-rich
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plasma, adipose-derived and bone marrow stem cells, gene therapy and tissue
engineering have been attempted to augment and improve the viability of fat grafts.
While these strategies are promising, most of the evidence is level five and only in animal
models, however, well-designed clinical trials are indicated to establish safety and
efficacy of interventions.

Due to the significant variability in fat grafting outcomes and tremendous interest of
ASCs graft retention, the final study attempts to describe the impact of a specific donor
physiological condition, obesity, on ASC functionality. Understanding how obesity
affects ASC function may help to elucidate why lean patients anecdotally have better fat
graft retention compared to obese patients. Our research suggests that obese patients may
have lower levels of satisfaction with fat grafting procedures and lower retention rates,
possibly due to reduced ASC proliferation and differentiation potential. Collectively, the
studies that comprise this dissertation generate and critically appraise evidence for the
safety, efficacy and outcomes of fat grafting in the setting of breast reconstruction.
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